University of Southern Denmark

# Industry sponsorship and research outcome

Lundh, Andreas; Lexchin, Joel; Mintzes, Barbara; Schroll, Jeppe B; Bero, Lisa

*Published in:*
Cochrane Database of Systematic Reviews

*DOI:*
10.1002/14651858.MR000033.pub3

*Publication date:*
2017

*Document version:*
Final published version

*Citation for pulished version (APA):*
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017). Industry sponsorship and research outcome. *Cochrane Database of Systematic Reviews*, *2017*(2), Article MR000033. https://doi.org/10.1002/14651858.MR000033.pub3

Go to publication entry in University of Southern Denmark's Research Portal

**Terms of use**
This work is brought to you by the University of Southern Denmark.
Unless otherwise specified it has been shared according to the terms for self-archiving.
If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim.
Please direct all enquiries to puresupport@bib.sdu.dk

Download date: 22. Sep. 2024

Cochrane Library

**Cochrane** Database of Systematic Reviews

# Industry sponsorship and research outcome (Review)

Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L

Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L.
Industry sponsorship and research outcome.
*Cochrane Database of Systematic Reviews* 2017, Issue 2. Art. No.: MR000033.
DOI: 10.1002/14651858.MR000033.pub3.

**www.cochranelibrary.com**


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

WILEY

## TABLE OF CONTENTS

HEADER . . . 1
ABSTRACT . . . 1
PLAIN LANGUAGE SUMMARY . . . 2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . 3
BACKGROUND . . . 5
OBJECTIVES . . . 5
METHODS . . . 5
RESULTS . . . 9
Figure 1. . . . 10
Figure 2. . . . 11
Figure 3. . . . 12
DISCUSSION . . . 17
AUTHORS' CONCLUSIONS . . . 21
ACKNOWLEDGEMENTS . . . 21
REFERENCES . . . 21
CHARACTERISTICS OF STUDIES . . . 34
DATA AND ANALYSES . . . 91
Analysis 1.1. Comparison 1 Results: Industry sponsored versus non-industry sponsored studies, Outcome 1 Number of studies with favorable efficacy results. . . . 95
Analysis 1.2. Comparison 1 Results: Industry sponsored versus non-industry sponsored studies, Outcome 2 Number of studies with favorable harms results. . . . 96
Analysis 2.1. Comparison 2 Results: Industry sponsorship by test treatment company versus sponsorship by comparator treatment company, Outcome 1 Number of studies with favorable test treatment efficacy results. . . . 97
Analysis 3.1. Comparison 3 Conclusions: industry sponsored versus non-industry sponsored studies, Outcome 1 Number of studies with favorable conclusions. . . . 98
Analysis 4.1. Comparison 4 Conclusions: Industry sponsorship by test treatment company versus sponsorship by comparator treatment company, Outcome 1 Number of studies with favorable test treatment conclusions. . . . 99
Analysis 5.1. Comparison 5 Risk of bias: industry sponsored versus non-industry sponsored studies, Outcome 1 Number of studies with low risk of bias from sequence generation. . . . 100
Analysis 5.2. Comparison 5 Risk of bias: industry sponsored versus non-industry sponsored studies, Outcome 2 Number of studies with low risk of bias from concealment of allocation. . . . 101
Analysis 5.3. Comparison 5 Risk of bias: industry sponsored versus non-industry sponsored studies, Outcome 3 Number of studies with low risk of bias from blinding-overall. . . . 102
Analysis 5.4. Comparison 5 Risk of bias: industry sponsored versus non-industry sponsored studies, Outcome 4 Number of studies with low risk from blinding-performance bias. . . . 103
Analysis 5.5. Comparison 5 Risk of bias: industry sponsored versus non-industry sponsored studies, Outcome 5 Number of studies with low risk from blinding-detection bias. . . . 104
Analysis 5.6. Comparison 5 Risk of bias: industry sponsored versus non-industry sponsored studies, Outcome 6 Number of studies with low risk of bias from loss to follow-up. . . . 105
Analysis 5.7. Comparison 5 Risk of bias: industry sponsored versus non-industry sponsored studies, Outcome 7 Number of studies with low risk of bias from selective outcome reporting. . . . 106
Analysis 6.1. Comparison 6 Concordance between study results and conclusions: industry sponsored versus non-industry sponsored studies, Outcome 1 Number of studies with concordant study results and conclusions. . . . 107
Analysis 7.1. Comparison 7 Subgroup analysis, Outcome 1 Number of studies with favorable efficacy results, stratified by risk of bias. . . . 108
Analysis 7.2. Comparison 7 Subgroup analysis, Outcome 2 Number of studies with favorable harms results, stratified by risk of bias. . . . 110
Analysis 7.3. Comparison 7 Subgroup analysis, Outcome 3 Number of studies with favorable conclusions, stratified by risk of bias. . . . 111
Analysis 7.4. Comparison 7 Subgroup analysis, Outcome 4 Number of studies with favorable efficacy results, stratified by type of intervention. . . . 113


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

Analysis 7.5. Comparison 7 Subgroup analysis, Outcome 5 Number of studies with favorable conclusions, stratified by type of intervention. . . . 115
Analysis 7.6. Comparison 7 Subgroup analysis, Outcome 6 Number of studies with favorable efficacy results, stratified by type of domain. . . . 117
Analysis 7.7. Comparison 7 Subgroup analysis, Outcome 7 Number of studies with favorable harms results, stratified by type of domain. . . . 119
Analysis 7.8. Comparison 7 Subgroup analysis, Outcome 8 Number of studies with favorable conclusions, stratified by type of domain. . . . 120
Analysis 8.1. Comparison 8 Sensitivity analysis, Outcome 1 Number of studies with favorable efficacy results, sponsorship recoded. . . . 122
Analysis 8.2. Comparison 8 Sensitivity analysis, Outcome 2 Number of studies with favorable harms results, sponsorship recoded. . . . 123
Analysis 8.3. Comparison 8 Sensitivity analysis, Outcome 3 Number of studies with favorable conclusions, sponsorship recoded. . . . 124
Analysis 8.4. Comparison 8 Sensitivity analysis, Outcome 4 Number of studies with favorable efficacy results, analysis adjusted for confounders. . . . 125
Analysis 8.5. Comparison 8 Sensitivity analysis, Outcome 5 Number of studies with favorable conclusions, analysis adjusted for confounders. . . . 126
Analysis 8.6. Comparison 8 Sensitivity analysis, Outcome 6 Number of studies with favorable efficacy results, fixed-effect model. . . . 127
Analysis 8.7. Comparison 8 Sensitivity analysis, Outcome 7 Number of studies with favorable harms results, fixed-effect model. . . . 128
Analysis 8.8. Comparison 8 Sensitivity analysis, Outcome 8 Number of studies with favorable test treatment efficacy results, fixed-effect model. . . . 129
Analysis 8.9. Comparison 8 Sensitivity analysis, Outcome 9 Number of studies with favorable conclusions, fixed-effect model. . . . 130
Analysis 8.10. Comparison 8 Sensitivity analysis, Outcome 10 Number of studies with favorable test treatment conclusions, fixed-effect model. . . . 131
Analysis 8.11. Comparison 8 Sensitivity analysis, Outcome 11 Number of studies with favorable conclusions, papers with unpublished studies excluded. . . . 132
Analysis 8.12. Comparison 8 Sensitivity analysis, Outcome 12 Number of studies with favorable efficacy results, restricted to specific domains. . . . 134
Analysis 8.13. Comparison 8 Sensitivity analysis, Outcome 13 Number of studies with favorable harms results, restricted to specific domains. . . . 135
Analysis 8.14. Comparison 8 Sensitivity analysis, Outcome 14 Number of studies with favorable test treatment efficacy results, restricted to specific domains. . . . 136
Analysis 8.15. Comparison 8 Sensitivity analysis, Outcome 15 Number of studies with favorable conclusions, restricted to specific domains. . . . 137
Analysis 8.16. Comparison 8 Sensitivity analysis, Outcome 16 Number of studies with favorable test treatment conclusions, restricted to specific domains. . . . 138
APPENDICES . . . 138
WHAT'S NEW . . . 139
CONTRIBUTIONS OF AUTHORS . . . 139
DECLARATIONS OF INTEREST . . . 139
SOURCES OF SUPPORT . . . 139
DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . 140
INDEX TERMS . . . 140


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

[Methodology Review]

# Industry sponsorship and research outcome

Andreas Lundh[1], Joel Lexchin[2], Barbara Mintzes[3], Jeppe B Schroll[4], Lisa Bero[5]

[1]Center for Evidence-Based Medicine, Odense University Hospital and University of Southern Denmark, Odense, Denmark. [2]School of Health Policy and Management, York University, Toronto, Canada. [3]Charles Perkins Centre and Faculty of Pharmacy, The University of Sydney, Sydney, Australia. [4]Department of Obstetrics and Gynaecology, Herlev Hospital, Herlev, Denmark. [5]Charles Perkins Centre and Faculty of Pharmacy, University of Sydney, Sydney, Australia

Contact address: Andreas Lundh, Center for Evidence-Based Medicine, Odense University Hospital and University of Southern Denmark, Sdr. Boulevard 29, Entrance 50 (Videncentret), Odense, 5000, Denmark. andreas.hover.lundh@rsyd.dk.

**Editorial group:** Cochrane Methodology Review Group.
**Publication status and date:** New search for studies and content updated (no change to conclusions), published in Issue 2, 2017.

**Citation:** Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. *Cochrane Database of Systematic Reviews* 2017, Issue 2. Art. No.: MR000033. DOI: 10.1002/14651858.MR000033.pub3.

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## ABSTRACT

### Background

Clinical research affecting how doctors practice medicine is increasingly sponsored by companies that make drugs and medical devices. Previous systematic reviews have found that pharmaceutical-industry sponsored studies are more often favorable to the sponsor's product compared with studies with other sources of sponsorship. A similar association between sponsorship and outcomes have been found for device studies, but the body of evidence is not as strong as for sponsorship of drug studies. This review is an update of a previous Cochrane review and includes empirical studies on the association between sponsorship and research outcome.

### Objectives

To investigate whether industry sponsored drug and device studies have more favorable outcomes and differ in risk of bias, compared with studies having other sources of sponsorship.

### Search methods

In this update we searched MEDLINE (2010 to February 2015), Embase (2010 to February 2015), the Cochrane Methodology Register (2015, Issue 2) and Web of Science (June 2015). In addition, we searched reference lists of included papers, previous systematic reviews and author files.

### Selection criteria

Cross-sectional studies, cohort studies, systematic reviews and meta-analyses that quantitatively compared primary research studies of drugs or medical devices sponsored by industry with studies with other sources of sponsorship. We had no language restrictions.

### Data collection and analysis

Two assessors screened abstracts and identified and included relevant papers. Two assessors extracted data, and we contacted authors of included papers for additional unpublished data. Outcomes included favorable results, favorable conclusions, effect size, risk of bias and whether the conclusions agreed with the study results. Two assessors assessed risk of bias of included papers. We calculated pooled risk ratios (RR) for dichotomous data (with 95% confidence intervals (CIs)).


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Main results**

Twenty-seven new papers were included in this update and in total the review contains 75 included papers. Industry sponsored studies more often had favorable efficacy results, RR: 1.27 (95% CI: 1.17 to 1.37) (25 papers) (moderate quality evidence), similar harms results RR: 1.37 (95% CI: 0.64 to 2.93) (four papers) (very low quality evidence) and more often favorable conclusions RR: 1.34 (95% CI: 1.19 to 1.51) (29 papers) (low quality evidence) compared with non-industry sponsored studies. Nineteen papers reported on sponsorship and efficacy effect size, but could not be pooled due to differences in their reporting of data and the results were heterogeneous. We did not find a difference between drug and device studies in the association between sponsorship and conclusions (test for interaction, P = 0.98) (four papers). Comparing industry and non-industry sponsored studies, we did not find a difference in risk of bias from sequence generation, allocation concealment, follow-up and selective outcome reporting. However, industry sponsored studies more often had low risk of bias from blinding, RR: 1.25 (95% CI: 1.05 to 1.50) (13 papers), compared with non-industry sponsored studies. In industry sponsored studies, there was less agreement between the results and the conclusions than in non-industry sponsored studies, RR: 0.83 (95% CI: 0.70 to 0.98) (six papers).

**Authors' conclusions**

Sponsorship of drug and device studies by the manufacturing company leads to more favorable efficacy results and conclusions than sponsorship by other sources. Our analyses suggest the existence of an industry bias that cannot be explained by standard 'Risk of bias' assessments.

## PLAIN LANGUAGE SUMMARY

**Industry sponsorship and research outcome**

Results from clinical studies on drugs and medical devices affect how doctors practice medicine and thereby the treatments offered to patients. However, clinical research is increasingly sponsored by companies that make these products, either because the companies directly perform the studies, or fully or partially fund them. Previous research has found that pharmaceutical industry sponsored studies tend to favor the sponsors' drugs more than studies with any other sources of sponsorship. This suggests that industry sponsored studies are biased in favor of the sponsor's products.

This review is an update of a previous review that looked at sponsorship of drug and device studies. The primary aim of the review was to find out whether the published results and overall conclusions of industry sponsored drug and device studies were more likely to favor the sponsors' products, compared with studies with other sources of sponsorship. The secondary aim was to find out whether such industry sponsored studies used methods that increase the risk of bias, again compared with studies with other sources of sponsorship. In this update, we carried out a comprehensive search of all relevant papers of empirical studies published from 2010 to February 2015 and included 27 new papers, yielding a total of 75 papers included in our review.

Industry sponsored drug and device studies more often had efficacy results that were favorable to the sponsors' products, (risk ratio (RR): 1.27, 95% confidence interval (CI): 1.17 to 1.37), similar harms results (RR: 1.37, 95% CI: 0.64 to 2.93) and favorable overall conclusions (RR: 1.34, 95% CI: 1.19 to 1.51), compared with non-industry sponsored drug and device studies. We did not find a difference between industry and non-industry sponsored studies with respect to standard methodological factors that may increase the risk of bias, except for blinding: industry sponsored studies reported satisfactory blinding more often than non-industry sponsored studies. In industry sponsored studies, there was less agreement between the results and the conclusions than in non-industry sponsored studies, RR: 0.83 (95% CI: 0.70 to 0.98).We did not find a difference between drug and device studies in the association between sponsorship and conclusions. Our analysis suggests that industry sponsored drug and device studies are more often favorable to the sponsor's products than non-industry sponsored drug and device studies due to biases that cannot be explained by standard 'Risk of bias' assessment tools.


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## SUMMARY OF FINDINGS FOR THE MAIN COMPARISON [Explanation]

**Results and conclusions: Industry sponsored compared to non-industry sponsored studies**

**Patient or population:** industry sponsorship and study results
**Intervention:** industry sponsored studies
**Comparator:** non-industry sponsored studies

| Outcomes | Illustrative comparative risks* (95% CI) | | Risk ratio (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments |
|---|---|---|---|---|---|---|
| | Assumed risk | Corresponding risk | | | | |
| | Non-industry sponsored studies | Industry sponsored studies | | | | |
| Number of studies with favorable efficacy results | 502 per 1000 | 638 per 1000 (588 to 688) | 1.27 (1.17 to 1.37) | 25 papers including 2923 studies | ⊕⊕⊕○ MODERATE | Upgraded as control for confounders and analysis of low risk of bias papers gave similar results |
| Number of studies with favorable harms results | 474 per 1000 | 649 per 1000 (303 to 1388) | 1.37 (0.64 to 2.93) | 4 papers including 826 studies | ⊕○○○ VERY LOW | Downgraded due to substantial heterogeneity (inconsistency) and wide confidence intervals (imprecision) |
| Number of studies with favorable conclusions | 644 per 1000 | 863 per 1000 (766 to 972) | 1.34 (1.19 to 1.51) | 29 papers including 4583 studies | ⊕⊕○○ LOW | Downgraded due to substantial heterogeneity (inconsistency). Upgraded as control for confounders and analysis of low risk of bias papers gave similar results |

*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).
**CI:** Confidence interval

GRADE Working Group grades of evidence
**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.
**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
**Very low quality:** We are very uncertain about the estimate.

The assumed risk of the control group (i.e. non-industry group) was calculated as the mean risk (i.e. number of studies with favorable results divided by total number of studies).


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

# BACKGROUND

## Description of the problem or issue

Clinical research sponsored by the pharmaceutical industry affects how doctors practice medicine (PhRMA 2008; Wyatt 1991). An increasing number of clinical trials at all stages in a product's life cycle are funded by the pharmaceutical industry, and the industry now spends more on medical research than do the National Institutes of Health in the USA (Moses 2015). Results and conclusions that are unfavorable to the sponsor (i.e. studies that find an expensive drug similarly or less effective or more harmful than drugs used to treat the same condition) can pose considerable financial risks to companies.

Several systematic reviews have documented that pharmaceutical industry sponsorship of drug studies is associated with findings that are favorable to the sponsor's product (Bekelman 2003; Lexchin 2003; Schott 2010a; Sismondo 2008a). There are several ways that industry can sponsor a study, including single-source sponsorship, shared sponsorship, and provision of free drugs or devices only. There are also several potential ways that industry sponsors can influence the outcome of a study, including the framing of the question, the design of the study, the conduct of the study, how data are analyzed, selective reporting of favorable results, and spin in reporting conclusions (Bero 1996; Lexchin 2012; Sismondo 2008b). Although some journals now require that the role of the sponsor in the design, conduct and publication of the study be described, this practice is not widespread (Tuech 2005). In addition, some have argued that because industry sponsored studies are often conducted for regulatory purposes, their methods must meet high standards (Rosefsky 2003). Therefore, it is important to examine differences not only in the outcomes of industry versus non-industry sponsored studies, but also differences in the methods or risks of bias.

## Why it is important to do this review

This systematic review is the update of an original systematic review by three of the authors (Lundh 2012), which investigated whether sponsorship by industry is associated with the publication of outcomes favorable to the sponsor. That review is now out of date. Developments, such as the adoption of trial registration could lessen the bias associated with industry sponsorship, as publication bias can be more readily detected (DeAngelis 2004). Furthermore, companies now publish results in trial registries suggesting a move toward increased transparency (Potthast 2014; Schwartz 2016). However, this may not be the case as a recent study found that reporting bias is also prevalent in registered trials, particular in industry sponsored trials (Jones 2013). In addition, the release of internal industry documents as a result of settlement agreements resulting from litigation against drug companies has revealed examples of industry manipulation of the conduct and publication of studies (Fugh-Berman 2010; Ross 2008; Steinman 2006; Vedula 2009).

# OBJECTIVES

The objectives were to investigate whether:

- sponsorship of drug and device studies by the pharmaceutical and device industries is associated with outcomes, including conclusions, that are favorable to the sponsor;
- drug and device studies sponsored by the pharmaceutical and device industries differ in their risk of bias compared with studies with other sources of sponsorship.

# METHODS

## Criteria for considering studies for this review

### Types of studies

This review includes reports of empirical studies that investigate samples of primary research studies. To avoid confusion we will use the terms 'studies' for the primary research studies and 'papers' for the reports of empirical studies of primary research studies. We will use the term trials to describe studies of a randomized clinical trial design.

We included papers of cross-sectional studies, cohort studies, systematic reviews or meta-analyses that quantitatively compared primary research of human drug or medical device studies sponsored by the pharmaceutical or device industries with studies that had other sources of sponsorship. These papers could report the results of methodological studies or systematic reviews that had a prespecified subgroup or sensitivity analysis by sponsorship source. We also included papers investigating sources of heterogeneity (e.g. using meta-regression) if sponsorship was investigated. Drugs were defined as medications that require approval by a regulatory authority as a prescription drug, recognizing that these approval standards vary worldwide. Devices were defined based on the Food and Drug Administration (FDA) definition as instruments intended for use in the diagnosis, treatment or prevention of disease.

We excluded papers without quantitative data related to our primary or secondary outcomes. We excluded papers of the effects of sponsorship by non-pharmaceutical or non-device (e.g. tobacco, food or chemical) industries, and papers that evaluated the effectiveness of herbal supplements or medical procedures. Papers examining mixed interventions (e.g. pharmaceuticals and educational interventions) were included if drug or device data were reported separately or could be obtained from the authors.


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

We excluded papers that quantitatively compared the association of sponsorship and results of syntheses of research studies (i.e. systematic reviews or meta-analyses) or pharmacoeconomic studies of drugs or devices. We also excluded analyses of pharmacokinetic studies and studies restricted to non humans (e.g. animal or cell cultures).

Only papers published in full, including structured research letters, were included. We excluded unstructured letters to the editor and conference abstracts. This decision was based on the poor reporting quality of data in letters and conference abstracts encountered in a previous version of our review (Lexchin 2003). A comment to the previous version of our review (Lundh 2012) suggested that the exclusion of conference abstracts and letters could have introduced publication bias. Therefore, we included conference abstracts and all types of letters in a sensitivity analysis (see below). We had no language restrictions.

### Types of data

Drug and device papers including human research studies comparing drug to placebo, device to sham, drug to drug, drug to device, device to device, or mixed comparisons where the effectiveness, efficacy or harms of the drug or device were evaluated. A few papers included data from both unpublished and published studies. If data were reported separately for the published studies or were available from the authors we used data from published studies only. The reason for this decision was that published studies represent what is available to users of the medical literature and our focus was on assessing biases in published studies.

### Types of methods

We defined sponsorship as funding or provision of free drug or devices. Drug or device studies with pharmaceutical or device industry funding versus those with other or undisclosed funding were included. We extracted the definition of industry funding verbatim from the included papers (see Data extraction and management) and reported this in the 'Characteristics of included studies' table. For analysis, we grouped the definitions into a variety of categories, including 100% pharmaceutical or device company funding, 100% non-industry funding, mixed funding (e.g. non-industry and industry collaboration), free provision of drug or device only, and undisclosed funding.

We included papers that compared industry sponsored studies with non-industry sponsored studies and also papers that compared studies of products by competing manufacturers (i.e. studies sponsored by the manufacturer of the test treatment with studies sponsored by the manufacturer of the control treatment); we analyzed the two types of papers separately.

### Types of outcome measures

#### Primary outcomes

We included two primary outcomes.

- Whether the results were favorable to the sponsor.
- Whether the conclusions were favorable to the sponsor.

We used the definition of favorable results as described in the methods of the included papers. For efficacy results, most papers considered favorable results to be those that were statistically significant (e.g. $P < 0.05$ or a 95% confidence interval excluding the possibility of no difference) in favor of the sponsor's product. Based on the previous review (Lundh 2012), which found very few studies that reported results unfavorable to the sponsor, unfavorable results were combined with studies that reported results that were neutral or not statistically significant. For harms results, most papers regarded favorable results to be those where harms results were not statistically significant (e.g. $P > 0.05$ or a 95% confidence interval including the possibility of no difference) or results that had a statistically significant higher number of harms in the comparator group.

Conclusions in which the sponsor's product was preferred over the control treatment were considered favorable to the sponsor. For conclusions we did not distinguish between efficacy and harms, as conclusions are often overall qualitative judgements based on a benefit to harm balance.

#### Secondary outcomes

We included three secondary outcomes.

- The size of the effect estimate in industry sponsored studies versus those with other sources of sponsorship.
- The risk of bias in industry sponsored studies versus those with other sources of sponsorship.
- The concordance between study results and conclusions, i.e. whether the conclusions agreed with the study results, in industry sponsored studies versus those with other sources of sponsorship.

We included papers that reported at least one of these secondary outcomes, even if it reported neither of the primary outcomes.

## Search methods for identification of studies

### Electronic searches

In this update, we searched Ovid MEDLINE (R) In-Process and other non-indexed citations and Ovid MEDLINE (R) (2010 to February 2015), Ovid Embase (2010 to February 2015) and the Cochrane Methodology Register (2015, Issue 2) (Wiley InterScience Online). We searched the Web of Science (June 2015) for papers that cited any of the papers included in our review.


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

### Search strategy

We used the strategy shown in Appendix 1 for Ovid MEDLINE and adapted it for the other databases.

### Searching other resources

Other sources of data included author files, searches of reference lists of included papers and previous systematic reviews.

## Data collection and analysis

### Selection of studies

Two pairs of assessors (LB and JS or BM and JL) screened the titles and abstracts, when available, of all retrieved records for obvious exclusions, and assessed the remaining papers based on full text. Any disagreements were resolved by consensus and reasons for exclusions of potentially eligible papers are described in the 'Characteristics of excluded studies' table. There was no need for translation of non-English papers.

### Data extraction and management

Two pairs of assessors (AL and JS or BM and JL) independently extracted data from included papers; differences in data extraction were resolved by consensus.

We extracted data on the following.

- Year published.
- Country of corresponding author.
- Study objective.
- Study design used in the paper (cohort, cross-sectional, systematic review or meta-analysis, other).
- Study domain - descriptive (e.g. oncology drug trials).
- Study domain - category (drug/device class, specific disease, medical specialty/type of diseases, mixed).
- Type of studies (drug, device, drug and device, mixed).
- Type of comparisons (drug versus drug, drug versus placebo, device versus device, device versus sham, device versus drug, mixed, other).
- Sample strategy used to locate research studies (electronic search only, electronic plus other, sampling of journals, sampling by venue (e.g. conference abstracts)).
- Whether there were language restrictions on the search.
- Number of studies included in the sample.
- Time period covered by studies in the paper.
- Sponsorship categories coded in the paper. Categories were:
  - 100% pharmaceutical/device company funded;
  - 100% non-profit funded;
  - mixed funding - e.g. non-industry and industry collaboration;
  - provision of drug or device only; and
  - undisclosed funding.
- Sponsorship categories used in analysis in the paper (e.g. 100% industry funded grouped with mixed funding for industry category).
- Description of role of the sponsor (if any). For example, definition of the sponsor's role in the design, implementation or reporting in the sample of studies.
- Criteria used to assess risk of bias of the studies included in the paper.
- Primary purpose of the study.
- Whether the paper commented on appropriateness of comparators.
- Data on sponsorship and results.
- Data on sponsorship and conclusions.
- Data on sponsorship and effect size.
- Data on sponsorship and risk of bias.
- Data on sponsorship and concordance between study results and conclusions.
- Additional relevant data.
- Funding source of included paper. As this item was not included in the previous version of the review we also extracted data from papers included in the previous version.

### Assessment of risk of bias in included studies

Since there are no validated criteria for assessing risk of bias in these types of papers, we developed our own criteria. We reviewed papers for high, low or unclear risk of bias for each of four criteria. If a criterion was met, it was regarded as having low risk of bias, and high risk of bias otherwise. If we could not determine whether a criterion was met, we coded it as unclear. We used the following criteria:

- whether explicit and well-defined criteria that could be replicated by others were used to select studies for inclusion/exclusion;
- whether there was an adequate study inclusion method, with two or more assessors selecting studies;
- whether the search for studies was comprehensive; and
- whether methodological differences and other characteristics that could introduce bias were controlled for or explored.

### Measures of the effect of the methods

We performed a meta-analysis of the papers that reported the association of sponsorship with favorable study outcomes in cases where a pooled risk ratio (RR) and its 95% confidence interval could be computed.

The definition of a favorable outcome varied among papers. In some papers favorable outcomes were defined as those that were favorable to the sponsor's product and in others favorable to the test treatment. This difference in terminology did not matter when the comparison was between active treatment and placebo, since the


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

sponsor's product was the active treatment and not placebo. For head-to-head comparisons, however, the sponsor could be either the manufacturer of the test treatment or the control treatment. In these cases, when data were available, we recoded outcomes as to whether they were favorable to the sponsor's product.

We separately analyzed papers of industry sponsored head-to-head studies, comparing studies sponsored by the manufacturer of the test treatment with studies sponsored by the manufacturer of the comparator treatment. This was done by assigning the newest treatment (most recent FDA approval date) as the 'test' treatment and the older treatment as the 'comparator' treatment using similar methods as described by Bero and colleagues (Bero 2007) and comparing the number of studies favorable to the test treatment in the two groups (i.e. sponsor produces test treatment or sponsor produces comparator treatment).

At the time many of the papers were published, the approach was to assess the methodological quality of studies as opposed to an assessment of the risk of bias of studies. We therefore recoded the data on methodological quality into 'Risk of bias' categories. So, for example, a trial with adequate concealment of allocation was coded as low risk of bias and a trial with inadequate concealment of allocation as high risk of bias. Some papers assessed risk of bias by summarizing results for individual domains into an overall methodological quality score (i.e. a scale approach). There are substantial methodological problems related to quality scales (Jüni 1999), and their use is not recommended. We therefore did not combine the results obtained with these scales, but report the results descriptively. The included papers assessed blinding using different approaches. Some papers rated blinding for the study overall, for example whether a study used matching placebo tablets (which could be considered blinded) and some papers assessed who was blinded, similar to the Cochrane 'Risk of bias' tool. The Cochrane 'Risk of bias' tool assesses blinding to protect against performance bias (e.g. clinicians or patients are blinded) and to protect against detection bias (e.g. outcome assessors are blinded). We therefore categorized each 'Risk of bias' assessment into the items blinding-overall, blinding-performance bias and blinding-detection bias.

### Dealing with missing data

We contacted authors of the original papers in an attempt to obtain missing data. If papers included studies reporting conflicts of interest, but not the source of funding, we contacted the authors in order to obtain separate data for funding. In total, we contacted authors of eight papers included in this update and received additional data for five of these papers.

### Assessment of heterogeneity

We assessed heterogeneity using $I^2$. We defined substantial statistical heterogeneity as an $I^2 > 50\%$ (Higgins 2011a).

### Data synthesis

We used Review Manager (RevMan 2014) to analyze data. For dichotomous data we used the Mantel-Haenszel random-effects model to create a pooled RR. In the previous version of this review (Lundh 2012), we used a fixed-effect model as default and a random-effects model when substantial heterogeneity was observed. However, due to the large clinical heterogeneity between papers (e.g. study domains, study designs and definition of outcomes), we decided that a random-effects model was more appropriate.

### Subgroup analysis and investigation of heterogeneity

We considered the following factors as potential explanations for heterogeneity and investigated them in separate subgroup analyses for our primary outcomes.

- We hypothesized that the association of industry sponsorship and favorable outcomes may be larger in high risk of bias papers. We assessed overall risk of bias of the included papers using the criteria described in 'Assessment of risk of bias in included studies'. We regarded papers with adequate study inclusion, a comprehensive search and controlling for bias as having a low risk of bias; others as having a high risk. We compared low risk of bias papers with high risk of bias papers in a subgroup analysis.
- We compared papers of drug studies with device studies, as the mechanisms of influencing study outcomes may differ between the industries. For example, drug trials are more regulated than device trials, which could have an influence on biases in the design, conduct and reporting of the trials. We compared this in a subgroup analysis.
- As the study domain might contribute to heterogeneity, we compared papers on specific treatments or diseases with papers of mixed domains in another subgroup analysis.

### Sensitivity analysis

We undertook the following sensitivity analyses to test the robustness of our findings for our primary outcomes.

- The primary analyses compared the number of favorable results and conclusions in papers with industry sponsorship to those with other sources of sponsorship; 'industry sponsorship' included 100% pharmaceutical/device company funding, mixed funding and provision of drug or device only. 'Non-industry sponsorship' included 100% government funding, 100% non-industry funding and undisclosed funding. In a sensitivity analysis, we excluded those studies with mixed funding sources and those with funding consisting solely of free product from the 'industry sponsorship' category, and excluded studies with undisclosed funding from the category of 'non-industry sponsorship', to determine if these had an impact on the initial analysis. As noted under 'Data extraction and management', we were reliant on how the studies in our review defined 'funding'.


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

- A sensitivity analysis restricted to papers that adjusted for confounders (e.g. adjusted for sample size and concealment of allocation using logistic regression) using adjusted estimates. We used the generic inverse variance method to pool adjusted odds ratios in a random-effects model.
- A sensitivity analysis where all analyses were based on a fixed-effect model.
- One paper (Finucane 2004), included unpublished abstracts from conference proceedings. One paper (Lynch 2007), included manuscripts submitted to a medical journal of which the majority were never published. However, based on the reported data it was not possible to extract data from the published studies separately. As these two papers included unpublished data and we planned to analyze only published data, we conducted a sensitivity analysis that excluded these two papers.
- Many of the included papers investigated similar domains (e.g. antidepressants or oncology drugs) or included studies from similar journals in overlapping time-periods. This is likely to lead to double counting if data from the same studies are included more than once and to an overestimate of the precision of effect estimates. Due to the way data were reported in the papers, it was not possible ensure that data was not double counted. Instead we performed a sensitivity analysis restricted to papers on specific treatments or diseases where none of the other included papers were related to the same domain.
- We included letters and conference abstracts reporting quantitative data in a sensitivity analysis.

**Quality of Evidence**

We created a 'Summary of findings' table using the GRADE approach (Higgins 2011a) and using the MAGICapp software (MAGICapp; Vandvik 2013).

# RESULTS

## Description of studies

See:Characteristics of included studies; Characteristics of excluded studies.

### Results of the search

See: Figure 1.


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Figure 1. Study flow diagram.**




After removal of duplicates, 3052 references were identified. From reading titles and abstracts, 2925 were eliminated as being not relevant to the review. Full-text papers were obtained for 127 references. From these 127 papers, 104 papers were excluded (see Characteristics of excluded studies) and 23 included (see Characteristics of included studies). Four additional papers were included from searching additional sources and 48 were included from the previous version of the review (see Characteristics of included studies). In total, 75 papers were included.

## Included studies

See: Characteristics of included studies.

The 75 papers were published between 1986 and 2015. Seventy-two papers included mainly published studies, one included studies presented at a conference, one included studies submitted to a medical journal, and one included studies submitted to eight medical journals. Fifty-seven papers included only drug studies, three only device studies, two drug and device studies and 13 included different types of interventions (e.g. drugs, devices, behavioral interventions). Thirty-four papers included studies related to specific drug classes, 16 related to specific medical specialties or types of diseases (e.g. endocrinology), 10 related to a specific disease, three related to a specific type of device, 11 included all types of research studies, and one did not state the domain. Various aspects of medicine were covered, but 16 (21%) papers were restricted to psychiatric diseases or drugs and eight (11%) to cancer treatment. Fifty-eight papers included only clinical trials, two only observational studies, and 15 both clinical trials and observational studies. Thirteen papers included only drug versus drug comparisons, eight only drug versus placebo, 49 mixed comparisons (e.g. drug


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

versus drug, drug versus placebo) and five did not describe the kind of comparisons. The median number of included studies per paper was 105 (range: nine to 930). Of the 75 papers, 27 reported data on both favorable outcomes and risk of bias, 44 on favorable outcomes only, and four on risk of bias only. Twenty-five papers were non-industry funded, two were industry funded (Freemantle 2000; van Lent 2014), one was funded by both industry and non-industry sources (Lynch 2007), 17 reported that they did not receive funding and 30 did not reported on funding.

## Risk of bias in included studies

See: Figure 2; Figure 3.

**Figure 2. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included papers.**





Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Figure 3. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included paper.**





**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

Sixty-eight papers had low risk of bias for the selection criteria for inclusion of studies, three were unclear and four had high risk. Twenty-one papers had low risk of bias for the study inclusion process, 40 were unclear and 14 had high risk. Sixty-six papers had low risk of bias from the search, one was unclear and eight had high risk. Thirty-one papers had low risk of bias due to lack of control for bias in the studies, five were unclear and 39 had high risk. Fourteen papers were regarded as having an overall low risk of bias and 61 as a high risk of bias according to our criteria.

## Effect of methods

See: **Summary of findings for the main comparison** Industry sponsored compared to non-industry sponsored studies for research outcome

### Favorable results: industry sponsored versus non-industry sponsored studies

See: Summary of findings for the main comparison

Twenty-six papers, including 3081 studies (3062 drug studies and 19 device studies), reported on sponsorship and efficacy results; 25 could be combined in a pooled analysis. An analysis based on these 25 papers, including 2923 studies, found that industry sponsored studies more often had favorable efficacy results (e.g. those with significant P values) compared with non-industry sponsored studies, risk ratio (RR): 1.27 (95% confidence interval (CI): 1.17 to 1.37), $I^2$: 28% (Analysis 1.1). The paper that could not be included in the pooled analysis (Bhandari 2004), which had included 158 drug studies in general medicine, found similar results, odds ratio (OR): 1.6 (95% CI: 1.1 to 2.8).

Four papers, including 826 studies, did not find a difference in favorable harms results in industry sponsored studies compared with non-industry sponsored studies, RR: 1.37 (95% CI: 0.64 to 2.93), $I^2$: 96%. (Analysis 1.2). The results of one paper (Als-Nielsen 2003), were opposite in direction to the other papers and resulted in the substantial heterogeneity. .

### Favorable results: industry sponsorship by test treatment company versus industry sponsorship by comparator treatment company

Three papers, including 151 studies (all drug trials), compared efficacy results of trials sponsored by the manufacturer of the test treatment with trials sponsored by the manufacturer of the comparator treatment; two could be combined in a pooled analysis. An analysis based on these two papers (Bero 2007; Rattinger 2009), which included 131 industry sponsored trials of statins and thiazolidinediones, found that trials were much more likely to favor the test treatment when they were sponsored by the manufacturer of the test treatment than when they were sponsored by the manufacturer of the comparator treatment, RR: 3.88 (95% CI: 1.26 to 11.94), $I^2$: 50% (Analysis 2.1). The paper that could not be included in the pooled analysis, which had included 20 selective serotonin reuptake inhibitor head-to-head trials, found that two trials favored the sponsor's drug, 18 had similar efficacy and none favored the comparator drug (Gartlehner 2010).

### Favorable conclusions: industry sponsored versus non-industry sponsored studies

See: Summary of findings for the main comparison

Thirty-two papers, including 5258 studies (4761 drug studies and 497 device studies), reported on sponsorship and conclusions, 29 of which could be combined in a pooled analysis. An analysis based on these 29 papers, including 4583 studies (4179 drug studies and 404 device studies), found that industry sponsored studies more often had favorable conclusions than non-industry sponsored studies, RR: 1.34 (95% CI: 1.19 to 1.51), $I^2$: 92% (Analysis 3.1). Three papers could not be included in the pooled analysis due to the reporting of data. Of these, one paper reporting on 301 psychiatric drug studies (Kelly 2006) found that industry sponsored studies more often had favorable conclusions than non-industry sponsored studies ($P < 0.001$) and similar findings were reported in a paper of 59 trials of antipsychotics ($P = 0.02$) (Montgomery 2004). A paper on 315 gastroenterology trials (222 drug trials and 93 device trials) did not find a difference in conclusions between industry sponsored trials and non-industry sponsored trials (industry: 86% favorable, non-industry: 83% favorable; $P = 0.57$) (Brown 2006).

### Favorable conclusions: industry sponsorship by test treatment company versus sponsorship by comparator treatment company

Five papers, including 348 drug trials, compared conclusions of studies sponsored by the manufacturer of the test treatment with studies sponsored by the manufacturer of the comparator treatment, and three could be combined in a pooled analysis. These three papers (Bero 2007; Heres 2006; Rattinger 2009) including 154 industry sponsored trials of statins, antipsychotics and thiazolidinediones, found that trials were much more likely to favor the test treatment when they were sponsored by the manufacturer of the test treatment than when they were sponsored by the manufacturer of the control treatment, RR: 5.92 (95% CI: 2.80 to 12.54). No heterogeneity was observed (Analysis 4.1). A paper including 138 psychiatric drug studies (Kelly 2006) had similar findings, RR 2.80 (95% CI: 2.02 to 3.88), and a paper on 56 non-steroidal anti-inflammatory drug (NSAID) trials (Rochon 1994), found that 16 trials favored the sponsor's drug, 40 concluded that the drugs had similar effect and none favored the comparator drug.


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

### Effect size: industry sponsored versus non-industry sponsored studies

Twenty-four papers, including 1517 studies (1476 drug studies and 41 device studies), reported on sponsorship and effect size, but could not be pooled due to differences in reporting of data. The results were heterogeneous and are described in Table 1 below.

**Table 1. Effect size in industry and non-industry sponsored studies.**

| Paper ID | Study domain | Effect size of industry versus non-industry studies |
|---|---|---|
| *Efficacy* | | |
| Als-Nielsen 2003 | 370 drug RCTs in Cochrane reviews | Primary outcome. Mean z-scores: industry: -1.48 (95% CI: -1.77 to -1.19); mixed: -1.77 (95% CI: -2.28 to -1.26); non-industry: -1.20 (95% CI: -1.81 to -0.59); not stated: -1.20 (95% CI: -1,49 to -0.91) (P > 0.05) |
| Avni 2014 | 36 RCTs of antibiotics for pneumonia | No difference in mortality and clinical failure. |
| Barden 2006 | 176 acute pain and migraine drug RCTs | No difference in pain relief. |
| Clark 2002 | 19 RCTs of erythropoietin for cancer-related anemia | Number of transfusions: industry: OR: 0.43 (95% CI: 0.35 to 0.54); non-industry OR: 0.22 (95% CI: 0.11 to 0.45) |
| Corona 2014a | 25 RCTs of testosterone for male sexual dysfunction | Erectile dysfunction. Standardized mean difference (SMD): industry: SMD: 1.36 (95% CI: 0.55 to 1.16) ; non-industry: SMD: 0.33 (95% CI: 0.13 to 0.54) (P = 0.02) |
| Davis 2008 | 124 RCTs of 2nd generation versus 1st generation antipsychotics | Effect on psychotic symptoms (P = 0.57). |
| Djulbegovic 2013 | 126 oncology drug RCTs | Primary outcome: industry: OR/hazard ratio (HR): 0.61 (99% CI: 0.47 to 0.78); non-industry OR/HR: 0.86 (99% CI: 0.74 to 1.00) (P = 0.003). Overall survival (P = 1.00) |
| Etter 2007 | 34 RCTs of nicotine replacement therapy | Effect: industry: OR: 1.90 (95% CI: 1.67 to 2.16); non-industry: OR: 1.61 (95% CI: 1.43 to 1.80) (P = 0.06) |
| Freemantle 2000 | 105 RCTs of selective serotonin reuptake inhibitors versus alternative antidepressants | No difference in effect. |
| Jinapriya 2011 | 31 of prostaglandin analogues for open-angle glaucoma | Effect on intraocular pressure (P = 0.83). |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

(*Continued*)

| | | |
|---|---|---|
| Killin 2014 | 14 RCTs of donepezil for Alzheimer's disease | Effect on cognitive scales: industry: SMD: 0.46 (95% CI: 0.38 to 0.54); non-industry: SMD: 0.33 (95% CI: 0.18 to 0.48) (P = 0.13) |
| Lubowitz 2007 | 23 studies of chondrocyte implantation | No difference in effect on various outcomes. |
| Moncrieff 2003 | 9 RCTs of clozapine versus conventional antipsychotics | Psychotic symptoms: industry: SMD: -0.83 (95% CI: -1.06 to -0.61); non-industry: SMD: -0.21 (95% CI: -0.34 to -0.07) (P < 0.001) |
| Naci 2014 | 183 statin RCTs | No difference in effect on mean change in LDL levels, after controlling for statin dose |
| Popelut 2010 | 41 clinical studies of dental implants | Failure rates. Industry versus non-industry: OR: 0.21 (95% CI: 0.12 to 0.38) |
| Rösner 2010 | 24 RCTs of acamprosate for alcohol dependence | Return to any drinking: industry: RR: 0.88 (95% CI: 0.80 to 0.97); mixed: RR: 0.84 (95% CI: 0.78 to 0.89) ; non-industry: RR: 0.86 (95%: CI 0.81 to 0.91) |
| Rösner 2010a | 26 RCTs of opioid antagonists for alcohol dependence | Return to any drinking: industry: RR: 0.90 (95% CI: 0.78 to 1.05); non-industry: RR: 0.84 (95% CI: 0.77 to 0.91) |
| Vlad 2007 | 15 RCTs of glucosamine for osteoarthritis | Primary outcome: industry: SMD: 0.47 (95% CI: 0. 24 to 0.70); non-industry: SMD: 0.05 (95% CI: -0.32 to 0.41) (P = 0.05) |
| Zhang 2013 | 12 RCTs of 2nd generation versus 1st generation antipsychotics | Short-term symptom reduction and response (P = 0. 007 and P = 0.046) |
| *Harms* | | |
| Corona 2014 | 26 RCTs of testosterone therapy for men | Cardiovascular events: industry: OR: 1.07 (95% CI: 0. 54 to 2.24); non-industry: OR: 0.94 (95% CI: 0.39 to 2.24) |
| Kemmeren 2001 | 9 observational studies of 3rd generation versus 2nd generation oral contraceptives | Thrombosis: industry: OR: 1.3 (95% CI: 1.0 to 1.7); non-industry: OR 2.3 (95% CI: 1.7 to 3.2) |
| Ma 2014 | 4 RCTs of fluoxetine for major depressive disorder | Harms: industry: OR: 2.34 (95% CI: 1.62 to 3.36); non-industry: OR: 2.78 (95% CI:1.76 to 4.38) |
| Xu 2013 | 27 RCTs of testosterone therapy for men | Cardiovascular events: industry: OR 0.89 (95%: CI 0. 50 to 1.60); non-industry: OR 2.06 (95% CI: 1.34 to 3.17) (P = 0.03) |
| *Efficacy and dosage* | | |


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

(*Continued*)

| | | |
|---|---|---|
| Sinyor 2012 | 58 industry head-to-head RCTs of antidepressants | Remission: sponsor's drug at higher dose OR: 1.28 (95% CI: 1.11 to 1.47) versus sponsor's drug at comparable or lower dose OR: 1.06 (95% CI: 0.96 to 1.17) (P = 0.04) |

Most papers (19 out of 24) compared effect sizes for efficacy results. Twelve of these papers, including 1131 drug studies, did not find a difference in effect sizes for efficacy estimates between industry sponsored studies and non-industry sponsored studies. In contrast, seven papers, including 262 studies (221 drug studies and 41 device studies) found higher effect sizes of efficacy estimates in industry sponsored studies. Two papers, including 30 drug studies, did not find a difference in effect size of harms between industry sponsored studies and non-industry sponsored studies. In contrast, two papers, including 36 drug studies, found lower effect size of harms in industry sponsored studies. Lastly, a paper on 58 industry-sponsored head-to-head trials of antidepressants (Sinyor 2012), found that the sponsor's antidepressants were often given at a higher dose than the comparator. Effects on remission were higher when the sponsor's drug was given at a higher dose, as compared to trials in which the sponsor's drug was given in comparable or lower dose OR: 1.28 (95% CI: 1.11 to 1.47) versus OR: 1.06 (95% CI: 0.96 to 1.17) (P = 0.04).

### Risk of bias: industry sponsored versus non-industry sponsored studies

Twelve papers, including 1660 studies (1482 drug studies and 178 device studies), compared risk of bias in industry versus non-industry studies using six different composite quality scales (Brown, Cho, Cochrane, Jadad, PEDro or Sackett) and the results were heterogeneous. Seven papers did not find a difference in risk of bias between industry sponsored and non-industry sponsored studies (Cho 1996; Clark 2002; Corona 2014; Jefferson 2009; Lynch 2007; Sung 2013; Vlad 2007), whereas five papers found lower risk of bias (i.e. higher methodological quality scores) in industry sponsored studies (Brown 2006; Djulbegovic 2000; Montgomery 2004; Pengel 2009; Perlis 2005a).

Nine papers, including 913 drug trials, did not find a difference in risk of bias from sequence generation in industry sponsored trials compared with non-industry sponsored trials, RR: 0.99 (95% CI: 0.78 to 1.27), $I^2$: 73% (Analysis 5.1). Sixteen papers, including 1886 trials (1867 drug trials and 19 device trials), did not find a difference in risk of bias from concealment of allocation in industry sponsored trials compared with non-industry sponsored trials, RR: 1.06 (95% CI: 0.85 to 1.31), $I^2$: 71% (Analysis 5.2). Thirteen papers, including 1578 trials (1559 drug trials and 19 device trials), found that industry sponsored trials more often had low risk of bias from overall blinding compared with non-industry sponsored trials, RR: 1.25 (95% CI: 1.05 to 1.50), $I^2$: 72% (Analysis 5.3). Three papers, including 128 drug trials, did not find a difference in risk of performance bias (e.g. blinding of clinicians or patients) in industry sponsored trials compared with non-industry sponsored trials, RR: 1.26 (95% CI: 0.60 to 2.62), $I^2$: 66% (Analysis 5.4). Four papers, including 307 drug trials, found that industry sponsored trials more often had low risk of detection bias (e.g. blinding of outcome assessors) compared with non-industry sponsored trials, RR: 1.47 (95% CI: 1.02 to 2.12). No heterogeneity was observed (Analysis 5.5). Six papers, including 416 drug trials, did not find a difference in risk of bias from loss to follow-up in industry sponsored trials compared with non-industry sponsored trials, RR: 1.05 (95% CI: 0.92 to 1.18), $I^2$: 2% (Analysis 5.6). Two papers, including 193 drug trials, did not find a difference in risk of reporting bias in industry sponsored trials compared with non-industry sponsored trials, RR: 1.49 (95% CI: 0.61 to 3.60), $I^2$: 79% (Analysis 5.7).

### Concordance between study results and conclusions: industry sponsored versus non-industry sponsored studies

Six papers, including 751 drug studies, reported on concordance between study efficacy results (e.g. as judged by their P values) and conclusions. Industry sponsored studies were less concordant than non-industry sponsored studies, RR: 0.83 (95% CI: 0.70 to 0.98), $I^2$: 63% (Analysis 6.1). One paper (Alasbali 2009), including 39 drug studies, found markedly higher lack of concordance in industry studies than the other four papers, and this was the reason for the high heterogeneity between papers.

One paper, of 211 corticosteroid studies with statistically significant harms results, found that industry sponsored studies more often concluded that the drug was safe than non-industry sponsored studies, RR: 3.68 (95% CI: 2.14 to 6.33) (Nieto 2007).

#### Subgroup analysis and investigation of heterogeneity

For efficacy results, the association between industry sponsorship and favorable results was stronger in papers with a low risk of bias than in those with a high risk of bias, RR: 1.46 (95% CI: 1.25 to 1.71) versus RR: 1.20 (95% CI: 1.11 to 1.30) (test for


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

subgroup differences P = 0.03) (Analysis 7.1). For harms results, the association between industry sponsorship and favorable harms results differed in papers with a low risk of bias compared with those with a high risk of bias, RR: 0.82 (95%: 0.72 to 0.93) versus RR: 1.87 (95% CI: 1.54 to 2.27) (test for subgroup differences P < 0.0001) (Analysis 7.2). For conclusions, the differences between the groups went in the same direction as for efficacy results, RR: 1.42 (95% CI: 1.12 to 1.79) versus RR: 1.32 (95% CI: 1.15 to 1.50) (test for subgroup differences P = 0.60) (Analysis 7.3).

For efficacy results, the association between industry sponsorship and favorable results were opposite in direction in drug studies compared with device studies, RR: 1.27 (95% CI: 1.17 to 1.38) versus RR: 0.50 (95% CI: 0.26 to 0.97) (test for subgroup differences P = 0.006) (Analysis 7.4). However, the analysis only included 19 device studies, of which only three were non-industry. We did not find a difference in the association between sponsorship and conclusions in drug studies compared with device studies (test for subgroup differences P = 0.98) (Analysis 7.5) or between sponsorship and efficacy results or conclusion in studies limited to specific treatments or diseases compared with studies of mixed domains (test for subgroup differences P = 0.67 and P = 0.49 ) (Analysis 7.6; Analysis 7.8). However, for harms results the association between industry sponsorship and favorable harms results differed in papers with mixed study domain compared with those of specific treatments or diseases, RR: 0.82 (95%: 0.72 to 0.93) versus RR: 1.87 (95% CI: 1.54 to 2.27) (test for subgroup differences P < 0.0001) (Analysis 7.7).

#### Sensitivity analysis

Our re-analyses of the outcomes using variations in definition of sponsorship categories gave similar results as our main analyses for efficacy results, harms results and conclusions (Analysis 8.1; Analysis 8.2; Analysis 8.3). Our analyses, taking into account papers that adjusted for confounding, based on pooling adjusted odds ratios, confirmed our findings that industry sponsored trials compared with non-industry sponsored trials more often had favorable results, OR: 3.15 (95% CI: 2.07 to 4.80), $I^2$: 0% and favorable conclusions, OR: 3.13 (95% CI: 1.66 to 5.93), $I^2$: 38% (Analysis 8.4; Analysis 8.5). Similarly, sensitivity analyses using a fixed-effect model rather than a random-effects model did not affect our results (Analysis 8.6; Analysis 8.8; Analysis 8.9; Analysis 8.10), except for harms results where they changed from RR: 1.37 (95% CI: 0.64 to 2.93) to RR: 1.29 (95% CI: 1.15 to 1.46) (Analysis 8.7). When we excluded papers sampling unpublished studies, it did not affect our analysis on favorable conclusions (Analysis 8.11). The same was found when we limited our analyses to papers from specific domains (i.e. papers on specific treatments or diseases where none of the other included papers were related to the same domain) (Analysis 8.12; ; Analysis 8.14; Analysis 8.15; Analysis 8.16), except for harms results where they changed from RR: 1.37 (95% CI: 0.64 to 2.93) to RR: 1.87 (95% CI: 1.54 to 2.27) (Analysis 8.13). Lastly, if we included the two additional papers that were only published as letters (Mandelkern 1999; Thomas 2002) our analysis on the association between sponsorship and favorable conclusions gave similar results RR: 1.35 (95% CI: 1.20 to 1.52), $I^2$: 91%.

## DISCUSSION

### Summary of main results

We found that drug and device studies sponsored by the manufacturing company more often had favorable efficacy results (e.g. those with statistically significant results, usually defined using P values) and conclusions than those that were sponsored by other sources. The findings were consistent across a wide range of diseases and treatments. We did not find any differences in harms results and risk of bias of drug and device trials sponsored by industry compared with non-industry sponsored trials, except in relation to blinding, where industry sponsored trials seemed to have lower risk of bias. Industry sponsored studies also had less concordance between results and conclusions than non-industry sponsored studies. The evidence from device studies was limited due to fewer data, but the association between sponsorship and favorable conclusions was similar to drug studies.

#### Reasons for observed heterogeneity

For the association between sponsorship and favorable efficacy results of drug and device studies the data had acceptable heterogeneity, but heterogeneity for the association between sponsorship and harms results and study conclusions was substantial with an $I^2$ of 96% and 92%, respectively.

The reason for the large heterogeneity related to harms results is attributed to the results of the Als-Nielsen paper (Als-Nielsen 2003), that was opposite in direction to the other papers (i.e. industry had less favorable harms results as opposed to more favorable harms results) (Halpern 2005; Kemmeren 2001; Nieto 2007), and the interaction tests in the subgroup analyses were statistically significant. The Als-Nielsen paper differs in some aspects from the three other included papers. First, it samples trials from various therapeutic areas, whereas the other papers each deal with harms results of single-drug classes (HIV drugs, oral contraceptives and inhaled corticosteroids). Second, the three papers related to single-drug classes had harms results as their primary outcome and only included studies with quantitative data, but Als-Nielsen had harms as a secondary outcome and also included trials without quantitative harms data. The number of trials without harms data was high, particularly in the non-industry group, 28% and 52%, respectively. Third, Als-Nielsen only included trials, whereas Halpern 2005 included both trials and observational


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

studies and Kemmeren 2001 and Nieto 2007 only included observational studies. Finally, we assessed Als-Nielsen 2003 as having an overall low risk of bias, compared to high risk of bias in the other three papers.

In relation to the substantial heterogeneity for study conclusions, one reason was likely that the coding of favorable results was similar across the different papers, using statistical significance as the cut-off, but coding varied for favorable conclusions. Some papers did not describe what they considered a favorable conclusion and this would involve some judgement. Others used scales, but for similar scales the cut-off varied between papers. For example, on the same six-point scale one paper used four as the cut-off (Djulbegovic 2000) and another used six as the cut-off (Als-Nielsen 2003).

Also, the proportion of studies with favorable conclusions in the non-industry sponsored group might have contributed to the size of the association and thereby the heterogeneity. For example, while the Chard and Liss papers (Chard 2000; Liss 2006) had a similar proportion of favorable industry sponsored studies (both 98%), they reported very different proportions of favorable non-industry sponsored studies (32% and 97%) and this explains why the risk ratios reported in the two studies were not the same: RR: 3.03 in Liss and RR: 1.01 in Chard. Variations in the definition of favorable conclusions might explain why the risk ratios reported in the two papers were not similar. For example, in the Chard paper, a conclusion was coded as favorable if the study authors supported the use of the treatment, even in the absence of a statistically significant result.

Our subgroup analyses stratifying papers in relation to risk of bias (low versus high), type of intervention (drug versus device) or study domain (mixed versus specific treatments or diseases) did not explain the observed heterogeneity, though this was a simplistic comparison and other factors might also contribute to heterogeneity.

We found mixed results on the relationship between sponsorship and effect size, with most papers not finding a difference. All but one of these papers were restricted to specific treatments, which may explain the different findings. A recent study of systematic reviews of nine different drugs found that the influence of reporting biases on effect sizes varied considerably between drugs (Hart 2012). Furthermore, one paper found that even when adjusting for effect size, industry sponsored studies more often had favorable conclusions, compared with non-industry sponsored studies (Als-Nielsen 2003). Therefore, while the direction of the relationship between sponsorship and favorable outcomes was consistent, the size of the effect likely varies depending on the type of treatment or treated condition.

#### Reasons for favorable outcomes in industry sponsored studies

The pharmaceutical and medical device industries have strong interests in scientific publications that present their products positively, as publications are the basis of regulatory, purchasing, and medical decisions. These interests can influence the design, conduct and publication of studies in ways that make the sponsor's product appear better than the comparator product (Bero 1996).

Several possible factors can explain the relationship between industry sponsorship and favorable outcomes. It has been argued that since many industry sponsored studies are undertaken to fulfill regulatory requirements, industry sponsored studies could have a lower risk of bias than non-industry sponsored studies (Rosefsky 2003). Even if this were true, it would not explain the association of industry sponsorship and favorable efficacy results and conclusions. In addition, we did not find evidence for differences in risk of bias except in relation to blinding, where industry sponsored trials tended to have a lower risk of bias, even when restricted to head-to-head trials (Bero 2007). The papers comparing blinding between trials with different sponsorship often used a description of double blinding as an indicator for low risk of bias. Double blinding is an inconsistent term and does not ensure that, for example, outcome assessors are blinded (Devereaux 2001). The more frequent use of double blinding may therefore be a reporting issue, with industry trials being better reported. This is further substantiated by the fact that nearly all the papers finding a higher methodological quality score in industry studies used the Jadad scale, a scale which has been criticized for having more focus on the quality of reporting than on methodological quality (Lundh 2008).

A few papers assessing a more specific definition of blinding related to performance bias and detection bias also found that industry sponsored studies had lower risk of bias. Evidence also suggests that for non-industry trials, companies may prevent proper blinding by restricting access to placebo drugs (Christensen 2012), and therefore differences in adequate blinding may be real. In addition, double blinding can be used as a proxy for low risk of bias and trials without double blinding are on average more likely to have favorable results (Pildal 2007). The effect of this bias is in the opposite direction of our findings, as it would lead to industry sponsored studies having less favorable results and conclusions, and our findings can therefore, not be explained by differences in risk of bias related to blinding between industry and non-industry sponsored studies.

Another possible explanation for our findings could be that industry studies have larger sample sizes, and would have a higher chance of achieving statistically significant results. Although industry trials seem in general to be of larger size (Als-Nielsen 2003; Booth 2008; Bourgeois 2010; Djulbegovic 2013; Etter 2007; Flacco 2015; Perlis 2005a), when we restricted our analysis to studies controlling for sample size and other confounders, the relationship between industry sponsorship and favorable results or conclusions was still present.

Industry representatives argues that the trials they sponsor are more likely to have favorable outcomes because they fund research that has a high chance of achieving success (Palmer 2003). However,


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

when independent investigators conduct non-industry sponsored trials, they in most cases test treatments that have been approved based on favorable industry trial results. Non-industry sponsored trials would therefore also be expected to achieve successful results, unless they are designed to answer different questions than industry sponsored trials. For example, non-industry sponsored studies may test a new treatment against a well-established treatment, while industry sponsored studies might test the new treatment against placebo or against an outdated, inferior treatment.

Accordingly, it seems most plausible that industry achieves overly positive results through a variety of biasing choices in the design, conduct and reporting of their studies. For example, industry protocols might include inferior comparators that will increase the chance of their product's success. Djulbegovic and colleagues (Djulbegovic 2003) have argued that industry sponsored studies violate equipoise by choosing inferior competing treatment alternatives. Previous studies have found that industry sponsored trials more often use placebo control (Als-Nielsen 2003; Djulbegovic 2000; Dunn 2013; Estellat 2012; Katz 2006; Lathyris 2010), active comparators in inferior doses (Rochon 1994; Safer 2002; Sinyor 2012), or inappropriate administration of the drugs (Johansen 1999). Industry may also selectively choose less clinical relevant outcomes as their primary outcome in order to get a higher chance of achieving an effect. For example, in the paper by Djulbegovic (Djulbegovic 2013) industry sponsored trials had higher effect size than non-industry sponsored trials on primary outcomes, but not overall survival. This could also be one of the possible explanations as to why industry sponsored trials more often have favorable results and conclusions while the effect sizes are often similar when comparing similar outcomes.

Industry sponsored studies may also be biased in the coding of events and their data analysis (Furukawa 2004; Psaty 2008; Psaty 2010). Industry and its sponsored investigators also may selectively report favorable outcomes, fail to publish whole studies with unfavorable results, or publish studies with favorable results multiple times (Chan 2004; Dwan 2008; Gtzsche 2011; McGauran 2010; Melander 2003; Rising 2008; Vedula 2009). While such biases in analyses and reporting have been documented in a number of cases, the papers included in this review focused on comparisons of published studies. Only two papers (Killin 2014; Naci 2014) included in our review compared risk of selective reporting between industry sponsored trials and non-industry sponsored trials and found no difference. However, confidence intervals were wide and the analysis was limited to two types of drugs (donepezil for Alzheimer's disease and statins). Therefore, we are unable to determine the extent to which selective analysis or reporting contribute to our findings. Similarly, we found no difference in harms results between industry sponsored and non-industry sponsored studies. Under-reporting of harms seems to be a major problem in both industry and non-industry sponsored studies with 28% of trials included in Als-Nielsen 2003 not reporting any harms data, which is in line with a recent systematic review that found that a median of 54% studies do not report harms data (Golder 2016).

Favorable conclusions in industry-sponsored trials may also be reached by over-interpreting results and use of spin in conclusions (Boutron 2010). We found that industry sponsored studies had less concordance between results and conclusions compared with non-industry sponsored studies, suggesting that conclusions of industry sponsored studies are less reliable.

It should also be noted that some studies in the non-industry group likely had authors with conflicts of interest related to the pharmaceutical or device industry, which may have influenced their interpretation of study results (Stelfox 1998; Wang 2010), thereby diluting the measured effect of industry bias on study conclusions. Also, we coded studies as non-industry sponsored if they did not state who sponsored the study. As some of these studies were likely industry sponsored, this misclassification will have led to similar bias towards the null. However, in our sensitivity analyses, we excluded studies without sponsorship statements and did not see a change in results.

Further evidence for industry bias stems from our comparison of studies sponsored by the manufacturer of the test treatment with those sponsored by the manufacturer of the control treatment. These studies had the advantage of comparing like with like, as they are restricted to specific drug classes or types of devices and have similar methodologies. Though limited to only three papers on drug trials, the findings show associations that are stronger than the comparison between industry and non-industry sponsored studies. These comparisons are restricted to drugs competing for the same market, which may put pressure on companies to influence outcomes to a greater degree than what is needed in placebo-controlled trials to present the drug in a good light.

In sum, the industry bias associated with favorable efficacy results and conclusions may be mediated by factors other than traditional measures of the risk of bias (e.g. lack of concealment of allocation, blinding and dropout) and sample size. This industry bias may be partially mediated by such factors as the choice of comparators, dosing and timing of comparisons, choice of outcomes, selective analysis, and selective reporting.

## Quality of the evidence

The majority of included papers were regarded as having a high risk of bias. Many lacked information on study conduct and did not control for confounders that could influence the relationship. Nevertheless, we did identify 14 papers with low risk of bias and analyses restricted to these papers actually strengthened the relationship between industry sponsorship and conclusions. In general, there is convincing and consistent evidence for the existence of an industry bias in studies; however, the body of evidence for device studies is not as strong as for drug studies. While many papers, including studies of devices and other interventions, have been published in the surgical field (Amiri 2014; Cunningham 2007; Khan 2008; Leopold 2003; Roach 2008; Shah 2005; Sun


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

2013; Yao 2007), the papers do not report separate data for device studies.

## Potential biases in the review process

We did a comprehensive search, our methods were based on pre-specified criteria in a protocol as outlined in *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0* (Higgins 2011a), and this updated review has substantially increased the number of included papers from our previous review (Lundh 2012). Nevertheless, there are some limitations. First, we decided only to include published papers. In our first version of the review (Lexchin 2003), we found problems with the completeness and quality of the data in conference abstracts and unstructured letters and therefore decided not to include them in this review. A comment to the previous version of this review (Lundh 2012), suggested that the exclusion of conference abstracts and letters could have introduced publication bias. In this update, we decided to include these papers in a sensitivity analysis, which gave similar results. However, we could only include quantitative data from two papers and we might have missed relevant papers. We expect that due to the high number of included papers such unidentified papers would not have major impact on our results. Due to the heterogeneity of included papers we decided not to assess publication bias using a funnel plot as it would be difficult to interpret.

Second, our assessment of risk of bias in the included papers was not based on validated criteria similar to 'Risk of bias' assessment for clinical trials (Higgins 2011b). As no validated assessment tools exist for these type of papers, we developed our own criteria and included items similar to assessment tools for systematic reviews (Oxman 1991; Shea 2007).

Third, one item not included in our assessment of risk of bias in the papers was whether coders of outcomes were blinded to the sponsorship status of the studies. If these types of papers were undertaken by authors with a particular view on the drug industry, knowledge of sponsorship status could introduce bias in the assessment of whether outcomes were favorable, particularly for conclusions, as this is an outcome that is qualitative in nature. Some of the included papers were written by authors who had published multiple times in the area, and as such could be at increased risk of bias. These papers used coders who were both blinded and unblinded to the sponsorship status of the studies. The agreement in coding was high, suggesting a lack of bias (Als-Nielsen 2003; Bero 2007; Kjaergard 2002). Likewise, all review authors (AL, BM, JL, JS, LB) have published several times in the field and one review author (LB) is the author of four of the included papers (Bero 2007; Cho 1996; Rasmussen 2009; Rattinger 2009), which could have introduced bias. Because of the way data were presented in the papers, it was not possible to blind our data extraction process. None of the data extractors were co-authors of the included papers. Furthermore, our data extraction of outcomes did not involve any qualitative interpretation as we extracted actual numbers.

Fourth, if the papers included in this review included some of the same studies, their findings would not be independent. Furthermore, some papers included some of the same studies (Corona 2014; Xu 2013), but had different results, which could be explained by differences in inclusion criteria and data extraction. In the majority of cases, it was not possible to assess the potential overlap of studies as most papers did not provide a reference list of included studies and we rarely had access to raw data. Instead we undertook sensitivity analyses restricted to papers on specific treatments or diseases where none of the other included papers were related to that domain. The analyses gave similar results, however with wider confidence intervals.

## Agreements and disagreements with other studies or reviews

Our results are in agreement with previous systematic reviews (Bekelman 2003; Lexchin 2003; Schott 2010a; Sismondo 2008a), though the risk ratios for the associations are less than previous quantitative estimates, but similar to our previous estimates (Lundh 2012). Previous reviews did not distinguish between favorable efficacy results or conclusions, but looked at the association between sponsorship and outcomes. Bekelman 2003 found OR 3.60 (95% CI: 2.63 to 4.91) and Lexchin 2003 OR 4.05 (95% CI: 2.98 to 5.51). Translated to odds ratios, we found 2.05 (95% CI: 1.66 to 2.52) for results and 2.69 (95% CI 2.04 to 3.54) for conclusions in our review. This difference could be due to chance or it could be because the earlier reviews also included pharmacoeconomic analyses, non-drug studies, unstructured letters and conference abstracts. It is also possible that the degree of industry bias has diminished over time, for example with a decrease in reporting bias due to trial registration. One paper on oncology drug trials (Djulbegovic 2013), suggested that the treatment effect size between industry sponsored and non-industry trials became more similar over time. However, the analysis included both published and unpublished trials and did not investigate the association between sponsorship and results or conclusions over time. In contrast, a recent paper found that reporting bias is also prevalent in registered trials, particular in industry sponsored trials (Jones 2013). Second, one of the most recent papers (Flacco 2015) sampled drug trials published in 2011 and found OR: 2.8 (95% CI: 1.6 to 4.7) for results, suggesting that industry bias has not changed over time.

For harms results one other systematic review (Golder 2008) has been published. Due to the anticipated heterogeneity of the data, the authors decided not to perform a meta-analysis. The results of the review are in line with our findings of no differences in harms results between industry sponsored and non-industry sponsored studies, but there are large variation in findings among individual papers.


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

# AUTHORS' CONCLUSIONS

## Implication for methodological research

Currently, the *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0* acknowledges problems in relation to sponsorship, but does not recommend assessing industry sponsorship as a separate domain in the 'Risk of bias' assessment (Higgins 2011b). The assumption is that the influence of the sponsor will be mediated through the mechanisms of bias that are currently assessed, such as selective reporting of favorable outcomes. A Cochrane review that examined the association of sponsorship and selective outcome reporting bias (Dwan 2011), found uncertain evidence for the association; however, assessment of selective outcome reporting is complex and bias may be difficult to detect (Kirkham 2010). Some studies that have documented the extensive selective reporting of favorable outcomes have examined only industry sponsored studies (Rising 2008; Vedula 2009), thus making comparison with non-industry sponsored studies impossible.

Our data suggest that the more favorable outcomes in industry sponsored studies are mediated by factors other than those documented in the 'Risk of bias' assessment tool in Cochrane reviews. It has been suggested that industry bias should be regarded as a meta-bias, as industry sponsorship in itself is not a bias-producing process - as for example lack of concealment of allocation is - but a risk factor for bias (Goodman 2011). However, the characteristics currently assessed in the standard risk of bias approach in Cochrane reviews likely do not capture the additional risk of bias in industry sponsored studies. For example, the *Handbook* states that design issues, such as dosage of comparators are not issues of bias, but of generalizability. Yet, pharmacological interventions have dose-response curves, and testing drugs that are not in comparable places on their dose-response curves sets up a systematic, unfair and biased comparison (Safer 2002).

Consequently, our data suggest that industry sponsorship should be treated as bias-inducing and industry bias should be treated as a separate domain. There are many subtle mechanisms through which sponsorship may influence outcomes, and an assessment of sponsorship should therefore be used as a proxy for these mechanisms. Interestingly, the AMSTAR tool for methodological quality assessment of systematic reviews includes funding and conflicts of interest as a domain (Shea 2007). Adaptations of Cochrane tools for assessing risk of bias in studies assessing environmental risks have also included funding source and conflicts of interest as a domain (Johnson 2016). Methods for reporting, assessing and handling industry bias and other biases in future systematic reviews must be developed. Specifically, further methodological research should focus on how industry bias is handled in Cochrane reviews.

# ACKNOWLEDGEMENTS

We thank Jeremy Cullis (clinical librarian) at Macquarie University for developing the search strategy and running the database searches of this update. We thank the authors of the included papers for sharing their raw data. We thank Sergio Sismondo and Octavian A. Busuioc who co-authored the previous review.

# REFERENCES

## References to studies included in this review

**Ahmer 2005** ***{published and unpublished data}***
Ahmer S, Arya P, Anderson D, Faruqui R. Conflict of interest in psychiatry. *Psychiatrist* 2005;**29**(8):302–4.

**Alasbali 2009** ***{published and unpublished data}***
Alasbali T, Smith M, Geffen N, Trope GE, Flanagan JG, Jin Y, et al. Discrepancy between results and abstract conclusions in industry- vs nonindustry-funded studies comparing topical prostaglandins. *American Journal of Ophthalmology* 2009;**147**(1):33–8.e2.

**Als-Nielsen 2003** ***{published data only (unpublished sought but not used)}***
Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?. *JAMA* 2003;**290**(7):921–8.

**Avni 2014** ***{published data only}***
Avni T, Shiber-Ofer S, Leibovici L, Paul M. Assessment of bias in outcomes reported in trials on pneumonia: a systematic review. *European Journal of Clinical Microbiology & Infectious Diseases* 2014;**33**(6):969–74.

**Barden 2006** ***{published data only}***
Barden J, Derry S, McQuay HJ, Moore RA. Bias from industry trial funding? A framework, a suggested approach, and a negative result. *Pain* 2006;**121**(3):207–18.

**Bariani 2013** ***{published and unpublished data}***
Bariani GM, de Celis Ferrari AC, Hoff PM, Krzyzanowska MK, Riechelmann RP. Self-reported conflicts of interest of authors, trial sponsorship, and the interpretation of editorials and related phase III trials in oncology. *Journal of Clinical Oncology* 2013;**31**(18):2289–95.

**Bartels 2012** ***{published data only}***
Bartels RH, Delye H, Boogaarts J. Financial disclosures of authors involved in spine research: an underestimated source of bias. *European Spine Journal* 2012;**21**(7):1229–33.

**Bero 2007** ***{published and unpublished data}***
Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug-drug comparisons:


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

why some statins appear more efficacious than others. *PLoS Medicine* 2007;**4**(6):e184.

**Bhandari 2004** ***{published data only (unpublished sought but not used)}***
Bhandari M, Busse JW, Jackowski D, Montori VM, Schünemann H, Sprague S, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. *CMAJ: Canadian Medical Association Journal* 2004;**170**(4):477–80.

**Bond 2012** ***{published and unpublished data}***
Bond K, Spooner C, Tjosvold L, Lemiere C, Rowe BH. The nature and influence of pharmaceutical industry involvement in asthma trials. *Canadian Respiratory Journal* 2012;**19**(4):267–71.

**Booth 2008** ***{published data only (unpublished sought but not used)}***
Booth CM, Cescon DW, Wang L, Tannock IF, Krzyzanowska MK. Evolution of the randomized controlled trial in oncology over three decades. *Journal of Clinical Oncology* 2008;**26**(33):5458–64.

**Bourgeois 2010** ***{published and unpublished data}***
Bourgeois FT, Murthy S, Mandl KD. Outcome reporting among drug trials registered in ClinicalTrials.gov. *Annals of Internal Medicine* 2010;**153**(3):158–66.

**Brown 2006** ***{published data only (unpublished sought but not used)}***
Brown A, Kraft D, Schmitz SM, Sharpless V, Martin C, Shah R, et al. Association of industry sponsorship to published outcomes in gastrointestinal clinical research. *Clinical Gastroenterology and Hepatology* 2006;**4**(12): 1445–51.

**Buchkowsky 2004** ***{published data only}***
Buchkowsky SS, Jewesson PJ. Industry sponsorship and authorship of clinical trials over 20 years. *Annals of Pharmacotherapy* 2004;**38**(4):579–85.

**Chard 2000** ***{published and unpublished data}***
Chard JA, Tallon D, Dieppe PA. Epidemiology of research into interventions for the treatment of osteoarthritis of the knee joint. *Annals of the Rheumatic Diseases* 2000;**59**(6): 414–8.

**Cho 1996** ***{published data only (unpublished sought but not used)}***
Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. *Annals of Internal Medicine* 1996; **124**(5):485–9.

**Clark 2002** ***{published and unpublished data}***
Clark O, Adams JR, Bennett CL, Djulbegovic B. Erythropoietin, uncertainty principle and cancer related anaemia. *BMC Cancer* 2002;**2**:23.

**Clifford 2002** ***{published data only (unpublished sought but not used)}***
Clifford TJ, Barrowman NJ, Moher D. Funding source, trial outcome and reporting quality: are they related? Results of a pilot study. *BMC Health Services Research* 2002;**2**(1):18.

**Corona 2014** ***{published data only}***
Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. *Expert Opinion on Drug Safety* 2014;**13**(10): 1327–51.

**Corona 2014a** ***{published data only}***
Corona G, Isidori AM, Buvat J, Aversa A, Rastrelli G, Hackett G, et al. Testosterone supplementation and sexual function: a meta-analysis study. *Journal of Sexual Medicine* 2014;**11**(6):1577–92.

**Crocetti 2010** ***{published and unpublished data}***
Crocetti MT, Amin DD, Scherer R. Assessment of risk of bias among pediatric randomized controlled trials. *Pediatrics* 2010;**126**(2):298–305.

**Davidson 1986** ***{published data only (unpublished sought but not used)}***
Davidson RA. Source of funding and outcome of clinical trials. *Journal of General Internal Medicine* 1986;**1**(3): 155–8.

**Davis 2008** ***{published data only}***
Davis JM, Chen N, Glick ID. Issues that may determine the outcome of antipsychotic trials: industry sponsorship and extrapyramidal side effect. *Neuropsychopharmacology* 2008;**33**(5):971–5.

**DeGeorge 2015** ***{published data only}***
DeGeorge BR Jr, Holland MC, Drake DB. The impact of conflict of interest in abdominal wall reconstruction with acellular dermal matrix. *Annals of Plastic Surgery* 2015;**74** (2):242–7.

**Djulbegovic 2000** ***{published data only (unpublished sought but not used)}***
Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, et al. The uncertainty principle and industry-sponsored research. *Lancet* 2000;**356**(9230): 635–8.

**Djulbegovic 2013** ***{published and unpublished data}***
Djulbegovic B, Kumar A, Miladinovic B, Reljic T, Galeb S, Mhaskar A, et al. Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials. *PLoS One* 2013;**8**(3):e58711.

**Etter 2007** ***{published data only (unpublished sought but not used)}***
Etter JF, Burri M, Stapleton J. The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a meta-analysis. *Addiction* 2007;**102**(5):815–22.

**Finucane 2004** ***{published data only}***
Finucane TE, Boult CE. Association of funding and findings of pharmaceutical research at a meeting of a medical professional society. *American Journal of Medicine* 2004;**117**(11):842–5.

**Flacco 2015** ***{published data only}***
Flacco ME, Manzoli L, Boccia S, Capasso L, Aleksovska K, Rosso A, et al. Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. *Journal of Clinical Epidemiology* 2015;**68**(7): 811–20.


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Freemantle 2000** ***{published data only (unpublished sought but not used)}***
Freemantle N, Anderson IM, Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis. *British Journal of Psychiatry* 2000;**177**:292–302.

**Gan 2012** ***{published data only}***
Gan HK, You B, Pond GR, Chen EX. Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. *Journal of the National Cancer Institute* 2012;**104**(8):590–8.

**Gartlehner 2010** ***{published data only}***
Gartlehner G, Morgan L, Thieda P, Fleg A. The effect of study sponsorship on a systematically evaluated body of evidence of head-to-head trials was modest: secondary analysis of a systematic review. *Journal of Clinical Epidemiology* 2010;**63**(2):117–25.

**Halpern 2005** ***{published data only}***
Halpern SD, Barton TD, Gross R, Hennessy S, Berlin JA, Strom BL. Epidemiologic studies of adverse effects of anti-retroviral drugs: how well is statistical power reported. *Pharmacoepidemiology and Drug Safety* 2005;**14**(3):155–61.

**Heres 2006** ***{published data only}***
Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. *American Journal of Psychiatry* 2006;**163**(2):185–94.

**Jefferson 2009** ***{published and unpublished data}***
Jefferson T, Di Pietrantonj C, Debalini MG, Rivetti A, Demicheli V. Relation of study quality, concordance, take home message, funding, and impact in studies of influenza vaccines: systematic review. *BMJ* 2009;**338**:b354.

**Jinapriya 2011** ***{published data only}***
Jinapriya D, Anraku A, Alasbali T, Trope GE, Buys YM. Evaluation of investigator bias in industry-funded clinical trials of latanoprost. *Canadian Journal of Ophthalmology* 2011;**46**(6):531–6.

**Jones 2010** ***{published data only}***
Jones R, Younie S, Macallister A, Thornton J. A comparison of the scientific quality of publicly and privately funded randomized controlled drug trials. *Journal of Evaluation in Clinical Practice* 2010;**16**(6):1322–5.

**Kelly 2006** ***{published and unpublished data}***
Kelly RE Jr, Cohen LJ, Semple RJ, Bialer P, Lau A, Bodenheimer A, et al. Relationship between drug company funding and outcomes of clinical psychiatric research. *Psychological Medicine* 2006;**36**(11):1647–56.

**Kemmeren 2001** ***{published data only}***
Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. *BMJ* 2001;**323**(7305):131–4.

**Khan 2012** ***{published data only}***
Khan NA, Lombeida JI, Singh M, Spencer HJ, Torralba KD. Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis. *Arthritis and Rheumatism* 2012;**64**(7): 2059–67.

**Killin 2014** ***{published data only}***
Killin LO, Russ TC, Starr JM, Abrahams S, Della Sala S. The effect of funding sources on donepezil randomised controlled trial outcome: a meta-analysis. *BMJ Open* 2014; **4**(4):e004083.

**Kjaergard 2002** ***{published and unpublished data}***
Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions: Epidemiological study of randomised clinical trials published in the BMJ. *BMJ* 2002; **325**(7358):249–52.

**Lee 2012** ***{published data only (unpublished sought but not used)}***
Lee YK, Chung CY, Koo KH, Lee KM, Ji HM, Park MS. Conflict of interest in the assessment of thromboprophylaxis after total joint arthroplasty: a systematic review. *Journal of Bone and Joint Surgery. American volume* 2012;**94**(1):27–33.

**Liss 2006** ***{published data only (unpublished sought but not used)}***
Liss H. Publication bias in the pulmonary/allergy literature: effect of pharmaceutical company sponsorship. *Israel Medical Association Journal* 2006;**8**(7):451–4.

**Lubowitz 2007** ***{published data only}***
Lubowitz JH, Appleby D, Centeno JM, Woolf SK, Reid JB 3rd. The relationship between the outcome of studies of autologous chondrocyte implantation and the presence of commercial funding. *American Journal of Sports Medicine* 2007;**35**(11):1809–16.

**Lynch 2007** ***{published and unpublished data}***
Lynch JR, Cunningham MR, Warme WJ, Schaad DC, Wolf FM, Leopold SS. Commercially funded and United States-based research is more likely to be published; good-quality studies with negative outcomes are not. *Journal of Bone and Joint Surgery. American volume* 2007;**89**(5):1010–8.

**Ma 2014** ***{published data only}***
Ma D, Zhang Z, Zhang X, Li L. Comparative efficacy, acceptability, and safety of medicinal, cognitive-behavioral therapy, and placebo treatments for acute major depressive disorder in children and adolescents: a multiple-treatments meta-analysis. *Current Medical Research and Opinion* 2014; **30**(6):971–95.

**Momeni 2009** ***{published and unpublished data}***
Momeni A, Becker A, Bannasch H, Antes G, Blümle A, Stark GB. Association between research sponsorship and study outcome in plastic surgery literature. *Annals of Plastic Surgery* 2009;**63**(6):661–4.

**Moncrieff 2003** ***{published and unpublished data}***
Moncrieff J. Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: A re-examination. *British Journal of Psychiatry* 2003;**183**:161–6.


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Montgomery 2004** ***{published data only (unpublished sought but not used)}***
Montgomery JH, Byerly M, Carmody T, Li B, Miller DR, Varghese F, et al. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. *Controlled Clinical Trials* 2004;**25**(6):598–612.

**Naci 2014** ***{published and unpublished data}***
Naci H, Dias S, Ades AE. Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. *BMJ* 2014;**349**:g5741.

**Nieto 2007** ***{published data only}***
Nieto A, Mazon A, Pamies R, Linana JJ, Lanuza A, Jiménez FO, et al. Adverse effects of inhaled corticosteroids in funded and nonfunded studies. *Archives of Internal Medicine* 2007;**167**(19):2047–53.

**Pengel 2009** ***{published and unpublished data}***
Pengel LH, Barcena L, Morris PJ. The quality of reporting of randomized controlled trials in solid organ transplantation. *Transplant International* 2009;**22**(4):377–84.

**Peppercorn 2007** ***{published data only (unpublished sought but not used)}***
Peppercorn J, Blood E, Winer E, Partridge A. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. *Cancer* 2007;**109**(7):1239–46.

**Perlis 2005a** ***{published data only (unpublished sought but not used)}***
Perlis CS, Harwood M, Perlis RH. Extent and impact of industry sponsorship conflicts of interest in dermatology research. *Journal of the American Academy of Dermatology* 2005;**52**(6):967–71.

**Perlis 2005b** ***{published and unpublished data}***
Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. *American Journal of Psychiatry* 2005;**162**(10):1957–60.

**Popelut 2010** ***{published and unpublished data}***
Popelut A, Valet F, Fromentin O, Thomas A, Bouchard P. Relationship between sponsorship and failure rate of dental implants: a systematic approach. *PLoS One* 2010;**5**(4): e10274.

**Printz 2013** ***{published data only (unpublished sought but not used)}***
Printz JO, Lee JJ, Knesek M, Urquhart AG. Conflict of interest in the assessment of hyaluronic acid injections for osteoarthritis of the knee: an updated systematic review. *Journal of Arthroplasty* 2013;**28**(8 Suppl):30–33.e1.

**Rasmussen 2009** ***{published and unpublished data}***
Rasmussen N, Lee K, Bero L. Association of trial registration with the results and conclusions of published trials of new oncology drugs. *Trials* 2009;**10**:116.

**Rattinger 2009** ***{published and unpublished data}***
Rattinger G, Bero L. Factors associated with results and conclusions of trials of thiazolidinediones. *PLoS One* 2009; **4**(6):e5826.

**Ridker 2006** ***{published data only (unpublished sought but not used)}***
Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. *JAMA* 2006;**295**(19): 2270–4.

**Rios 2008** ***{published and unpublished data}***
Rios LP, Odueyungbo A, Moitri MO, Rahman MO, Thabane L. Quality of reporting of randomized controlled trials in general endocrinology literature. *Journal of Clinical Endocrinology and Metabolism* 2008;**93**(10):3810–6.

**Rochon 1994** ***{published data only (unpublished sought but not used)}***
Rochon PA, Gurwitz JH, Simms RW, Fortin PR, Felson DT, Minaker KL, et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. *Archives of Internal Medicine* 1994;**154**(2):157–63.

**Roper 2014** ***{published and unpublished data}***
Roper N, Zhang N, Korenstein D. Industry collaboration and randomized clinical trial design and outcomes. *JAMA Internal Medicine* 2014;**174**(10):1695–6.

**Rösner 2010** ***{published data only}***
Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. *Cochrane Database of Systematic Reviews* 2010, Issue 9. DOI: 10.1002/14651858.CD004332.pub2

**Rösner 2010a** ***{published data only}***
Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. *Cochrane Database of Systematic Reviews* 2010, Issue 12. DOI: 10.1002/14651858.CD001867.pub3

**Sinyor 2012** ***{published data only}***
Sinyor M, Schaffer A, Smart KA, Levitt AJ, Lanctot KL, Grysman NH. Sponsorship, antidepressant dose, and outcome in major depressive disorder: meta-analysis of randomized controlled trials. *Journal of Clinical Psychiatry* 2012;**73**(2):e277–87.

**Spanemberg 2012** ***{published data only}***
Spanemberg L, Massuda R, Lovato L, Paim L, Vares EA, Sica da Rocha N, et al. Pharmacological treatment of bipolar depression: qualitative systematic review of double-blind randomized clinical trials. *Psychiatric Quarterly* 2012; **83**(2):161–75.

**Sung 2013** ***{published data only}***
Sung KH, Chung CY, Lee KM, Lee YK, Lee SY, Lee J, et al. Conflict of interest in the assessment of botulinum toxin A injections in patients with cerebral palsy: a systematic review. *Journal of Pediatric Orthopedics* 2013;**33**(5): 494–500.

**Tulikangas 2006** ***{published data only}***
Tulikangas PK, Ayers A, O'Sullivan DM. A meta-analysis comparing trials of antimuscarinic medications funded by industry or not. *BJU International* 2006;**98**(2):377–80.

**Tungaraza 2007** ***{published data only (unpublished sought but not used)}***
Tungaraza T, Poole R. Influence of drug company authorship and sponsorship on drug trial outcomes. *British Journal of Psychiatry* 2007;**191**:82–3.


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**van Lent 2014** ***{published data only}***
van Lent M, Overbeke J, Out HJ. Role of editorial and peer review processes in publication bias: analysis of drug trials submitted to eight medical journals. *PLoS One* 2014;**9**(8): e104846.

**Vlad 2007** ***{published data only (unpublished sought but not used)}***
Vlad SC, LaValley MP, McAlindon TE, Felson DT. Glucosamine for pain in osteoarthritis: why do trial results differ?. *Arthritis and Rheumatism* 2007;**56**(7):2267–77.

**Xu 2013** ***{published data only}***
Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. *BMC Medicine* 2013;**11**:108.

**Zhang 2013** ***{published data only}***
Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. *International Journal of Neuropsychopharmacology* 2013;**16** (6):1205–18.

## References to studies excluded from this review

**Adams 2013** ***{published data only}***
Adams CE, Bergman H, Irving CB, Lawrie S. Haloperidol versus placebo for schizophrenia. *Cochrane Database of Systematic Reviews* 2013, Issue 11. DOI: 10.1002/14651858.CD003082.pub3

**Adams 2014** ***{published data only}***
Adams CE, Awad GA, Rathbone J, Thornley B, Soares-Weiser K. Chlorpromazine versus placebo for schizophrenia. *Cochrane Database of Systematic Reviews* 2014, Issue 1. DOI: 10.1002/14651858.CD000284.pub3

**Afshari 2011** ***{published data only}***
Afshari A. Evidence based evaluation of immuno-coagulatory interventions in critical care. *Danish Medical Bulletin* 2011;**58**(9):B4316.

**Alves 2013** ***{published data only}***
Alves M, Fonseca EC, Alves MF, Malki LT, Arruda GV, Reinach PS, et al. Dry eye disease treatment: a systematic review of published trials and a critical appraisal of therapeutic strategies. *Ocular Surface* 2013;**11**(3):181–92.

**Amiri 2014** ***{published data only (unpublished sought but not used)}***
Amiri AR, Kanesalingam K, Cro S, Casey AT. Does source of funding and conflict of interest influence the outcome and quality of spinal research?. *Spine Journal* 2014;**14**(2): 308–14.

**Aneja 2013** ***{published data only (unpublished sought but not used)}***
Aneja A, Esquitin R, Shah K, Iyengar R, Nisenbaum R, Melo M, et al. Authors' self-declared financial conflicts of interest do not impact the results of major cardiovascular trials. *Journal of the American College of Cardiology* 2013;**61** (11):1137–43.

**Apler 2011** ***{published data only}***
Apler A. Citalopram for major depressive disorder in adults: a systematic review and meta-analysis of published placebo-controlled trials. *BMJ Open* 2011;**1**(2):e000106.

**Auerbach 2013** ***{published data only}***
Auerbach JD, McGowan KB, Halevi M, Gerling MC, Sharan AD, Whang PG, et al. Mitigating adverse event reporting bias in spine surgery. *Journal of Bone and Joint Surgery. American volume* 2013;**95**(16):1450–6.

**Baethge 2013** ***{published data only}***
Baethge C, Assall OP, Baldessarini RJ. Systematic review of blinding assessment in randomized controlled trials in schizophrenia and affective disorders 2000-2010. *Psychotherapy and Psychosomatics* 2013;**82**(3):152–60.

**Bailey 2011** ***{published data only}***
Bailey CS, Fehlings MG, Rampersaud YR, Hall H, Wai EK, Fisher CG. Industry and evidence-based medicine: Believable or conflicted? A systematic review of the surgical literature. *Canadian Journal of Surgery* 2011;**54**(5):321–6.

**Baker 2013** ***{published data only}***
Baker JR, Vandal AC, Yeoh J, Zeng I, Wong S, Ryan SN. Clinical trial participation improves outcome: a matched historical cohort study. *Clinical Trials* 2013;**10**(5):735–43.

**Bala 2013** ***{published data only}***
Bala MM, Akl EA, Sun X, Bassler D, Mertz D, Mejza F, et al. Randomized trials published in higher vs. lower impact journals differ in design, conduct, and analysis. *Journal of Clinical Epidemiology* 2013;**66**(3):286–95.

**Balevi 2011** ***{published data only}***
Balevi B. Industry sponsored research may report more favourable outcomes. *Evidence-Based Dentistry* 2011;**12**(1): 5–6.

**Barbui 2011** ***{published data only}***
Barbui C, Cipriani A, Patel V, Ayuso-Mateos JL, van Ommeren M. Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis. *British Journal of Psychiatry* 2011;**198**(1):11-6, sup 1.

**Batalla 2011** ***{published data only}***
Batalla A, Garcia-Doval I, Aranegui B, Garcia-Cruz A. Who funds research by Spanish dermatologists? Comparative analysis of articles published in 2008 [¿Quien financia la investigacion de los dermatologos espanoles? Analisis del ano 2008 y comparacion con otros grupos.]. *Actas Dermo-Sifiliograficas* 2011;**102**(7):517–26.

**Bennett 2010** ***{published data only}***
Bennett CL, Lai SY, Henke M, Barnato SE, Armitage JO, Sartor O. Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents. *Archives of Internal Medicine* 2010;**170**(16):1490–8.

**Bourgeois 2012** ***{published data only}***
Bourgeois FT, Murthy S, Mandl KD. Comparative effectiveness research: an empirical study of trials registered in ClinicalTrials.gov. *PLoS One* 2012;**7**(1):e28820.


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Brignardello-Petersen 2013** ***{published data only}***
Brignardello-Petersen R, Carrasco-Labra A, Yanine N, Ulloa C, Araya I, Pintor F, et al. Positive association between conflicts of interest and reporting of positive results in randomized clinical trials in dentistry. *Journal of the American Dental Association* 2013;**144**(10):1165–70.

**Buesching 2012** ***{published data only}***
Buesching DP, Luce BR, Berger ML. The role of private industry in pragmatic comparative effectiveness trials. *Journal of Comparative Effectiveness Research* 2012;**1**(2): 147–56.

**Califf 2012** ***{published data only}***
Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. *JAMA* 2012;**307**(17): 1838–47.

**Catala-Lopez 2013** ***{published data only}***
Catala-Lopez F, Sanfelix-Gimeno G, Ridao M, Peiro S. When are statins cost-effective in cardiovascular prevention? A systematic review of sponsorship bias and conclusions in economic evaluations of statins. *PLoS One* 2013;**8**(7): e69462.

**Chaturvedi 2014** ***{published data only}***
Chaturvedi S, Lipszyc DH, Licht C, Craig JC, Parekh R. Pharmacological interventions for hypertension in children. *Evidence-Based Child Health : a Cochrane Review Journal* 2014;**9**(3):498–580.

**Chen 2012** ***{published data only}***
Chen Z, Ba G, Shen T, Fu Q. Recombinant human bone morphogenetic protein-2 versus autogenous iliac crest bone graft for lumbar fusion: a meta-analysis of ten randomized controlled trials. *Archives of Orthopaedic and Trauma Surgery* 2012;**132**(12):1725–40.

**Chowers 2009** ***{published data only}***
Chowers MY, Gottesman BS, Leibovici L, Pielmeier U, Andreassen S, Paul M. Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review. *Journal of Antimicrobial Chemotherapy* 2009;**64**(2):239–50.

**Cipriani 2012** ***{published data only}***
Cipriani A, Purgato M, Furukawa TA, Trespidi C, Imperadore G, Signoretti A, et al. Citalopram versus other anti-depressive agents for depression. *Cochrane Database of Systematic Reviews* 2012, Issue 7. DOI: 10.1002/14651858.CD006534.pub2

**Cipriani 2012a** ***{published data only}***
Cipriani A, Koesters M, Furukawa TA, Nose M, Purgato M, Omori IM, et al. Duloxetine versus other anti-depressive agents for depression. *Cochrane Database of Systematic Reviews* 2012, Issue 10. DOI: 10.1002/14651858.CD006533.pub2

**Conen 2008** ***{published data only}***
Conen D, Torres J, Ridker PM. Differential citation rates of major cardiovascular clinical trials according to source of funding a survey from 2000 to 2005. *Circulation* 2008;**118** (13):1321–7.

**Cordoba 2010** ***{published data only}***
Cordoba G, Schwartz L, Woloshin S, Bae H, Gøtzsche PC. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. *BMJ* 2010; **341**:c3920.

**Cosgrove 2011** ***{published data only}***
Cosgrove L, Shi L, Creasey DE, Anaya-McKivergan M, Myers JA, Huybrechts KF. Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers' financial associations with industry. *PLoS One* 2011;**6**(4): e18210.

**Cunningham 2007** ***{published data only (unpublished sought but not used)}***
Cunningham MR, Warme WJ, Schaad DC, Wolf FM, Leopold SS. Industry-funded positive studies not associated with better design or larger size. *Clinical Orthopaedics and Related Research* 2007;**457**:235–41.

**Deb 2014** ***{published data only}***
Deb S, Farmah BK, Arshad E, Deb T, Roy M, Unwin GL. The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder--a systematic review. *Research in Developmental Disabilities* 2014;**35**(3):711–25.

**Demicheli 2014** ***{published data only}***
Demicheli V, Jefferson T, Al-Ansary LA, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. *Cochrane Database of Systematic Reviews* 2014, Issue 3. DOI: 10.1002/14651858.CD001269.pub5

**Do 2015** ***{published data only}***
Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, et al. Blood pressure control for diabetic retinopathy. *Cochrane Database of Systematic Reviews* 2015, Issue 1. DOI: 10.1002/14651858.CD006127.pub2

**Dufka 2014** ***{published data only}***
Dufka FL, Dworkin RH, Rowbotham MC. How transparent are migraine clinical trials? Repository of Registered Migraine Trials (RReMiT). *Neurology* 2014;**83** (15):1372–81.

**Dunn 2012** ***{published data only}***
Dunn AG, Gallego B, Coiera E. Industry influenced evidence production in collaborative research communities: a network analysis. *Journal of Clinical Epidemiology* 2012; **65**(5):535–43.

**Dunn 2014** ***{published data only}***
Dunn AG, Arachi D, Hudgins J, Tsafnat G, Coiera E, Bourgeois FT. Financial conflicts of interest and conclusions about neuraminidase inhibitors for influenza: an analysis of systematic reviews. *Annals of Internal Medicine* 2014;**161** (7):513–8.

**Faggion 2014** ***{published data only}***
Faggion CM Jr, Atieh M, Zanicotti DG. Reporting of sources of funding in systematic reviews in periodontology and implant dentistry. *British Dental Journal* 2014;**216**(3): 109–12.


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Finnerup 2015** ***{published data only}***
Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *Lancet Neurology* 2015;**14**(2):162–73.

**Fleurence 2010** ***{published data only}***
Fleurence RL, Spackman DE, Hollenbeak C. Does the funding source influence the results in economic evaluations? A case study in bisphosphonates for the treatment of osteoporosis. *Pharmacorconomics* 2010;**28**(4): 295–306.

**Friedman 2004** ***{published data only (unpublished sought but not used)}***
Friedman LS, Richter ED. Relationship between conflicts of interest and research results. *Journal of General Internal Medicine* 2004;**19**(1):51–6.

**Fu 2013** ***{published data only}***
Fu R, Selph S, McDonagh M, Peterson K, Tiwari A, Chou R, et al. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. *Annals of Internal Medicine* 2013; **158**(12):890–902.

**Fukunaga 2014** ***{published data only}***
Fukunaga S, Kusama M, Ono S. The effect size, study design, and development experience in commercially sponsored studies for new drug applications in approved drugs. *SpringerPlus* 2014;**3**:740.

**Furuse 2011** ***{published data only}***
Furuse J, Okusaka T, Bridgewater J, Taketsuna M, Wasan H, Koshiji M, et al. Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer. *Critical Reviews in Oncology/Hematology* 2011;**80**(1):31–9.

**Garattini 2010** ***{published data only}***
Garattini L, Koleva D, Casadei G. Modeling in pharmacoeconomic studies: funding sources and outcomes. *International Journal of Technology Assessment in Health Care* 2010;**26**(3):330–3.

**Garrison 2010** ***{published data only}***
Garrison KR, Shemilt I, Donell S, Ryder JJ, Mugford M, Harvey I, et al. Bone morphogenetic protein (BMP) for fracture healing in adults. *Cochrane Database of Systematic Reviews* 2010, Issue 6. DOI: 10.1002/14651858.CD006950.pub2

**Gasparyan 2013** ***{published data only}***
Gasparyan AY, Ayvazyan L, Akazhanov NA, Kitas GD. Conflicts of interest in biomedical publications: considerations for authors, peer reviewers, and editors. *Croatian Medical Journal* 2013;**54**(6):600–8.

**Gerrald 2010** ***{published data only}***
Gerrald KR, Malone RM, Shillida BB. Clinical benefit of self-monitoring of blood glucose is uncertain for non-insulin-treated patients with type 2 diabetes. *Clinical Diabetes* 2012;**28**(3):121–3.

**Gewandter 2014** ***{published data only}***
Gewandter JS, Smith SM, McKeown A, Burke LB, Hertz SH, Hunsinger M, et al. Reporting of primary analyses and multiplicity adjustment in recent analgesic clinical trials: ACTTION systematic review and recommendations. *Pain* 2014;**155**(3):461–6.

**Glick 2006** ***{published data only}***
Glick N, MacDonald I, Knoll G, Brabant A, Gourishankar S. Factors associated with publication following presentation at a transplantation meeting. *American Journal of Transplantation* 2006;**6**(3):552–6.

**Glujovsky 2012** ***{published data only}***
Glujovsky D, Riestra B, Coscia A, Boggino C, Comande D, Ciapponi A. Assessment of research quality in major infertility journals. *Fertility and Sterility* 2012;**98**(6): 1539–43.

**Goswami 2014** ***{published data only}***
Goswami ND, Tsalik EL, Naggie S, Miller WC, Horton JR, Pfeiffer CD, et al. A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010: the relationship between industry sponsorship and randomized study design. *Trials* 2014;**15**:31.

**Graham 2012** ***{published data only}***
Graham CN, Mauskopf JA, Lawson AH, Ascher-Svanum H, Bruhn D. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia. *Value in Health* 2012;**15**(1):55–64.

**Grillo-Ardila 2014** ***{published data only}***
Grillo-Ardila CF, Angel-Muller E, Salazar-Diaz LC, Gaitan HG, Ruiz-Parra AI, Lethaby A. Imiquimod for anogenital warts in non-immunocompromised adults. *Cochrane Database of Systematic Reviews* 2014, Issue 11. DOI: 10.1002/14651858.CD010389.pub2

**Guaiana 2013** ***{published data only}***
Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M. Agomelatine versus other antidepressive agents for major depression. *Cochrane Database of Systematic Reviews* 2013, Issue 12. DOI: 10.1002/14651858.CD008851.pub2

**Guo 2013** ***{published data only}***
Guo SW, Evers JL. Lack of transparency of clinical trials on endometriosis. *Obstetrics and Gynecology* 2013;**121**(6): 1281–90.

**Guo 2014** ***{published data only}***
Guo SW. An overview of the current status of clinical trials on endometriosis: issues and concerns. *Fertility and Sterility* 2014;**101**(1):183–190.e4.

**Hall 2007** ***{published data only}***
Hall R, de Antueno C, Webber A, Canadian Research Ethics Board. Publication bias in the medical literature: A review by a Canadian Research Ethics Board. *Canadian Journal of Anaesthesia* 2007;**54**(5):380–8.

**Hartling 2011** ***{published data only}***
Hartling L, Bond K, Vandermeer B, Seida J, Dryden DM, Rowe BH. Applying the risk of bias tool in a systematic


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

review of combination long-acting beta-agonists and inhaled corticosteroids for persistent asthma. *PLoS One* 2011;**6**(2): e17242.

**Hartung 2014** ***{published data only}***
Hartung DM, Zarin DA, Guise JM, McDonagh M, Paynter R, Helfand M. Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications. *Annals of Internal Medicine* 2014;**160**(7): 477–83.

**Hashmi 2014** ***{published data only}***
Hashmi S, Noureldin M, Khan SN. Lessons from the infuse trials: do we need a classification of bias in scientific publications and editorials?. *Current Reviews in Musculoskeletal Medicine* 2014;**7**(3):193–9.

**Hill 2007** ***{published data only}***
Hill CL, Buchbinder R, Osborne R. Quality of reporting of randomized clinical trials in abstracts of the 2005 annual meeting of the American College of Rheumatology. *Journal of Rheumatology* 2007;**34**(12):2476–80.

**Hodgson 2014** ***{published data only}***
Hodgson R, Allen R, Broderick E, Bland JM, Dumville JC, Ashby R, et al. Funding source and the quality of reports of chronic wounds trials: 2004 to 2011. *Trials* 2014;**15**:19.

**Hughes 2014** ***{published data only}***
Hughes S, Cohen D, Jaggi R. Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study. *BMJ open* 2014;**4**(7):e005535.

**Ioannidis 2013** ***{published data only}***
Ioannidis JP, Karassa FB, Druyts E, Thorlund K, Mills EJ. Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales. *Nature Reviews Rheumatology* 2013;**9**(11):665–73.

**Ipser 2015** ***{published data only}***
Ipser JC, Wilson D, Akindipe TO, Sager C, Stein DJ. Pharmacotherapy for anxiety and comorbid alcohol use disorders. *Cochrane Database of Systematic Reviews* 2015, Issue 1. DOI: 10.1002/14651858.CD007505.pub2

**Jagsi 2009** ***{published data only (unpublished sought but not used)}***
Jagsi R, Sheets N, Jankovic A, Motomura AR, Amarnath S, Ubel PA. Frequency, nature, effects, and correlates of conflicts of interest in published clinical cancer research. *Cancer* 2009;**115**(12):2783–91.

**Jang 2010** ***{published data only}***
Jang S, Chae YK, Haddad T, Majhail NS. Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review. *Breast Cancer Research and Treatment* 2010;**121**(2):273–9.

**Jefferson 2012** ***{published data only}***
Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V, Ferroni E. Vaccines for preventing influenza in healthy children. *Cochrane Database of Systematic Reviews* 2012, Issue 8. DOI: 10.1002/14651858.CD004879.pub4

**Jefferson 2014** ***{published data only}***
Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports. *BMJ Open* 2014;**4**(9):e005253.

**Jones 2013** ***{published data only}***
Jones CW, Handler L, Crowell KE, Keil LG, Weaver MA, Platts-Mills TF. Non-publication of large randomized clinical trials: cross sectional analysis. *BMJ* 2013;**347**: f6104.

**Kaiser 2012** ***{published data only}***
Kaiser KA, Cofield SS, Fontaine KR, Glasser SP, Thabane L, Chu R, et al. Is funding source related to study reporting quality in obesity or nutrition randomized control trials in top-tier medical journals?. *International Journal of Obesity* 2012;**36**(7):977–81.

**Khan 2008** ***{published data only (unpublished sought but not used)}***
Khan SN, Mermer MJ, Myers E, Sandhu HS. The roles of funding source, clinical trial outcome, and quality of reporting in orthopedic surgery literature. *American Journal of Orthopedics* 2008;**37**(12):E205–12.

**Kjaergard 1999** ***{published data only (unpublished sought but not used)}***
Kjaergard LL, Nikolova D, Gluud C. Randomized clinical trials in HEPATOLOGY: predictors of quality. *Hepatology* 1999;**30**(5):1134–8.

**Komossa 2011** ***{published data only}***
Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, et al. Risperidone versus other atypical antipsychotics for schizophrenia. *Cochrane Database of Systematic Reviews* 2011, Issue 1. DOI: 10.1002/14651858.CD006626.pub2

**Krauth 2014** ***{published data only}***
Krauth D, Anglemyer A, Philipps R, Bero L. Nonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis. *PLoS Biology* 2014;**12**(1):e1001770.

**Krzyzanowska 2003** ***{published data only}***
Krzyzanowska MK, Pintilie M, Tannock IF. Factors associated with failure to publish large randomized trials presented at an oncology meeting. *JAMA* 2003;**290**(4): 495–501.

**Kulier 2004** ***{published data only}***
Kulier R, Helmerhorst FM, Maitra N, Gülmezoglu AM. Effectiveness and acceptability of progestogens in combined oral contraceptives - A systematic review. *Reproductive Health* 2004;**1**(1):1.

**Kulkarni 2007** ***{published data only}***
Kulkarni AV, Busse JW, Shams I. Characteristics associated with citation rate of the medical literature. *PLoS One* 2007; **2**(5):e403.

**Lai 2006** ***{published data only (unpublished sought but not used)}***
Lai R, Chu R, Fraumeni M, Thabane L. Quality of randomized controlled trials reporting in the primary treatment of brain tumors. Journal of Clinical Oncology 2006; Vol. 24, issue 7:1136–44.


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Lawrie 2011** ***{published data only}***
Lawrie TA, Helmerhorst FM, Maitra NK, Kulier R, Bloemenkamp K, Gulmezoglu AM. Types of progestogens in combined oral contraception: effectiveness and side-effects. *Cochrane Database of Systematic Reviews* 2011, Issue 5. DOI: 10.1002/14651858.CD004861.pub2

**Leopold 2003** ***{published data only (unpublished sought but not used)}***
Leopold SS, Warme WJ, Fritz Braunlich E, Shott S. Association between funding source and study outcome in orthopaedic research. *Clinical Orthopaedics and Related Research* 2003;**415**:293–301.

**Lethaby 2013** ***{published data only}***
Lethaby A, Lopez-Olivo MA, Maxwell L, Burls A, Tugwell P, Wells GA. Etanercept for the treatment of rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2013, Issue 5. DOI: 10.1002/14651858.CD004525.pub2

**Leucht 2009a** ***{published data only}***
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet* 2009;**373** (9657):31–41.

**Leucht 2009b** ***{published data only}***
Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. *American Journal of Psychiatry* 2009;**166**(2):152–63.

**Li 2013** ***{published data only}***
Li XQ, Yang GL, Tao KM, Zhang HQ, Zhou QH, Ling CQ. Comparison of registered and published primary outcomes in randomized controlled trials of gastroenterology and hepatology. *Scandinavian Journal of Gastroenterology* 2013;**48**(12):1474–83.

**Lopez 2014** ***{published data only}***
Lopez J, Prifogle E, Nyame TT, Milton J, May JW Jr. The impact of conflicts of interest in plastic surgery: an analysis of acellular dermal matrix, implant-based breast reconstruction. *Plastic and Reconstructive Surgery* 2014;**133** (6):1328–34.

**Lundh 2012** ***{published data only}***
Lundh A, Krogsbøll LT, Gøtzsche PC. Sponsors' participation in conduct and reporting of industry trials: a descriptive study. *Trials* 2012;**13**:146.

**Lunn 2014** ***{published data only}***
Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. *Cochrane Database of Systematic Reviews* 2014, Issue 1. DOI: 10.1002/14651858.CD007115.pub3

**Magni 2013** ***{published data only}***
Magni LR, Purgato M, Gastaldon C, Papola D, Furukawa TA, Cipriani A, et al. Fluoxetine versus other types of pharmacotherapy for depression. *Cochrane Database of Systematic Reviews* 2013, Issue 7. DOI: 10.1002/14651858.CD004185.pub3

**Manzoli 2011** ***{published data only}***
Manzoli L, De Vito C, Salanti G, D'Addario M, Villari P, Ioannidis JP. Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines. *PLoS One* 2011;**6**(9):e24384.

**Manzoli 2014** ***{published data only}***
Manzoli L, Flacco ME, D'Addario M, Capasso L, De Vito C, Marzuillo C, et al. Non-publication and delayed publication of randomized trials on vaccines: survey. *BMJ* 2014;**348**:g3058.

**McIlvennan 2014** ***{published data only}***
McIlvennan CK, Magid KH, Ambardekar AV, Thompson JS, Matlock DD, Allen LA. Clinical outcomes after continuous-flow left ventricular assist device: a systematic review. *Circulation: Heart Failure* 2014;**7**(6):1003–13.

**McLennan 2008** ***{published data only}***
McLennan M, Leong FC, Steele A, Harris J. The influence of industry sponsorship on the acceptance of abstracts and their publication. *American Journal of Obstetrics and Gynecology* 2008;**198**(5):579.e1–4.

**Montedori 2011** ***{published data only}***
Montedori A, Bonacini MI, Casazza G, Luchetta ML, Duca P, Cozzolino F, et al. Modified versus standard intention-to-treat reporting: are there differences in methodological quality, sponsorship, and findings in randomized trials? A cross-sectional study. *Trials* 2011;**12**:58.

**Montori 2005** ***{published data only}***
Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, et al. Randomized trials stopped early for benefit: a systematic review. *JAMA* 2005;**294**(17): 2203–9.

**Moteshafi 2012** ***{published data only}***
Moteshafi H, Zhornitsky S, Brunelle S, Stip E. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis. *Drug Safety* 2012;**35**(10): 819–36.

**Nkansah 2009** ***{published data only}***
Nkansah N, Nguyen T, Iraninezhad H, Bero L. Randomized trials assessing calcium supplementation in healthy children: relationship between industry sponsorship and study outcomes. *Public Health Nutrition* 2009;**12**(10):1931–7.

**Okike 2007** ***{published data only (unpublished sought but not used)}***
Okike K, Kocher MS, Mehlman CT, Bhandari M. Conflict of interest in orthopaedic research: An association between findings and funding in scientific presentations. *Journal of Bone and Joint Surgery* 2007;**89**(3):608–13.

**Okike 2008** ***{published data only}***
Okike K, Kocher MS, Mehlman CT, Heckman JD, Bhandari M. Nonscientific factors associated with acceptance for publication in The Journal of Bone and Joint Surgery (American Volume). *Journal of Bone and Joint Surgery* 2008;**90**(11):2432–7.

**Peura 2012** ***{published data only}***
Peura PK, Martikainen JA, Purmonen TT, Turunen JH. Sponsorship-related outcome selection bias in published


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

economic studies of triptans: systematic review. *Medical Decision Making* 2012;**32**(2):237–45.

**Phillips 2012** ***{published data only}***
Phillips JL, Wassersug RJ, McLeod DL. Systemic bias in the medical literature on androgen deprivation therapy and its implication to clinical practice. *International Journal of Clinical Practice* 2012;**66**(12):1189–96.

**Polyzos 2011** ***{published data only}***
Polyzos NP, Valachis A, Mauri D, Ioannidis JP. Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test. *CMAJ: Canadian Medical Association Journal* 2011;**183**(6): E337–43.

**Probst 2014** ***{published data only}***
Probst P, Grummich K, Ulrich A, Buchler MW, Knebel P, Diener MK. Association of industry sponsorship and positive outcome in randomised controlled trials in general and abdominal surgery: protocol for a systematic review and empirical study. *Systematic Reviews* 2014;**3**:138.

**Procyshyn 2004** ***{published data only (unpublished sought but not used)}***
Procyshyn RM, Chau A, Fortin P, Jenkins W. Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine. *Canadian Journal of Psychiatry* 2004;**49**(9):601–6.

**Purgato 2014** ***{published data only}***
Purgato M, Papola D, Gastaldon C, Trespidi C, Magni LR, Rizzo C, et al. Paroxetine versus other anti-depressive agents for depression. *Cochrane Database of Systematic Reviews* 2014, Issue 4. DOI: 10.1002/14651858.CD006531.pub2

**Radecki 2011** ***{published data only}***
Radecki RP. Pharmaceutical sponsorship bias influences thrombolytic literature in acute ischemic stroke. *Western Journal of Emergency Medicine* 2011;**12**(4):435–41.

**Ramagopalan 2014** ***{published data only}***
Ramagopalan S, Skingsley AP, Handunnetthi L, Klingel M, Magnus D, Pakpoor J, et al. Prevalence of primary outcome changes in clinical trials registered on ClinicalTrials.gov: a cross-sectional study. *F1000Research* 2014;**3**:77.

**Rattehalli 2010** ***{published data only}***
Rattehalli RD, Jayaram MB, Smith M. Risperidone versus placebo for schizophrenia. *Cochrane Database of Systematic Reviews* 2010, Issue 1. DOI: 10.1002/14651858.CD006918.pub2

**Roach 2008** ***{published data only (unpublished sought but not used)}***
Roach JW, Skaggs DL, Sponseller PD, Macleod LM. Is research presented at the scoliosis research society annual meeting influenced by industry funding?. *Spine* 2008;**33**(20):2208–12.

**Sanossian 2006** ***{published data only}***
Sanossian N, Ohanian AG, Saver JL, Kim LI, Ovbiagele B. Frequency and determinants of nonpublication of research in the stroke literature. *Stroke* 2006;**37**:2588–92.

**Sawata 2011** ***{published data only}***
Sawata H, Tsutani K. How can the evidence from global large-scale clinical trials for cardiovascular diseases be Improved?. *BMC Research Notes* 2011;**4**:222.

**Schott 2010** ***{published data only}***
Schott G, Pachl H, Ludwig WD. The relation between publication bias and clinical trials funding [Publikationsbias in Abhangigkeit von der Art der Finanzierung bei klinischen Studien.]. *Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen* 2010;**104**(4):314–22.

**Schott 2010a** ***{published data only}***
Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD, Lieb K. The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. *Deutsches Arzteblatt international* 2010;**107**(16):279–85.

**Schott 2013** ***{published data only}***
Schott G, Dunnweber C, Muhlbauer B, Niebling W, Pachl H, Ludwig WD. Does the pharmaceutical industry influence guidelines?: two examples from Germany. *Deutsches Arzteblatt international* 2013;**110**(35-36):575–83.

**Shah 2005** ***{published data only (unpublished sought but not used)}***
Shah RV, Albert TJ, Bruegel-Sanchez V, Vaccaro AR, Hilibrand AS, Grauer JN. Industry support and correlation to study outcome for papers published in spine. *Spine* 2005; **30**(9):1099–104.

**Shamliyan 2012** ***{published data only}***
Shamliyan TA, Kane RL, Wyman J, Sainfort F. Results availability from clinical research of female urinary incontinence. *Neurourology and Urodynamics* 2012;**31**(1): 22–9.

**Shen 2014** ***{published data only}***
Shen C, Chien CR, Geynisman DM, Smieliauskas F, Shih YC. A review of economic impact of targeted oral anticancer medications. *Expert Review of Pharmacoeconomics & Outcomes Research* 2014;**14**(1):45–69.

**Stamatakis 2013** ***{published data only}***
Stamatakis E, Weiler R, Ioannidis JP. Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review. *European Journal of Clinical Investigation* 2013;**43**(5):469–75.

**Strupp 2010** ***{published data only}***
Strupp M. Pharmacotherapy: why industry-sponsored trials are more often positive and other useful information. *Journal of Neurology* 2010;**257**(2):309–12.

**Sun 2011** ***{published data only}***
Sun X, Briel M, Busse JW, You JJ, Akl EA, Mejza F, et al. The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: systematic review. *BMJ* 2011;**342**:d1569.

**Sun 2013** ***{published data only}***
Sun GH, Houlton JJ, MacEachern MP, Bradford CR, Hayward RA. Influence of study sponsorship on head and


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

neck cancer randomized trial results. *Head & Neck* 2013;**35**(10):1515–20.

**Thirugnanam 2012** ***{published data only}***
Thirugnanam S, Pinto R, Cook DJ, Geerts WH, Fowler RA. Economic analyses of venous thromboembolism prevention strategies in hospitalized patients: a systematic review. *Critical Care* 2012;**16**(2):R43.

**Thomas 2008** ***{published data only}***
Thomas O, Thabane L, Douketis J, Chu R, Westfall AO, Allison DB. Industry funding and the reporting quality of large long-term weight loss trials. *International Journal of Obesity* 2008;**32**(10):1531–6.

**Thomson 2010** ***{published data only}***
Thomson D, Hartling L, Cohen E, Vandermeer B, Tjosvold L, Klassen TP. Controlled trials in children: quantity, methodological quality and descriptive characteristics of pediatric controlled trials published 1948-2006. *PLoS One* 2010;**5**(9):pii: e13106..

**Valachis 2012** ***{published data only}***
Valachis A, Polyzos NP, Nearchou A, Lind P, Mauri D. Financial relationships in economic analyses of targeted therapies in oncology. *Journal of Clinical Oncology* 2012;**30**(12):1316–20.

**van Lent 2013** ***{published data only}***
van Lent M, Overbeke J, Out HJ. Recommendations for a uniform assessment of publication bias related to funding source. *BMC Medical Research Methodology* 2013;**13**:120.

**Wang 2010** ***{published data only}***
Wang AT, McCoy CP, Murad MH, Montori VM. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. *BMJ* 2010;**340**:c1344.

**Watanabe 2010** ***{published data only}***
Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, et al. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. *CNS Drugs* 2010;**24**(1):35–53.

**Yao 2007** ***{published data only (unpublished sought but not used)}***
Yao F, Singer M, Rosenfeld RM. Randomized controlled trials in otolaryngology journals. *Otolaryngology-Head and Neck Surgery* 2007;**137**(4):539–44.

**Yaphe 2001** ***{published data only (unpublished sought but not used)}***
Yaphe J, Edman R, Knishkowy B, Herman J. The association between funding by commercial interests and study outcome in randomized controlled drug trials. *Family Practice* 2001;**18**(6):565–8.

**Yuan 2011** ***{published data only}***
Yuan JC, Shyamsunder N, Barao VA, Lee DJ, Sukotjo C. Publication bias in five dental implant journals: an observation from 2005 to 2009. *International Journal of Oral & Maxillofacial Implants* 2011;**26**(5):1024–32.

**Yue 2013** ***{published data only}***
Yue J, Dong BR, Yang M, Chen X, Wu T, Liu GJ. Linezolid versus vancomycin for skin and soft tissue infections. *Cochrane Database of Systematic Reviews* 2013, Issue 7. DOI: 10.1002/14651858.CD008056.pub3

**Zani 2011** ***{published data only}***
Zani B, Pienaar ED, Oliver J, Siegfried N. Randomized controlled trials of HIV/AIDS prevention and treatment in Africa: results from the Cochrane HIV/AIDS Specialized Register. *PLoS One* 2011;**6**(12):e28759.

**Zulman 2011** ***{published data only}***
Zulman DM, Sussman JB, Chen X, Cigolle CT, Blaum CS, Hayward RA. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. *Journal of General Internal Medicine* 2011;**26**(7):783–90.

## Additional references

**Bekelman 2003**
Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. *JAMA* 2003;**289**(4):454–65.

**Bero 1996**
Bero LA, Rennie D. Influences on the quality of published drug studies. *International Journal of Technology Assessment in Health Care* 1996;**12**(2):209–37.

**Boutron 2010**
Boutron I, Dutton S, Ravaud P, Altman DG. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. *JAMA* 2010;**303**(20):2058–64.

**Chan 2004**
Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. *JAMA* 2004;**291**(20):2457–65.

**Christensen 2012**
Christensen M, Knop FK. The unobtainable placebo: control of independent clinical research by industry?. Lancet 2012; Vol. 379, issue 9810:30.

**DeAngelis 2004**
DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA 2004; Vol. 292, issue 11:1363–4.

**DeAngelis 2010**
DeAngelis CD, Fontanarosa PB. The importance of independent academic statistical analysis. *Biostatistics* 2010;**11**(3):383–4.

**Devereaux 2001**
Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C, Montori VM, et al. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. *JAMA* 2001;**285**(15):2000–3.


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Djulbegovic 2003**
Djulbegovic B, Cantor A, Clarke M. The importance of preservation of the ethical principle of equipoise in the design of clinical trials: relative impact of the methodological quality domains on the treatment effect in randomized controlled trials. *Accountability in Research* 2003;**10**(4):301–15.

**Doshi 2012**
Doshi P, Jones M, Jefferson T. Rethinking credible evidence synthesis. *BMJ* 2012;**344**:d7898.

**Doshi 2013**
Doshi P, Dickersin K, Healy D, Vedula SS, Jefferson T. Restoring invisible and abandoned trials: a call for people to publish the findings. *BMJ* 2013;**346**:f2865.

**Dunn 2013**
Dunn AG, Mandl KD, Coiera E, Bourgeois FT. The effects of industry sponsorship on comparator selection in trial registrations for neuropsychiatric conditions in children. *PLoS One* 2013;**8**(12):e84951.

**Dwan 2008**
Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E, et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. *PLoS One* 2008;**3**(8):e3081.

**Dwan 2011**
Dwan K, Altman DG, Cresswell L, Blundell M, Gamble CL, Williamson PR. Comparison of protocols and registry entries to published reports for randomised controlled trials. *Cochrane Database of Systematic Reviews* 2011, Issue 1. DOI: 10.1002/14651858.MR000031.pub2

**Estellat 2012**
Estellat C, Ravaud P. Lack of head-to-head trials and fair control arms: randomized controlled trials of biologic treatment for rheumatoid arthritis. *Archives of Internal Medicine* 2012;**172**(3):237–44.

**Fugh-Berman 2010**
Fugh-Berman AJ. The haunting of medical journals: how ghostwriting sold "HRT". *PLoS Medicine* 2010;**7**(9): e1000335.

**Furukawa 2004**
Furukawa TA. All clinical trials must be reported in detail and made publicly available. BMJ 2004; Vol. 329, issue 7466:626.

**Godlee 2009**
Godlee F. We want raw data, now. *BMJ* 2009;**339**:b5405.

**Golder 2008**
Golder S, Loke YK. Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?. *British Journal of Clinical Pharmacology* 2008;**66**(6):767–73.

**Golder 2016**
Golder S, Loke YK, Wright K, Norman G. Reporting of adverse events in published and unpublished studies of health care interventions: a systematic review. *PLoS Medicine* 2016;**13**(9):e1002127.

**Goodman 2011**
Goodman S, Dickersin K. Metabias: a challenge for comparative effectiveness research. Annals of Internal Medicine 2011; Vol. 155, issue 1:61–2.

**Gøtzsche 2011**
Gøtzsche PC. Why we need easy access to all data from all clinical trials and how to accomplish it. Trials 2011; Vol. 12:249.

**Hart 2012**
Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. *BMJ* 2012;**344**:d7202.

**Higgins 2011a**
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

**Higgins 2011b**
Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

**Johansen 1999**
Johansen HK, Gøtzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. *JAMA* 1999;**282**(18):1752–9.

**Johnson 2016**
Johnson PI, Koustas E, Vesterinen HM, Sutton P, Atchley DS, Kim AN, et al. Application of the Navigation Guide systematic review methodology to the evidence for developmental and reproductive toxicity of triclosan. *Environment International* 2016;**92-93**:716–28.

**Jüni 1999**
Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. *JAMA* 1999; **282**(11):1054–60.

**Katz 2006**
Katz KA, Karlawish JH, Chiang DS, Bognet RA, Propert KJ, Margolis DJ. Prevalence and factors associated with use of placebo control groups in randomized controlled trials in psoriasis: a cross-sectional study. *Journal of the American Academy of Dermatology* 2006;**55**(5):814–22.

**Kirkham 2010**
Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. *BMJ* 2010;**340**:c365.

**Krleza-Jeric 2005**
Krleza-Jeric K, Chan AW, Dickersin K, Sim I, Grimshaw J, Gluud C. Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1). *BMJ* 2005;**330**(7497):956–8.


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Lathyris 2010**
Lathyris DN, Patsopoulos NA, Salanti G, Ioannidis JP. Industry sponsorship and selection of comparators in randomized clinical trials. *European Journal of Clinical Investigation* 2010;**40**(2):172–82.

**Le Noury 2015**
Le Noury J, Nardo JM, Healy D, Jureidini J, Raven M, Tufanaru C, et al. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. *BMJ* 2015;**351**:h4320.

**Lexchin 2012**
Lexchin J. Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications. *Science and Engineering Ethics* 2012;**18**(2):247–61.

**Lundh 2008**
Lundh A, Gøtzsche PC. Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. *BMC Medical Research Methodology* 2008;**8**:22.

**MAGICapp [Computer program]**
MAGIC authoring and publication platform (MAGICapp) for improving patient care through guidelines, evidence summaries and decision aids that we can all trust, use and share. Version Accessed May 24, 2016.

**Mandelkern 1999**
Mandelkern M. Manufacturer support and outcome. Journal of Clinical Psychiatry 1999; Vol. 60, issue 2:122–3.

**McGauran 2010**
McGauran N, Wieseler B, Kreis J, Schuler YB, Kolsch H, Kaiser T. Reporting bias in medical research - a narrative review. *Trials* 2010;**11**:37.

**Melander 2003**
Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. *BMJ* 2003;**326**(7400):1171–3.

**Moses 2015**
Moses H 3rd, Matheson DH, Cairns-Smith S, George BP, Palisch C, Dorsey ER. The anatomy of medical research: US and international comparisons. *JAMA* 2015;**313**(2): 174–89.

**Oxman 1991**
Oxman AD, Guyatt GH, Singer J, Goldsmith CH, Hutchison BG, Milner RA, et al. Agreement among reviewers of review articles. *Journal of Clinical Epidemiology* 1991;**44**(1):91–8.

**Palmer 2003**
Palmer RH. Results of clinical trials sponsored by for-profit vs nonprofit entities. JAMA 2003; Vol. 290, issue 23:3070.

**PhRMA 2008**
PhRMA. Pharmaceutical marketing in perspective: its value and role as one of many factors informing prescribing. http://www.phrma.org/issues/sales-marketing (accessed 22 February 2012).

**Pildal 2007**
Pildal J, Hróbjartsson A, Jørgensen KJ, Hilden J, Altman DG, Gøtzsche PC. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. *International Journal of Epidemiology* 2007;**36**(4):847–57.

**Potthast 2014**
Potthast R, Vervolgyi V, McGauran N, Kerekes MF, Wieseler B, Kaiser T. Impact of inclusion of industry trial results registries as an information source for systematic reviews. *PLoS One* 2014;**9**(4):e92067.

**Psaty 2008**
Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. *JAMA* 2008;**299**(15):1813–7.

**Psaty 2010**
Psaty BM, Prentice RL. Minimizing bias in randomized trials: the importance of blinding. *JAMA* 2010;**304**(7): 793–4.

**RevMan 2014 [Computer program]**
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3.5. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

**Rising 2008**
Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. *PLoS Medicine* 2008;**5**(11): e217.

**Rosefsky 2003**
Rosefsky JB. Results of clinical trials sponsored by for-profit vs nonprofit entities. JAMA 2003; Vol. 290, issue 23: 3070–1.

**Roseman 2011**
Roseman M, Milette K, Bero LA, Coyne JC, Lexchin J, Turner EH, et al. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. *JAMA* 2011;**305**(10):1008–17.

**Roseman 2012**
Roseman M, Turner EH, Lexchin J, Coyne JC, Bero LA, Thombs BD. Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. *BMJ* 2012; **345**:e5155.

**Ross 2008**
Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. *JAMA* 2008;**299**(15):1800–12.

**Safer 2002**
Safer DJ. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. *Journal of Nervous and Mental Disease* 2002;**190**(9):583–92.

**Schwartz 2016**
Schwartz LM, Woloshin S, Zheng E, Tse T, Zarin DA. ClinicalTrials.gov and Drugs@FDA: A comparison of


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

results reporting for new drug approval trials. *Annals of Internal Medicine* 2016;**165**(6):421–30.

**Shea 2007**
Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC Medical Research Methodology* 2007;**7**:10.

**Sismondo 2008a**
Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. *Contemporay Clinical Trials* 2008;**29**(2):109–13.

**Sismondo 2008b**
Sismondo S. How pharmaceutical industry funding affects trial outcomes: causal structures and responses. *Social Science & Medicine* 2008;**66**(9):1909–14.

**Steinman 2006**
Steinman MA, Bero LA, Chren M-M, Landefeld S. The promotion of gabapentin: an analysis of internal industry documents. *Annals of Internal Medicine* 2006;**145**(4): 284–93.

**Stelfox 1998**
Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. *New England Journal of Medicine* 1998;**338**(2):101–6.

**Thomas 2002**
Thomas PS, Tan KS, Yates DH. Sponsorship, authorship, and accountability. Lancet 2002; Vol. 359, issue 9303:351.

**Tuech 2005**
Tuech JJ, Moutel G, Pessaux P, Thoma V, Schraub S, Herve C. Disclosure of competing financial interests and role of sponsors in phase III cancer trials. *European Journal of Cancer* 2005;**41**(15):2237–40.

**Vandvik 2013**
Vandvik PO, Brandt L, Alonso-Coello P, Treweek S, Akl EA, Kristiansen A, et al. Creating clinical practice guidelines we can trust, use, and share: a new era is imminent. *Chest* 2013;**144**(2):381–9.

**Vedula 2009**
Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. *New England Journal of Medicine* 2009;**361**(20): 1963–71.

**Wyatt 1991**
Wyatt J. Use and sources of medical knowledge. *Lancet* 1991;**338**(8779):1368–73.

## References to other published versions of this review

**Lexchin 2003**
Lexchin J, Bero L, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: a systematic review. *BMJ* 2003;**326**(7400):1167–70.

**Lundh 2011**
Lundh A, Lexchin J, Sismondo S, Busuioc OA, Bero L. Industry sponsorship and research outcome. *Cochrane Database of Systematic Reviews* 2011, Issue 9. DOI: 10.1002/14651858.MR000033

**Lundh 2012**
Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. *Cochrane Database of Systematic Reviews* 2012, Issue 12. DOI: 10.1002/14651858.MR000033.pub2

* *Indicates the major publication for the study*


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

# CHARACTERISTICS OF STUDIES

## Characteristics of included studies *[ordered by study ID]*

### Ahmer 2005

| | |
|---|---|
| Methods | To study the association between study support and outcome in randomized controlled trials (RCTs) of psychotropic drugs. All RCTs published in *Acta Psychiatrica Scandinavica* (APS), *American Journal of Psychiatry* (AJP), *Archives of General Psychiatry* (AGP) and *British Journal of Psychiatry* (BJP) from July 1998 to June 2003. |
| Data | 188 psychotropic drug RCTs (various comparators). |
| Comparisons | Manufacturer support and no support. |
| Outcomes | Study conclusions. |
| Funding | Not reported. |
| Notes | |

***Risk of bias***

| Item | Authors' judgement | Description |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | Database and handsearch. |
| Control for bias? | No | Subgroup analysis, but only of journal name. |

### Alasbali 2009

| | |
|---|---|
| Methods | To investigate the relationship between industry vs non-industry funded publications comparing the efficacy of topical prostaglandin analogs by evaluating the correspondence between the statistical significance of the publication's main outcome measure and its abstract conclusions. Studies published from 1966 to November 2007 |
| Data | 39 reports of head-to-head comparisons of topical prostaglandins in ophthalmology (various study designs) |
| Comparisons | Industry and non-industry funding. |
| Outcomes | Study conclusions, study results and concordance between study results and conclusions |
| Funding | No funding provided. |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Alasbali 2009** (*Continued*)

| | | |
|---|---|---|
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Unclear | Not clear which study designs and whether placebo-controlled studies were included, cannot be replicated |
| Adequate study inclusion process? | Unclear | Three assessors for data extraction, but unclear in relation to study inclusion |
| Comprehensive search? | Yes | MEDLINE and handsearching. |
| Control for bias? | Unclear | Not described. |

**Als-Nielsen 2003**

| | |
|---|---|
| Methods | To explore whether the association between funding and conclusions in randomized drug trials reflects treatment effects or adverse events. All randomized trials included in eligible meta-analyses from a random sample of Cochrane reviews obtained in May 2001 (RCTs from 1971 to 2000) |
| Data | 370 drug RCTs (mixed comparisons). |
| Comparisons | Funding from non-profit organizations, not reported, both non-profit and for-profit organizations, and for-profit organizations |
| Outcomes | Study conclusions, effect size and risk of bias (generation of randomization sequence, concealment of allocation and double-blinding) |
| Funding | Danish Centre for Evaluation and Health Technology Assessment (DACEHTA), The Danish Medical Research Council, and The Copenhagen Hospital Corporation's Medical Research Council |
| Notes | |

***Risk of bias***

| **Item** | **Authors' judgement** | **Description** |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Yes | One assessor screened and two involved in final inclusion. |


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Als-Nielsen 2003** (*Continued*)

| | | |
|---|---|---|
| Comprehensive search? | Yes | Identification via Cochrane reviews. |
| Control for bias? | Yes | Logistic regression adjusting for treatment effect, adverse events, and other potentially confounding trial variables (methodological quality, sample size, whether preset sample size was estimated and reached, meta-analysis, year of publication, and journal impact factor). Adjusted for treatment effect and double-blinding in final model |

**Avni 2014**

| | |
|---|---|
| Methods | To compare effect estimates for clinical failure and all-cause mortality in clinical trials of antibiotic treatment of pneumonia. Trials assessing adults with pneumonia, comparing different antibiotics published between 2005 and 2012 |
| Data | 36 antibiotic RCTs for pneumonia (drug vs drug). |
| Comparisons | Industry-sponsored and not industry-sponsored. |
| Outcomes | Effect size and risk of bias (sequence generation, concealment of allocation and blinding) |
| Funding | Not reported. |
| Notes | |

***Risk of bias***

| **Item** | **Authors' judgement** | **Description** |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Yes | Two authors included studies. |
| Comprehensive search? | Yes | PubMed, the Cochrane Library, LILACS, KOREAMED, NLM gateway and reference lists |
| Control for bias? | Yes | Meta-regression was used. |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Barden 2006**

| | | |
|---|---|---|
| Methods | To study if industry-sponsored trials yield a better result than trials not sponsored by industry, and if a particular drug would perform better as the test drug in trials funded by its manufacturer and worse as the comparator drug in trials funded by a competitor. RCTs from published systematic reviews in acute pain and migraine (reviews from 1999 to 2004) | |
| Data | 176 acute pain or migraine drug RCTs (active comparator or placebo-controlled) | |
| Comparisons | Industry versus non-industry and manufacturer versus competitor funding | |
| Outcomes | Effect size and risk of bias (Jadad score, 0-5 point scale). | |
| Funding | The study was supported by Pain Research funds and the Oxford Pain Relief Trust | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Yes | From Cochrane reviews, seems more than one assessor was used |
| Comprehensive search? | Yes | Identification via Cochrane reviews. |
| Control for bias? | No | No control for bias. |

**Bariani 2013**

| | | |
|---|---|---|
| Methods | To study the association between authors' conclusions and self-reported conflicts of interest or trial sponsorship in cancer studies. Phase III oncology RCTs (from January 2008 to October 2011) published in *JCO, Journal of the National Cancer Institute, The Lancet Oncology, Annals of Oncology, and The Cancer Journal*. | |
| Data | 150 oncology RCTs of which 105 are testing oncology drugs (mixed comparisons) | |
| Comparisons | Industry, mixed, non-industry and not stated. | |
| Outcomes | Study results and study conclusions. | |
| Funding | Not reported. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Bariani 2013** (*Continued*)

| | | |
|---|---|---|
| Adequate selection criteria? | No | Not objective inclusion criteria. |
| Adequate study inclusion process? | Yes | Two authors included trials. |
| Comprehensive search? | Yes | Handsearching of journals. |
| Control for bias? | Yes | Multivariate logistic regression analysis adjusted for conflicts of interest, study results, type of intervention, type of outcome and sponsorship for outcome study conclusions |

**Bartels 2012**

| | |
|---|---|
| Methods | To determine what effect reporting a financial disclosure has on the conclusion of an article. Articles on interspinous devices and cervical disc prostheses, published from January 2008 to December 2010 |
| Data | 160 interspinous device and cervical disc prosthesis studies (comparison not stated) |
| Comparisons | Commercial versus non-commercial funding. |
| Outcomes | Study conclusions. |
| Funding | Not reported. |
| Notes | |

***Risk of bias***

| **Item** | **Authors' judgement** | **Description** |
|---|---|---|
| Adequate selection criteria? | No | Not objective inclusion criteria. |
| Adequate study inclusion process? | No | Not adequate study inclusions process. |
| Comprehensive search? | No | Only English written papers from PubMed search in limited time period |
| Control for bias? | Unclear | Not reported. |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Bero 2007**

| | |
|---|---|
| Methods | To examine the associations between research funding source, study design characteristics aimed at reducing bias, and other factors that potentially influence results and conclusions in randomized controlled trials of statin-drug comparisons. All statin RCTs with active comparators from January 1999 to May 2005 |
| Data | 192 statin RCTs (active comparators). |
| Comparisons | Industry, none disclosed/no funding and government/private non-profit funding |
| Outcomes | Study results, study conclusions, risk of bias (concealment of allocation, blinding and follow-up) and concordance between study results and conclusions |
| Funding | California Tobacco-Related Disease Research Program Grant. |
| Notes | |

***Risk of bias***

| Item | Authors' judgement | Description |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Yes | Two or more assessors included studies. |
| Comprehensive search? | Yes | MEDLINE and references. |
| Control for bias? | Yes | Multivariate logistic regression analysis. Final model controlled for journal Impact Factor, sample size and blinding |

**Bhandari 2004**

| | |
|---|---|
| Methods | To study the association between industry funding and the statistical significance of results in recently published medical and surgical trials. RCTs from January 1999 to June 2001 in 8 leading surgical journals (*Journal of Bone and Joint Surgery* [American and British volumes], *Clinical Orthopaedics and Related Research*, *Acta Orthopaedica Scandinavica*, *Annals of Surgery*, *American Journal of Surgery*, *Plastic and Reconstructive Surgery and Journal of Neurosurgery*) and 5 medical journals (*Lancet, BMJ, JAMA, Annals of Internal Medicine and New England Journal of Medicine*) . |
| Data | 332 RCTs of drug, surgery, and other types of interventions (no description of comparisons) |
| Comparisons | Industry-for-profit, not-for-profit and undeclared funding. |
| Outcomes | Study results and risk of bias (Detsky quality index, 0-21 point scale) |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Bhandari 2004** (*Continued*)

| | | |
|---|---|---|
| Funding | Mohit Bhandari is funded, in part, by a Clinical Scientist Fellowship, Department of Clinical Epidemiology and Biostatistics, McMaster University. Jason Busse is funded by a Canadian Institutes of Health Research Fellowship Award. P.J. Devereaux is funded by a Heart and Stroke Foundation of Canada/Canadian Institutes of Health Research Fellowship Award | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | Handsearch and MEDLINE used. |
| Control for bias? | Yes | Multivariate logistic regression with adjustment for sample size, study quality and type of intervention |

**Bond 2012**

| | | |
|---|---|---|
| Methods | To describe the frequency of industry involvement in ICS/LABA trials and explore associations among significant outcomes, type of industry involvement and type of primary outcome. RCTs up to February/March 2006 | |
| Data | 91 RCTs of drugs for asthma (drug vs drug), of which 71 had relevant data | |
| Comparisons | Industry, non-industry, mixed and not stated. | |
| Outcomes | Study results. | |
| Funding | Partly by Canadian Agency for Drugs and Technologies in Health | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Yes | Two reviewers. |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Bond 2012** (*Continued*)

| | | |
|---|---|---|
| Comprehensive search? | Yes | Searches of electronic databases including BIOSIS Previews, Embase, MEDLINE, CENTRAL and Web of Science were conducted. References to studies included in other reviews |
| Control for bias? | Unclear | Not reported. |

**Booth 2008**

| | |
|---|---|
| Methods | To describe trends in methodology and reporting of RCTs, in addition to sponsorship, outcomes, and authors' interpretation of results. All RCTs of systemic therapy in breast, colorectal cancer, and non-small-cell lung cancer published during three decades (1975 through 2004) in:*Journal of Clinical Oncology*, *Journal of the National Cancer Institute*, *Cancer Treatment/Chemotherapy Reports*, *New England Journal of Medicine*, *Lancet*, and *JAMA*. |
| Data | 321 oncology drug RCTs (active comparators and placebo-controlled) |
| Comparisons | For-profit/mixed, non-profit and not known funding. |
| Outcomes | Study results, study conclusions and effect size. |
| Funding | Not reported. |
| Notes | |

***Risk of bias***

| Item | Authors' judgement | Description |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | Database and handsearch. |
| Control for bias? | Yes | Multivariate logistic regression, final model controlled for time to event, effect size and P value |

**Bourgeois 2010**

| | |
|---|---|
| Methods | To describe characteristics of drug trials listed in ClinicalTrials.gov and examine whether the funding source of these trials is associated with favorable published outcomes. Clinical trials registered from 2000 to 2006 and published up to 2010 |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Bourgeois 2010** (*Continued*)

| | | |
|---|---|---|
| Data | 546 clinical trials of cholesterol-lowering drugs, antidepressants, antipsychotics, proton-pump inhibitors and vasodilators (active or placebo-controlled) of which 345 had relevant data | |
| Comparisons | Industry, government and non-profit/non-federal (with or without industry contributions) funding | |
| Outcomes | Study results. | |
| Funding | National Library of Medicine and National Institute of Child Health and Human Development, National Institutes of Health | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Yes | Two assessors independently carried out the literature search and disagreements were resolved by consensus |
| Comprehensive search? | Yes | Four databases, trial registries and contact to investigators and companies |
| Control for bias? | Yes | Post hoc multivariate logistic regression analysis to assess the association between funding source and trial outcome, while controlling for other trial characteristics (drug class, approval status of indication, study phase, multicenter status, anticipated sample size, age of study population, comparator type, and length of study) |

**Brown 2006**

| | |
|---|---|
| Methods | To evaluate the trends in the source of funding for gastrointestinal clinical research during the period from 1992 to 2002-2003; to determine whether the source of study funding predicted the likelihood that a study would publish results that favor the drug or device being tested; and to determine whether differences exist in the methodologic quality of the investigational study methods used in studies funded by private industry versus other sources. Clinical trials published in 4 gastrointestinal journals (*Gastroenterology*, *The American Journal of Gastroenterology*, *Hepatology*, and *Gastrointestinal Endoscopy*). |
| Data | 450 clinical trials of drugs and devices in gastroenterology (active or placebo-controlled) |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Brown 2006** (*Continued*)

| | | |
|---|---|---|
| Comparisons | Private industry sponsored, federal/state government sponsored, national society/non-profit agency sponsored and not specified | |
| Outcomes | Study conclusions and risk of bias (Brown score, 0 to 5 point scale multiplied by 100) | |
| Funding | Amos Scholars Program of the Robert Wood Johnson Foundation and the Center for Gastrointestinal Biology and Disease at the University of North Carolina at Chapel Hill | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | Handsearching of journals. |
| Control for bias? | No | No control for bias. |

**Buchkowsky 2004**

| | | |
|---|---|---|
| Methods | To characterize clinical trial funding, reporting, and sources; investigate author-industry affiliation; and describe clinical outcome trends over time. Random papers from January 1981 to December 2000 from *Annals of Internal Medicine*, *BMJ*,*JAMA*,*Lancet* and *New England Journal of Medicine*. | |
| Data | 500 clinical drug trials (drug versus placebo, active comparator or non-drug comparator) | |
| Comparisons | Industry, mixed, non-industry and not stated funding. | |
| Outcomes | Study conclusions. | |
| Funding | No funding provided. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

| | | |
|---|---|---|
| Comprehensive search? | Yes | Handsearching of journals. |
| Control for bias? | Unclear | Investigates choice of comparators over time, might have assessed other sources of bias |

**Chard 2000**

| | |
|---|---|
| Methods | To assess the published research base for interventions for osteoarthritis of the knee, and to identify areas in need of further research. Studies from 1950 to 1998 |
| Data | 930 studies of different interventions (various study designs with various comparators) |
| Comparisons | Commercial, government and not stated funding. |
| Outcomes | Study conclusions. |
| Funding | Medical Research Council-Health Services Research Collaboration |
| Notes | |

***Risk of bias***

| **Item** | **Authors' judgement** | **Description** |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | No | One assessor on all studies and one on 10% sample, but only 87% agreement indicating two needed for all studies |
| Comprehensive search? | Yes | MEDLINE, Embase, BIDS, the Cochrane Library, previous reviews and experts contacted |
| Control for bias? | No | No control for bias. |

**Cho 1996**

| | |
|---|---|
| Methods | To compare the quality, relevance, and structure of drug studies published in symposium proceedings that are sponsored by drug companies with 1) articles from symposia with other sponsors and 2) articles in the peer-reviewed parent journals of symposium proceedings; and to study the relation between drug company sponsorship and study outcome. Random selection of symposia from 625 symposia that had been identified for a previous study |
| Data | 127 drug studies (various study designs with various comparators) |
| Comparisons | Drug company support and no support. |


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Cho 1996** (*Continued*)

| | | |
|---|---|---|
| Outcomes | Study conclusions and risk of bias (Cho scale, 0-1 point). | |
| Funding | In part by the American Association for Retired Persons, the Cigarette and Tobacco Surtax Fund of the State of California through the Tobacco-Related Disease Research Program of the University of California (award 4RT0035), the Pew Charitable Trusts, and the Veterans Affairs Office of Academic Affairs and Health Services Research and Development Service Research Funds | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Unclear | Not clear enough to replicate how symposia were chosen and how matching papers were chosen |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | Comprehensive search within their own database. |
| Control for bias? | Yes | Subgroup analysis of study design. |

**Clark 2002**

| | | |
|---|---|---|
| Methods | To evaluate if erythropoietin (EPO) is effective in the treatment of cancer-related anemia, and if its effect remains unchanged when data are analyzed according to various clinical and methodological characteristics of the studies. RCTs from 1993 to 2001 | |
| Data | 30 EPO RCTs (drug vs placebo), only 19 RCTs for some outcomes | |
| Comparisons | Industry and academic. | |
| Outcomes | Study results, study conclusions, effect size and risk of bias (Jadad scores, 0-5 point scale, randomization and blinding) | |
| Funding | No funding provided. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Clark 2002** (*Continued*)

| | | |
|---|---|---|
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | Previous systematic review and updated search of MEDLINE, LILACS and CANCERLIT |
| Control for bias? | Yes | Subgroup analysis and meta-regression. |

**Clifford 2002**

| | |
|---|---|
| Methods | To examine the relationship between funding source, trial outcome and reporting quality; 100 RCTs from *Annals of Internal Medicine*, *BMJ, JAMA*, *Lancet, New England Journal of Medicine*. From January 1999 to October 2000 with 20 RCTs/journal. |
| Data | 100 drug RCTs (various comparators). |
| Comparisons | Entirely industry, entirely not-for-profit, mixed and not reported funding |
| Outcomes | Study results, risk of bias (Jadad score, 0-5 point scale and concealment of allocation) |
| Funding | Not reported. |
| Notes | |

***Risk of bias***

| Item | Authors' judgement | Description |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | Handsearching of journals. |
| Control for bias? | No | No evidence of 'Risk of bias' assessment. |

**Corona 2014**

| | |
|---|---|
| Methods | To examine cardiovascular risk associated with testosterone-boosting medications. Search from January 1969 to January 2014 |
| Data | 75 RCTs of testosterone supplementation (drug vs placebo). |
| Comparisons | Drug company supported and not supported. |
| Outcomes | Effect size and risk of bias (sequence generation, blinding-overall and follow-up) |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Corona 2014** (*Continued*)

| | | |
|---|---|---|
| Funding | Not reported. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Yes | Two assessors included studies. |
| Comprehensive search? | Yes | MEDLINE, Embase and the Cochrane Library, www.clinicaltrials.gov and handsearch |
| Control for bias? | Yes | Meta-regression. |

**Corona 2014a**

| | | |
|---|---|---|
| Methods | To examine the effect of testosterone supplementation on male sexual function and its synergism with the use of phosphodiesterase type 5 inhibitors. Search from January 1969 to June 2013 | |
| Data | 29 studies of testosterone supplementation (drug vs placebo) | |
| Comparisons | Drug company supported and not supported. | |
| Outcomes | Effect size. | |
| Funding | Not reported. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Yes | Two assessors included studies. |
| Comprehensive search? | Yes | MEDLINE, Embase and the Cochrane Library, www.clinicaltrials.gov and handsearch |
| Control for bias? | Yes | Meta-regression. |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Crocetti 2010**

| | |
|---|---|
| Methods | To assess the risk of bias among pediatric RCTs reported in 8 high-impact journals (5 pediatric and 3 general medical) from July 2007 to June 2008 |
| Data | 146 pediatric drug, behavioral/educational and nutritional RCTs (various comparators) of which 57 had relevant data |
| Comparisons | Government, industry, internal hospital grant, multiple sources, none and private foundation funding |
| Outcomes | Risk of bias (sequence generation; allocation concealment; masking of participants, personnel, and outcome assessors; incomplete outcome data reporting; selective outcome reporting; and other sources of bias) |
| Funding | Not reported. |
| Notes | |

***Risk of bias***

| Item | Authors' judgement | Description |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | MEDLINE search of selected journals. |
| Control for bias? | Yes | Multivariate logistic regression to test for an association between the presence of a high risk of bias according to domain and the independent variables of funding source, intervention type, author number, and trial registration status |

**Davidson 1986**

| | |
|---|---|
| Methods | An analysis of the results of clinical trials according to funding source. Clinical trials from 1984 in *New England Journal of Medicine*, *Annals of Internal Medicine*,*the American Journal of Medicine*, *Archives of Internal Medicine*, and the *Lancet.* |
| Data | 107 drug and non-drug clinical trials (various comparators). |
| Comparisons | Pharmaceutical support and general support. |
| Outcomes | Study conclusions. |
| Funding | In part by NIH grant. |
| Notes | |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Davidson 1986** (*Continued*)

| *Risk of bias* | | |
|---|---|---|
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | No | Single assessor. |
| Comprehensive search? | Yes | Journals handsearched. |
| Control for bias? | No | Control for bias seems unlikely to have been done. |

**Davis 2008**

| | |
|---|---|
| Methods | The influence of several potentially biasing factors (e.g. industry support, extrapyramidal side effects) on efficacy of studies comparing second-generation antipsychotic with first-generation drugs. Dataset from previously published meta-analysis (search from 1953 to 2002) |
| Data | 124 RCTs of second-generation antipsychotics versus first-generation antipsychotics |
| Comparisons | Industry and non-industry funding. |
| Outcomes | Effect size. |
| Funding | In part by National Institute of Mental Health Grant. |
| Notes | |

| *Risk of bias* | | |
|---|---|---|
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | Comprehensive database search including search for unpublished data |
| Control for bias? | Unclear | Carried out various sensitivity analysis, but not clear whether they assessed bias in relation to funding and effect size |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**DeGeorge 2015**

| | | |
|---|---|---|
| Methods | To examine the impact of financial relationships with industry sponsorship and conflicts of interest reporting on surgical outcomes of abdominal wall reconstruction with acellular dermal matrices (from January 2004 to December 2013) | |
| Data | 124 studies of abdominal wall reconstruction with acellular dermal matrices (type of comparison not stated) | |
| Comparisons | Industry, federal or state government, national society or nonprofit organization and none | |
| Outcomes | Study conclusions. | |
| Funding | Not reported. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Not objective inclusion criteria. |
| Adequate study inclusion process? | Unclear | Not reported. |
| Comprehensive search? | No | Searched only PubMed. |
| Control for bias? | No | No control for bias. |

**Djulbegovic 2000**

| | | |
|---|---|---|
| Methods | To evaluate whether the uncertainty principle was upheld, comparison of the number of studies favoring experimental treatments over standard ones according to the source of funding. All RCTs for multiple myeloma from 1996 to 1998 | |
| Data | 136 multiple myeloma drug RCTs (various comparators). | |
| Comparisons | Commercial and public funding. | |
| Outcomes | Study conclusions and risk of bias (Jadad score, 0-5 point scale) | |
| Funding | Not reported. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Djulbegovic 2000** (*Continued*)

| | | |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | No | Seems only one author involved in study inclusion. |
| Comprehensive search? | Yes | Using the Cochrane search strategy to identify trials. |
| Control for bias? | Yes | Controlled for types of comparator (active versus placebo/no treatment) |

**Djulbegovic 2013**

| | |
|---|---|
| Methods | To assess if commercially sponsored trials are associated with higher success rates than publicly-sponsored trials. RCTs from 1980 to 2010 |
| Data | 96 published oncology RCTs (mixed comparisons) of which 85 comparisons had relevant data |
| Comparisons | Industry and non-industry. |
| Outcomes | Study results, study conclusions and risk of bias (sequence generation, concealment of allocation, blinding and follow-up) |
| Funding | National Institutes of Health. |
| Notes | |

***Risk of bias***

| **Item** | **Authors' judgement** | **Description** |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Yes | Two authors included studies. |
| Comprehensive search? | Yes | Clinical Trials Group provided list of non-industry trials. GSK clinical trial registry was searched for industry trials |
| Control for bias? | Yes | Sensitivity analyses according to the methodological quality of trials (bias and random error), publication status, choice of control intervention as well as according to most important cancer outcomes and types of treatment |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Etter 2007**

| | | |
|---|---|---|
| Methods | To assess whether source of funding affected the results of trials of nicotine replacement therapy for smoking cessation. RCTs from 1979 to 2003 identified from Cochrane review | |
| Data | 105 RCTs of nicotine replacement therapy (gum or patch versus placebo or no treatment) | |
| Comparisons | Industry/mixed and non-industry/not acknowledged funding. | |
| Outcomes | Study results and effect size. | |
| Funding | Not reported. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Yes | From Cochrane review, seems more than one assessors was used |
| Comprehensive search? | Yes | Identification via Cochrane review. |
| Control for bias? | Yes | Multivariate logistic regression with adjustment for sample size |

**Finucane 2004**

| | | |
|---|---|---|
| Methods | To evaluate the association between funding and findings of pharmaceutical research presented at an annual meeting of a clinically oriented US medical professional society | |
| Data | 48 presentations of drug studies (observational studies, RCTs and other study designs) | |
| Comparisons | Industry supported and not industry supported. | |
| Outcomes | Study conclusions. | |
| Funding | Not reported. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Finucane 2004** (*Continued*)

| | | |
|---|---|---|
| Adequate selection criteria? | Unclear | Unclear what "any abstract that reported results about effectiveness or safety of drugs" means. Not clear which study designs and whether reviews were included |
| Adequate study inclusion process? | Yes | Seems likely that two assessors were used. |
| Comprehensive search? | Yes | Comprehensive search within conference. |
| Control for bias? | Yes | Subgroup analysis of study design. |

**Flacco 2015**

| | |
|---|---|
| Methods | To map the current status of head-to-head comparative randomized evidence and to assess whether funding may impact on trial design and results. Random sample of PubMed RCTs indexed in 2011 with ≥ 100 participants |
| Data | 319 head-to-head drug RCTs. |
| Comparisons | Pharmaceutical companies, nonprofit and not reported. |
| Outcomes | Study results. |
| Funding | No funding provided. |
| Notes | |

***Risk of bias***

| **Item** | **Authors' judgement** | **Description** |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | Random sample of PubMed indexed RCTs. |
| Control for bias? | Yes | Logistic regression adjusting for sample size and study design (superiority vs non-inferiority). Affiliation, registration, impact factor, country, intervention type, conflict of interest) was significantly associated with favorable results in the final model, but none remained statistically significant when funding source and study design were adjusted for in the model |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Freemantle 2000**

| | |
|---|---|
| Methods | To assess whether specific pharmacological characteristics of alternative antidepressants resulted in altered efficacy compared to that of selective serotonin reuptake inhibitors (SSRI) in the treatment of major depression. All RCTs of SSRI versus alternative antidepressants (search from 1966 to 1997) |
| Data | 105 SSRI versus alternative antidepressant RCTs. |
| Comparisons | Sponsor and not sponsor. |
| Outcomes | Effect size. |
| Funding | Study sponsored by an unrestricted grant from Wyeth Laboratories |
| Notes | |

***Risk of bias***

| Item | Authors' judgement | Description |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | MEDLINE, Embase, references and reviews. |
| Control for bias? | No | No assessment of bias in relation to funding and effect size |

**Gan 2012**

| | |
|---|---|
| Methods | To evaluate how reliably the expected benefit approximates the observed benefit in RCTs that evaluated cancer treatment. RCTs from January 2005 to December 2009 published in: *Annals of Oncology, Breast Cancer Research & Treatment, British Journal of Cancer, Cancer, European Journal of Cancer, Journal of Clinical Oncology, Journal of the National Cancer Institute, Lancet, Lancet Oncology,* and*New England Journal of Medicine*. |
| Data | 253 oncology drug trials (mixed comparisons). |
| Comparisons | Any industry funding, no industry funding and unknown. |
| Outcomes | Study results. |
| Funding | Victorian Cancer Agency. |
| Notes | |

***Risk of bias***


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Gan 2012** (*Continued*)

| Item | Authors' judgement | Description |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | Identified via MEDLINE search of journals. |
| Control for bias? | No | Subgroup analysis of various predictors, but not in relation to study result outcome |

**Gartlehner 2010**

| | |
|---|---|
| Methods | The objective of this study was to determine the effect of industry bias in a systematically reviewed sample of head-to-head trials. Trials of SSRI head-to-head comparisons from 1993 to 2005 |
| Data | 29 SSRI RCTs of head-to-head comparisons. |
| Comparisons | Sponsor and not sponsor. |
| Outcomes | Study results and effect size. |
| Funding | Not reported. |
| Notes | |

***Risk of bias***

| Item | Authors' judgement | Description |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Yes | Two assessors included studies. |
| Comprehensive search? | Yes | MEDLINE, Embase, the Cochrane Library, the International Pharmaceutical Abstracts database, references and reviews and letters to the editor. In addition, the Center for Drug Evaluation and Research database to identify unpublished research submitted to the US Food and Drug Administration (FDA) |
| Control for bias? | Yes | Sensitivity analysis based on definition of funding. |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Halpern 2005**

| | | |
|---|---|---|
| Methods | To determine whether there is a difference in average statistical power between pharmacoepidemiologic studies of anti-retroviral adverse drug effects sponsored by for-profit versus non-profit organizations (drugs approved from 1987 to 1999 and published until 2002) | |
| Data | 48 pharmacoepidemiological studies of adverse effects of anti-retroviral drugs | |
| Comparisons | Non-profit, for-profit, charity/institution, none or unable to determine funding | |
| Outcomes | Study results (harms). | |
| Funding | Agency for Healthcare Research and Quality (AHRQ) Centers for Education and Research on Therapeutics | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | No | One assessor only. |
| Comprehensive search? | Yes | MEDLINE, Embase and reference lists. |
| Control for bias? | No | No control for bias. |

**Heres 2006**

| | | |
|---|---|---|
| Methods | To review the results of head-to-head studies of second-generation antipsychotics funded by pharmaceutical companies to determine if a relationship exists between the sponsor of the trial and the drug favored in the study's overall outcome. All head-to-head trials of second-generation antipsychotics from 1997 to 2005 | |
| Data | 42 head-to-head RCTs of second-generation antipsychotics. | |
| Comparisons | Industry only (sponsor of test drug or comparator). | |
| Outcomes | Study conclusions. | |
| Funding | No funding provided. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Heres 2006** (*Continued*)

| | | |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | No | MEDLINE and screen of selected conference proceedings. Sample of conference proceedings limited to 1999 to 2004, which may introduce bias due to differences in approval dates for the different drugs |
| Control for bias? | Yes | Sensitivity analysis of peer-reviewed trials only. |

**Jefferson 2009**

| | |
|---|---|
| Methods | To explore the relation between study concordance, take home message, funding, and dissemination of comparative studies assessing the effects of influenza vaccines. Studies of various designs from 1961 to 2006 |
| Data | 274 studies of influenza vaccine versus placebo/no treatment |
| Comparisons | Government/private/unfunded, industry/mixed and not stated funding |
| Outcomes | Study conclusions, risk of bias (Cochrane risk of bias) and concordance between study results and conclusions |
| Funding | ASL AL, Alessandria, Piemonte, Italy (regional health services) |
| Notes | |

***Risk of bias***

| **Item** | **Authors' judgement** | **Description** |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Yes | Two assessors included studies. |
| Comprehensive search? | Yes | MEDLINE, Embase, the Cochrane Library, web, and likely references and previous reviews since it is based on Cochrane reviews |
| Control for bias? | Yes | Sensitivity analysis based on definition of funding and regression analysis of various factors |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Jinapriya 2011**

| | | |
|---|---|---|
| Methods | To determine whether sponsorship of prostaglandin analogue clinical trials results in investigator bias in outcomes when studying intraocular pressure. RCTs up to August 2008 | |
| Data | 43 RCTs of topical prostaglandin analogues (comparison not stated) | |
| Comparisons | Parent company, competing company and non-industry. | |
| Outcomes | Effect size. | |
| Funding | Not reported. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Yes | Two assessors included studies. |
| Comprehensive search? | Yes | PubMed and reference lists were searched. |
| Control for bias? | Unclear | No control for bias. |

**Jones 2010**

| | | |
|---|---|---|
| Methods | To compare the quality of publicly or privately funded randomized controlled trials. Trials included in Cochrane reviews on hypertension and preterm labour | |
| Data | 105 drug trials (mixed comparisons). | |
| Comparisons | Commercial, mixed and non-commercial. | |
| Outcomes | Risk of bias (selection bias, performance bias, detection bias and attrition bias) | |
| Funding | No funding provided. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Jones 2010** (*Continued*)

| | | |
|---|---|---|
| Comprehensive search? | Yes | Based on searches from Cochrane reviews. |
| Control for bias? | No | No control for bias. |

**Kelly 2006**

| | |
|---|---|
| Methods | To investigate the relationship between industry support and study outcome in the general psychiatric literature. Clinical studies from 1992 and 2002 in *American Journal of Psychiatry, Archives of General Psychiatry,* and *Journal of Clinical Psychopharmacology.* |
| Data | 301 psychiatric drug studies (mixed comparisons). |
| Comparisons | Non-industry and industry (sponsor of test drug or comparator) funding |
| Outcomes | Study results, study conclusions and concordance between study results and conclusions |
| Funding | Not reported. |
| Notes | |

***Risk of bias***

| **Item** | **Authors' judgement** | **Description** |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | Sample of journals. |
| Control for bias? | Yes | Explanatory analysis of various mediating variables. |

**Kemmeren 2001**

| | |
|---|---|
| Methods | To evaluate quantitatively articles that compared effects of second- and third-generation oral contraceptives on risk of venous thrombosis. Cohort and case-control studies from 1995 to 2000 |
| Data | 12 cohort and case control studies of second- versus third-generation oral contraceptives |
| Comparisons | Industry and non-industry funding. |
| Outcomes | Study results and effect size. |
| Funding | No funding provided. |


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

| | | |
|---|---|---|
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | MEDLINE, reviews, relevant papers and experts. |
| Control for bias? | No | Multiple regression used, but not for the association between funding and results or effect size |

**Khan 2012**

| | | |
|---|---|---|
| Methods | To assess the association of industry funding with the characteristics, outcome, and reported quality of randomized controlled trials of drug therapy for rheumatoid arthritis. RCTs from 2002 to 2003 and 2006 to 2007 | |
| Data | 103 RCTs of drugs for rheumatoid arthritis (mixed comparisons) | |
| Comparisons | Industry, mixed, non-industry and not stated. | |
| Outcomes | Study results and risk of bias (sequence generation, concealment of allocation and blinding) | |
| Funding | Partly by NIH. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | No | PubMed and the Cochrane Central Register of Controlled Trials databases searched, but with very limited search terms used |
| Control for bias? | Yes | Logistic regression adjusted for potential confounders (not stated) |


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Killin 2014**

| | |
|---|---|
| Methods | To investigate whether there is a difference in the treatment effect of donepezil on cognition in Alzheimer's disease between industry-funded and independent RCTs. Search for RCTs up to October 2012 |
| Data | 14 RCTs of donezepil for Alzheimer's disease (mixed comparisons) |
| Comparisons | Industry and non-industry. |
| Outcomes | Effect size and risk of bias (sequence generation, concealment of allocation, performance bias, detection bias, attrition bias and reporting bias) |
| Funding | No funding provided. |
| Notes | |

***Risk of bias***

| Item | Authors' judgement | Description |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | Update of previous review using PubMed. Previous review with comprehensive search |
| Control for bias? | No | No control for bias. |

**Kjaergard 2002**

| | |
|---|---|
| Methods | To assess the association between competing interests and authors' conclusions. RCTs published in *BMJ* 1997 to 2001. |
| Data | 159 RCTs of mixed interventions (various comparators). |
| Comparisons | Profit, non-profit, non-profit and profit, non-profit and free drug, free drug only and no funding/not stated |
| Outcomes | Study conclusions and risk of bias (sequence generation, concealment of allocation and blinding) |
| Funding | Danish Medical Research Council; 1991 Pharmacy Foundation, Denmark; Copenhagen Hospital Corporation, Medical Research Council; Danish Institute of Health Technology Assessments |
| Notes | |

***Risk of bias***

| Item | Authors' judgement | Description |
|---|---|---|


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Kjaergard 2002** (*Continued*)

| | | |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | No | Only one assessor included studies. |
| Comprehensive search? | Yes | MEDLINE journal search. |
| Control for bias? | Yes | Regression analysis for potential confounders. |

**Lee 2012**

| | |
|---|---|
| Methods | To determine what proportion of studies on thromboprophylaxis after total joint arthroplasty were sponsored by industry and whether the assessments of thromboprophylaxis after total joint arthroplasty were associated with industry support. Studies published from 2004 to 2010 |
| Data | 71 prospective studies of thromboprophylaxis after total joint arthroplasty (mixed comparisons and interventions) |
| Comparisons | Industry, non-industry and not stated. |
| Outcomes | Study conclusions. |
| Funding | No funding provided. |
| Notes | |

***Risk of bias***

| **Item** | **Authors' judgement** | **Description** |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | No | Only one author included studies. |
| Comprehensive search? | No | PubMed in limited time period and limited to English language |
| Control for bias? | No | No control for bias. |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Liss 2006**

| | |
|---|---|
| Methods | To determine whether drug studies in the pulmonary/allergy literature also demonstrate a publication bias towards more favorable results when a pharmaceutical company funds the study. Primary research studies of drug interventions published in *Allergy, American Journal of Respiratory and Critical Care Medicine, Annals of Allergy Asthma and Immunology, Chest, European Respiratory Journal, Journal of Allergy and Clinical Immunology, Respiratory Medicine,* and *Thorax* in 2002 to 2003. |
| Data | Studies of nasal or oral inhaled corticosteroids, long- or short-acting bronchodilators, and leukotriene receptor antagonists (various designs and comparisons) |
| Comparisons | Pharmaceutically and not pharmaceutically funded. |
| Outcomes | Study conclusions. |
| Funding | Not reported. |
| Notes | |

***Risk of bias***

| Item | Authors' judgement | Description |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | No | Only one assessor included studies. |
| Comprehensive search? | Yes | Handsearch of journals indirectly described. |
| Control for bias? | No | No control for bias. |

**Lubowitz 2007**

| | |
|---|---|
| Methods | To compare outcomes (and levels of evidence) between published Autologous Chondrocyte Implantation outcome studies that were commercially funded and studies that were not commercially funded. Clinical studies from 1994 to 2005 |
| Data | 23 studies of chondrocyte implantation (various designs and comparisons) |
| Comparisons | Commercially funded and not commercially funded. |
| Outcomes | Effect size. |
| Funding | Not reported. |
| Notes | |

***Risk of bias***


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Lubowitz 2007** (*Continued*)

| Item | Authors' judgement | Description |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | No | MEDLINE only, time period not stated and few search terms used |
| Control for bias? | No | No control for bias. |

**Lynch 2007**

| | |
|---|---|
| Methods | To test the following hypotheses regarding orthopedic manuscripts submitted for review: (1) non-scientific variables, including receipt of commercial funding, affect the likelihood that a peer-reviewed submission will conclude with a report of a positive study outcome, and (2) positive outcomes and other, non-scientific variables are associated with acceptance for publication. Cohort of manuscripts submitted involving original research on the subject of adult hip or knee reconstruction to *The Journal of Bone and Joint Surgery* (American Volume) from January 2004 to June 2005. |
| Data | 209 studies of knee or hip surgery (various designs, interventions and comparisons) of which 99 had relevant data |
| Comparisons | Commercial, non-funded and non-commercial/philanthropic funding |
| Outcomes | Study conclusions and risk of bias (Sackett scale, 0 to 100%) |
| Funding | University of Washington Friends of Orthopaedic Research and Education Foundation. Zimmer, Inc., Warsaw, Indiana, made an unrestricted gift to the University of Washington Friends of Orthopaedic Research and Education in 2002 |
| Notes | |

***Risk of bias***

| Item | Authors' judgement | Description |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | Sample of papers via journal submission system. |
| Control for bias? | No | No control for bias. |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Ma 2014**

| | |
|---|---|
| Methods | To assess efficacy, acceptability, and safety of contemporary interventions in children and adolescents with major depressive disorder. RCTs from January 1988 to March 2013 |
| Data | 21 RCTs of new-generation antidepressants and cognitive behavioural therapy depression in children and adolescents (mixed comparisons) |
| Comparisons | Industry and non-industry. |
| Outcomes | Effect size. |
| Funding | No funding provided. |
| Notes | |

***Risk of bias***

| Item | Authors' judgement | Description |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Yes | Two authors included studies. |
| Comprehensive search? | Yes | Search of the Cochrane Library, AMED, CINAHL, Embase, LILACS, MEDLINE, PsycINFO, PSYNDEX, and Journal of Medicine and Pharmacy. Additional search of reference lists, regulatory reports, scientific proceedings, clinical trial registries and contact with individual investigators |
| Control for bias? | No | No control for bias. |

**Momeni 2009**

| | |
|---|---|
| Methods | To investigate if plastic surgical trials with industry-funding are more likely to be associated with statistically significant pro-industry findings. Trials in 4 plastic surgery journals (*Plastic and Reconstructive Surgery, British Journal of Plastic Surgery*, *Annals of Plastic Surgery,* and *Aesthetic Plastic Surgery*) from 1990 to 2005. |
| Data | 346 RCTs and controlled clinical trials (various designs, interventions and comparisons) |
| Comparisons | Industry, public, university and not specified funding. |
| Outcomes | Study results. |
| Funding | Not reported. |
| Notes | |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Momeni 2009** (*Continued*)

| *Risk of bias* | | |
|---|---|---|
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | Handsearch of journals. |
| Control for bias? | No | No control for bias. |

**Moncrieff 2003**

| | |
|---|---|
| Methods | To re-evaluate the evidence comparing clozapine with conventional antipsychotics and to investigate sources of heterogeneity. RCTs from 1988 to 2001 |
| Data | 9 RCTs of clozapine versus conventional antipsychotics. |
| Comparisons | Industry, other and not declared funding. |
| Outcomes | Study results and effect size. |
| Funding | Not reported. |
| Notes | |

| *Risk of bias* | | |
|---|---|---|
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | No | Only one assessor included studies. |
| Comprehensive search? | Yes | MEDLINE, Embase and Cochrane review. |
| Control for bias? | No | Univariate controlled for various predictors in relation to effect size only |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Montgomery 2004**

| | | |
|---|---|---|
| Methods | To analyze RCTs of second-generation antipsychotics in schizophrenia with respect to funding source (industry versus non-industry funding). RCTs from 1974 to 2002 | |
| Data | 86 RCTs of 2nd generation antipsychotics versus other types (various comparisons) | |
| Comparisons | Industry and non-industry. | |
| Outcomes | Study conclusions and risk of bias (Jadad score, 0-5 point scale) | |
| Funding | No funding provided. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | MEDLINE, PsycINFO and references. |
| Control for bias? | No | No control for bias. |

**Naci 2014**

| | | |
|---|---|---|
| Methods | To explore the risk of industry sponsorship bias in a systematically identified set of placebo-controlled and active comparator trials of statins. RCTs from January 1985 to March 2013 | |
| Data | 183 RCTs of statins (mixed comparisons). | |
| Comparisons | Industry and non-industry. | |
| Outcomes | Effect size and risk of bias (sequence generation, concealment of allocation, blinding, attrition bias and selective outcome reporting) | |
| Funding | No funding provided. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Naci 2014** (*Continued*)

| | | |
|---|---|---|
| Adequate study inclusion process? | Yes | Two authors included studies. |
| Comprehensive search? | Yes | MEDLINE, Embase, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials and reference lists from published trials and review articles |
| Control for bias? | No | Meta-regressions seem only to include covariates of dosage. |

**Nieto 2007**

| | |
|---|---|
| Methods | To evaluate differences between studies funded by the pharmaceutical manufacturer of the drug and those with no pharmaceutical funding regarding the findings and interpretation of adverse effects of inhaled corticosteroids. Studies from 1993 to 2002 |
| Data | 504 studies of inhaled corticosteroids (various study designs with various comparators) |
| Comparisons | Pharmaceutical funded and not pharmaceutical funded. |
| Outcomes | Study results (harms), study conclusions (harms) and concordance between study results and conclusions (harms) |
| Funding | Not reported. |
| Notes | |

***Risk of bias***

| **Item** | **Authors' judgement** | **Description** |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | Sample of journals were identified by MEDLINE. |
| Control for bias? | Yes | Controlled for confounders using multivariate model. |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Pengel 2009**

| | |
|---|---|
| Methods | To examine the quality of reporting of RCTs in solid organ transplantation that were published from 2004 to 2006 |
| Data | 332 trials in solid organ transplantation (mixed interventions and comparisons) |
| Comparisons | Commercial, non-profit, mixed, no funding and not described. |
| Outcomes | Risk of bias (concealment of allocation and Jadad score, 0-5 point scale) |
| Funding | Not reported. |
| Notes | |

***Risk of bias***

| Item | Authors' judgement | Description |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | MEDLINE, Embase and the Cochrane Library. |
| Control for bias? | No | No control for bias. |

**Peppercorn 2007**

| | |
|---|---|
| Methods | To evaluate the correlations between pharmaceutical company involvement, study design, and study outcome and to explore changes in these areas over time. Breast cancer trials of medical therapies that were published in the years 1993, 1998, and 2003 in 10 select English-language medical journals |
| Data | 140 breast cancer drug trials (single-arm studies and RCTs). |
| Comparisons | Pharmaceutical studies versus non-pharmaceutical studies. |
| Outcomes | Study conclusions. |
| Funding | Not reported. |
| Notes | |

***Risk of bias***

| Item | Authors' judgement | Description |
|---|---|---|


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Peppercorn 2007** (*Continued*)

| | | |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | Handsearch and MEDLINE used. |
| Control for bias? | No | Only assessment of differences in study design in relation to funding |

**Perlis 2005a**

| | |
|---|---|
| Methods | To determine the extent and impact of industry sponsorship conflicts of interest in dermatology research. Drug trials from *Journal of Investigative Dermatology, Archives of Dermatology, British Journal of Dermatology,* and *Journal of the American Academy of Dermatology* from 2000 to 2003. |
| Data | 179 RCTs of dermatological drugs (various comparators). |
| Comparisons | Industry and non-industry funding. |
| Outcomes | Study conclusions and risk of bias(blinding and Jadad score, 0-5 point scale) |
| Funding | No funding provided. |
| Notes | |

***Risk of bias***

| Item | Authors' judgement | Description |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | Sample of journals. |
| Control for bias? | Yes | Multivariate regression analysis adjusted for conflict of interest, Jadad score, and sample size |

**Perlis 2005b**

| | |
|---|---|
| Methods | To study the extent and implications of industry sponsorship and financial conflicts of interest in psychiatric trials. Drug trials from the *American Journal of Psychiatry, Archives of General Psychiatry, Journal of Clinical Psychiatry, and Journal of Clinical Psychopharmacology* from 2001 to 2003. |
| Data | 397 psychiatric clinical drug trials (various comparators). |


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Perlis 2005b** (*Continued*)

| | | |
|---|---|---|
| Comparisons | Industry and non-industry funding. | |
| Outcomes | Study results. | |
| Funding | Not reported. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Not sure if 3 assessors extracting data were involved in including studies |
| Comprehensive search? | Yes | MEDLINE and handsearch of journals. |
| Control for bias? | Yes | Logistic regression adjusted for confounders. |

**Popelut 2010**

| | | |
|---|---|---|
| Methods | To examine financial sponsorship of dental implant trials, and to evaluate whether research funding sources affects the annual failure rate. Clinical trials from 1988 to 2005 | |
| Data | 41 clinical trials of dental implants (single arm and active control) | |
| Comparisons | Industry, non-industry and unknown funding. | |
| Outcomes | Effect size. | |
| Funding | Grant from the University Paris Diderot, U.F.R. of Odontologie (Paris, France) | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | No | Inclusion criteria reported, but not possible to decipher and seems subjective |
| Adequate study inclusion process? | Yes | Two assessors included studies. |
| Comprehensive search? | Yes | MEDLINE and handsearch. |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Popelut 2010** (*Continued*)

| | | |
|---|---|---|
| Control for bias? | Yes | Controlled for confounders using multivariate analysis. |

**Printz 2013**

| | |
|---|---|
| Methods | Whether the qualitative conclusions by the authors about the therapeutic effects of the hyaluronic acid drug were associated with either industry sponsorship or the financial conflicts of interest of the authors. RCTs from January 2010 to April 2012 |
| Data | 48 RCTs of hyaluronic acid injections for osteoarthritis (drug vs placebo) |
| Comparisons | Industry and non-industry sponsorship. |
| Outcomes | Study conclusions. |
| Funding | Not reported. |
| Notes | |

***Risk of bias***

| **Item** | **Authors' judgement** | **Description** |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | No | Only one assessor included studies. |
| Comprehensive search? | Yes | PubMed, Embase, Scopus, Web of Science and other sources searched |
| Control for bias? | No | No control for bias. |

**Rasmussen 2009**

| | |
|---|---|
| Methods | To compare the prevalence of favorable results and conclusions among published reports of registered and unregistered RCTs of new oncology drugs. Cohort of trials from 25 drugs granted first-time Food and Drug Administration (FDA) approval for oncology indications from 2000 to 2005 and published from 1996 to 2008 |
| Data | 137 RCTs of oncology drugs (placebo or active control). |
| Comparisons | Industry sponsor and other funding. |
| Outcomes | Study results, study conclusions, risk of bias (blinding) and concordance between study results and conclusions |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Rasmussen 2009** (*Continued*)

| | | |
|---|---|---|
| Funding | National Center for Research Resources (a component of the National Institutes of Health) and the Australian Research Council | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | MEDLINE and the Cochrane Library. |
| Control for bias? | Yes | Logistic regression adjusted for confounders. |

**Rattinger 2009**

| | | |
|---|---|---|
| Methods | To examine the association between research funding source, study design characteristics aimed at reducing bias, and other factors with the results and conclusions of RCTs of thiazolidinediones compared to other oral hypoglycemic agents (search from 1996 to 2006) | |
| Data | 61 RCTs of thiazolidinediones (active or placebo control). | |
| Comparisons | Test drug company, other drug company, all others and not declared funding | |
| Outcomes | Study results, study conclusions, risk of bias (sequence generation and allocation concealment, blinding and follow-up) and concordance between study results and conclusions | |
| Funding | California Tobacco-Related Disease Research Program. The statistical analysis was funded by a Pathway Project Grant from the UCSF School of Pharmacy Vince Isnardi Opportunity Fund | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | MEDLINE, the Cochrane Library, references and reviews. |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Rattinger 2009** (*Continued*)

| | | |
|---|---|---|
| Control for bias? | Yes | Intended multivariate analysis, but due to few associations only univariate performed |

**Ridker 2006**

| | |
|---|---|
| Methods | To determine in contemporary randomized cardiovascular trials the association between funding source and the likelihood of reporting positive findings. Cardiovascular RCTs published in *JAMA*, *Lancet*, and the *New England Journal of Medicine* from 2000 to 2005. |
| Data | 349 RCTs (mixed interventions and comparators). |
| Comparisons | For profit, mixed and not for profit funding. |
| Outcomes | Study conclusions. |
| Funding | Not reported. |
| Notes | |

***Risk of bias***

| **Item** | **Authors' judgement** | **Description** |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | Sample of journals identified via MEDLINE. |
| Control for bias? | No | No control for bias. |

**Rios 2008**

| | |
|---|---|
| Methods | To assess the reporting quality of RCTs in general endocrinology and to identify predictors for better reporting quality. RCTs published in the *Journal of Clinical Endocrinology* and *Metabolism, Clinical Endocrinology,* and the *European Journal of Endocrinology* from 2005 to 2006. |
| Data | 89 endocrinology drug RCTs (various comparators). |
| Comparisons | Industry, mixed, non-industry and not stated funding. |
| Outcomes | Risk of bias (concealment of allocation and blinding). |
| Funding | Not reported. |
| Notes | |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Rios 2008** (*Continued*)

| *Risk of bias* | | |
|---|---|---|
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Yes | Two assessors included studies. |
| Comprehensive search? | Yes | Handsearch of journals. |
| Control for bias? | Yes | Controlled for confounders using multivariate analysis. |

**Rochon 1994**

| | |
|---|---|
| Methods | To study the relation between reported drug performance in published trials and support of the trials by the manufacturer of the drug under evaluation. All non-steroidal anti-inflammatory (NSAID) RCTs from September 1987 to May 1990 |
| Data | 56 NSAID RCTs (placebo and head-to-head comparisons). |
| Comparisons | Manufacturer associated only. |
| Outcomes | Study results (efficacy and harms), study conclusions (efficacy and harms) and risk of bias (Chalmers' scale, 0-100 points) |
| Funding | Agency for Health Care Policty and Research, Public Health Service, Department of Health and Humar Resources; research fellowship at Brockton/West Roxbury Division if the Boston (Mass) area Geriatric Research Education and Clinical Center (Dr Rochon); clinical Investigators award from the National Institute of Aging, National Institutes of Helath, Bethesda, MD (Dr Gurwittz); and Le Fonds de la Recherche en Sante du Quebec and Arthritis Society of Canada (Toronto, Ontario) (Dr Fortin) |
| Notes | |

| *Risk of bias* | | |
|---|---|---|
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | MEDLINE searched. |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Rochon 1994** (*Continued*)

| | | |
|---|---|---|
| Control for bias? | No | Control for bias seems unlikely to have been done. |

**Roper 2014**

| | |
|---|---|
| Methods | To examine whether industry funding with collaboration was associated with certain trial design features and outcomes. RCTs from December 2011 to November 2012 in 10 high impact biomedical journals |
| Data | 219 drug and device RCTs (placebo and active comparators) of which 216 had relevant data |
| Comparisons | Industry with collaboration, industry without collaboration and neither industry or collaboration |
| Outcomes | Study results and risk of bias (concealment of allocation and blinding) |
| Funding | Not reported. |
| Notes | |

***Risk of bias***

| Item | Authors' judgement | Description |
|---|---|---|
| Adequate selection criteria? | No | Does not describe selection criteria. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Unclear | Does not describe search strategy. |
| Control for bias? | No | No control for bias. |

**Rösner 2010**

| | |
|---|---|
| Methods | To determine the effectiveness and tolerability of acamprosate in comparison to placebo and other pharmacological agents. RCTs from 1966 to January 2009 |
| Data | 24 RCTs of acamprosate for alcohol dependence (mixed comparisons) |
| Comparisons | Industry, mixed and non-industry. |
| Outcomes | Effect size. |
| Funding | Internal sources (Ludwig Maximilian University of Munich and Technical University of Munich provided infrastructure and related services). External sources (Federal Ministry of Education and Research in Germany provided financial support / salary) |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

| | | |
|---|---|---|
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | No | Only one author included studies. |
| Comprehensive search? | Yes | Cochrane Central Register of Controlled Trials, MEDLINE, Embase and CINAHL. Other sources were: Trial registries, investigators, experts, public sponsors and drug manufacturer (Merck Serono) and reference lists of included trials and reviews |
| Control for bias? | No | No control for bias. |

**Rösner 2010a**

| | |
|---|---|
| Methods | To determine the effectiveness and tolerability of opioid antagonists in the treatment of alcohol dependence. RCTs from 1966 to January 2010 |
| Data | 50 RCTs of opioid antagonists for alcohol dependence (mixed comparisons) |
| Comparisons | Industry and non-industry. |
| Outcomes | Effect size. |
| Funding | Internal sources (Ludwig Maximilian University of Munich (Germany), Technical University of Munich (Germany), Chiang Mai University (Thailand) provided infrastructure and related services). External sources (Federal Ministry of Education and Research in Germany provided financial support / salary) |
| Notes | |

| ***Risk of bias*** | | |
|---|---|---|
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | No | Only one author included studies. |
| Comprehensive search? | Yes | Cochrane Central Register of Controlled Trials, MEDLINE, Embase and CINAHL. Other |


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

| | | |
|---|---|---|
| | | sources were: trial registries, investigators, experts, public sponsors and drug manufacturers and reference lists of included trials and reviews |
| Control for bias? | No | No control for bias. |

**Sinyor 2012**

| | |
|---|---|
| Methods | This study aims to determine the relationship between sponsorship and antidepressant dosing and efficacy in RCTs for major depressive disorder. RCTs from 1996 to June 2010 |
| Data | 58 RCTs of antidepressants for major depressive disorder (drug vs drug) |
| Comparisons | Sponsor vs non-sponsor company. |
| Outcomes | Effect size. |
| Funding | No funding provided. |
| Notes | |

***Risk of bias***

| **Item** | **Authors' judgement** | **Description** |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | MEDLINE and PsycINFO. Pharmaceutical websites were searched for unpublished RCTs |
| Control for bias? | No | No control for bias. |

**Spanemberg 2012**

| | |
|---|---|
| Methods | To carry out a qualitative analysis of RCT methodology in the treatment of bipolar depression. RCTs from 1990 to June 2010 |
| Data | 30 drug RCTs for bipolar depression (mixed comparisons). |
| Comparisons | Industry, non-industry and not stated. |
| Outcomes | Study results and risk of bias (follow-up). |
| Funding | Not reported. |


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Spanemberg 2012** (*Continued*)

| | | |
|---|---|---|
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Yes | Two authors included studies. |
| Comprehensive search? | No | Only PubMed searched. |
| Control for bias? | No | No control for bias. |

**Sung 2013**

| | | |
|---|---|---|
| Methods | To determine as to what proportion of prospectively designed comparative studies on botulinum toxin A injections in patients with cerebral palsy was industry sponsored and whether the qualitative conclusions by the study authors about the use of the botulinum toxin A injection was associated with the financial sponsorship of the studies. Search from January 1991 to November 2011 | |
| Data | 66 prospective comparative studies of botulinum toxin A injections in cerebral palsy (mixed comparisons) | |
| Comparisons | Industry, non-industry and not stated. | |
| Outcomes | Study results, study conclusions and risk of bias (PEDro score, 0-10 point scale) | |
| Funding | No funding provided. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | No | Only one assessor included studies. |
| Comprehensive search? | No | PubMed. |
| Control for bias? | No | No control for bias. |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Tulikangas 2006**

| | | |
|---|---|---|
| Methods | To determine if there is a significant difference in outcomes of clinical trials funded by industry or not of antimuscarinic medications used to treat overactive bladder symptoms and detrusor overactivity. RCTs from 1980 to 2002 | |
| Data | 24 RCTs of antimuscarinic drugs (various comparators). | |
| Comparisons | Industry funded and public funded. | |
| Outcomes | Study results. | |
| Funding | Not reported. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | MEDLINE and references. |
| Control for bias? | No | No control for bias. |

**Tungaraza 2007**

| | | |
|---|---|---|
| Methods | To compare drug trials reported in three major psychiatric journals to investigate whether treatments are more likely to report favorable outcomes when they are funded by the pharmaceutical industry. Studies published in the *British Journal of Psychiatry*, *American Journal of Psychiatry* and *Archives of General Psychiatry* from 2000 to 2004. | |
| Data | 198 psychiatric drug trials (various designs and comparators) | |
| Comparisons | Industry sponsored, industry authored and independent. | |
| Outcomes | Study conclusions. | |
| Funding | No funding provided. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

| | | |
|---|---|---|
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | Handsearch of journals. |
| Control for bias? | No | No control for bias. |

**van Lent 2014**

| | | |
|---|---|---|
| Methods | To evaluate whether submitted manuscripts onRCTs with drugs are more likely to be accepted if they report positive results. Manuscripts of drug trials submitted from January 2010 through April 2012 to one general medical journal (BMJ) and seven specialty journals (*Annals of the Rheumatic Diseases, British Journal of Ophthalmology, Gut, Heart, Thorax, Diabetologia,* and *Journal of Hepatology*). | |
| Data | Sample of 472 drug RCTs (mixed comparisons) of which 98 had relevant data | |
| Comparisons | Industry, industry-supported and non-industry. | |
| Outcomes | Study results. | |
| Funding | Unrestricted educational grant from MSD. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | No | Only one assessor included studies. |
| Comprehensive search? | Yes | Access to manuscripts provided by journal editors. |
| Control for bias? | No | No control for bias. |

**Vlad 2007**

| | |
|---|---|
| Methods | To identify factors that explain heterogeneity in trials of glucosamine. RCTs of glucosamine from 1980 to 2006 |
| Data | 15 RCTs of glucosamine versus placebo for osteoarthritis. |
| Comparisons | Industry funding, industry participation, industry author and independent |


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Vlad 2007** (*Continued*)

| | | |
|---|---|---|
| Outcomes | Study results, effect size and risk of bias (concealment of allocation and Jadad score, 0-5 point scale) | |
| Funding | NIH. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | MEDLINE, the Cochrane Library, conference abstracts, references and reviews |
| Control for bias? | Yes | Exploration of heterogeneity. |

**Xu 2013**

| | | |
|---|---|---|
| Methods | To examine the overall risk of cardiovascular-related events associated with testosterone therapy. RCTs from up to December 2012 | |
| Data | 27 RCTs of testosterone therapy for men (drug vs placebo). | |
| Comparisons | Industry and non-industry. | |
| Outcomes | Effect size and risk of bias (concealment of allocation, detection bias and performance bias) | |
| Funding | No funding provided. | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Yes | Two assessors included studies. |
| Comprehensive search? | Yes | PubMed, WHO Trial Registry, reference lists and reviews. |
| Control for bias? | No | No control for bias. |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Zhang 2013**

| | | |
|---|---|---|
| Methods | To compare second-generation vs first-generation antipsychotics in first-episode psychosis. RCTs up to December 2010 | |
| Data | RCTs of second-generation vs first-generation antipsychotics in first-episode psychosis (drug vs drug) | |
| Comparisons | Industry and government. | |
| Outcomes | Effect size. | |
| Funding | Supported in part by The Zucker Hillside Hospital Advanced Center for Intervention and Services Research for the Study of Schizophrenia and Center for Intervention Development and Applied Research from the National Institute of Mental Health | |
| Notes | | |
| ***Risk of bias*** | | |
| **Item** | **Authors' judgement** | **Description** |
| Adequate selection criteria? | Yes | Objective criteria used. |
| Adequate study inclusion process? | Unclear | Does not describe number of assessors. |
| Comprehensive search? | Yes | PubMed and Web of Science. Additional sources were reference lists of RCTs and reviews, conference abstracts and contact to manufacturers |
| Control for bias? | No | No control for bias. |

RCT: Randomized controlled trial

## Characteristics of excluded studies *[ordered by study ID]*

| Study | Reason for exclusion |
|---|---|
| Adams 2013 | No industry versus non-industry comparison. |
| Adams 2014 | No industry versus non-industry comparison. |
| Afshari 2011 | No industry versus non-industry comparison. |
| Alves 2013 | No industry versus non-industry comparison. |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

(*Continued*)

| | |
|---|---|
| Amiri 2014 | No separate drug or device data. |
| Aneja 2013 | No separate drug or device data. |
| Apler 2011 | No industry versus non-industry comparison. |
| Auerbach 2013 | No industry versus non-industry comparison. |
| Baethge 2013 | No relevant outcomes. |
| Bailey 2011 | No relevant outcomes. |
| Baker 2013 | No industry versus non-industry comparison. |
| Bala 2013 | No relevant outcomes. |
| Balevi 2011 | No quantitative data. |
| Barbui 2011 | No industry versus non-industry comparison. |
| Batalla 2011 | No relevant outcomes. |
| Bennett 2010 | Includes non human studies. |
| Bourgeois 2012 | No relevant outcomes. |
| Brignardello-Petersen 2013 | No industry versus non-industry comparison. |
| Buesching 2012 | No industry versus non-industry comparison. |
| Califf 2012 | No industry versus non-industry comparison. |
| Catala-Lopez 2013 | No relevant outcomes. |
| Chaturvedi 2014 | No industry versus non-industry comparison. |
| Chen 2012 | No industry versus non-industry comparison. |
| Chowers 2009 | No relevant outcomes. |
| Cipriani 2012 | No industry versus non-industry comparison. |
| Cipriani 2012a | No industry versus non-industry comparison. |
| Conen 2008 | No relevant outcomes. |
| Cordoba 2010 | No industry versus non-industry comparison. |


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

(*Continued*)

| | |
|---|---|
| Cosgrove 2011 | No industry versus non-industry comparison. |
| Cunningham 2007 | No separate drug or device data. |
| Deb 2014 | No industry versus non-industry comparison. |
| Demicheli 2014 | No industry versus non-industry comparison. |
| Do 2015 | No industry versus non-industry comparison. |
| Dufka 2014 | No industry versus non-industry comparison. |
| Dunn 2012 | No industry versus non-industry comparison. |
| Dunn 2014 | Includes systematic reviews. |
| Faggion 2014 | Includes systematic reviews. |
| Finnerup 2015 | No industry versus non-industry comparison. |
| Fleurence 2010 | No relevant outcomes. |
| Friedman 2004 | Conflicts of interest, not funding. |
| Fu 2013 | No industry versus non-industry comparison. |
| Fukunaga 2014 | No industry versus non-industry comparison. |
| Furuse 2011 | No industry versus non-industry comparison. |
| Garattini 2010 | No relevant outcomes. |
| Garrison 2010 | No industry versus non-industry comparison. |
| Gasparyan 2013 | No quantitative data. |
| Gerrald 2010 | No industry versus non-industry comparison. |
| Gewandter 2014 | No relevant outcomes. |
| Glick 2006 | No relevant outcomes. |
| Glujovsky 2012 | No industry versus non-industry comparison. |
| Goswami 2014 | No relevant outcomes. |
| Graham 2012 | No industry versus non-industry comparison. |


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

(*Continued*)

| | |
|---|---|
| Grillo-Ardila 2014 | No industry versus non-industry comparison. |
| Guaiana 2013 | No industry versus non-industry comparison. |
| Guo 2013 | No industry versus non-industry comparison. |
| Guo 2014 | No relevant outcomes. |
| Hall 2007 | No relevant outcomes. |
| Hartling 2011 | No relevant outcomes. |
| Hartung 2014 | No industry versus non-industry comparison. |
| Hashmi 2014 | No quantitative data. |
| Hill 2007 | No relevant outcomes (not methodological quality, but reporting quality) |
| Hodgson 2014 | No relevant outcomes. |
| Hughes 2014 | No industry versus non-industry comparison. |
| Ioannidis 2013 | No relevant outcomes. |
| Ipser 2015 | No relevant outcomes. |
| Jagsi 2009 | No separate drug or device data. |
| Jang 2010 | Includes economic analyses. |
| Jefferson 2012 | No industry versus non-industry comparison. |
| Jefferson 2014 | No relevant outcomes. |
| Jones 2013 | No relevant outcomes. |
| Kaiser 2012 | No relevant outcomes. |
| Khan 2008 | No separate drug or device data. |
| Kjaergard 1999 | No separate drug or device data. |
| Komossa 2011 | No relevant outcomes. |
| Krauth 2014 | Includes non human studies. |
| Krzyzanowska 2003 | No relevant outcomes. |


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

(*Continued*)

| | |
|---|---|
| Kulier 2004 | No quantitative data. |
| Kulkarni 2007 | No relevant outcomes. |
| Lai 2006 | No separate drug or device data. |
| Lawrie 2011 | No relevant outcomes. |
| Leopold 2003 | No separate drug or device data. |
| Lethaby 2013 | No relevant outcomes. |
| Leucht 2009a | No relevant outcomes. |
| Leucht 2009b | No relevant outcomes. |
| Li 2013 | No relevant outcomes. |
| Lopez 2014 | Conflicts of interest, not funding. |
| Lundh 2012 | No industry versus non-industry comparison. |
| Lunn 2014 | No relevant outcomes. |
| Magni 2013 | No relevant outcomes. |
| Manzoli 2011 | No relevant outcomes. |
| Manzoli 2014 | No relevant outcomes. |
| McIlvennan 2014 | No relevant outcomes. |
| McLennan 2008 | No relevant outcomes. |
| Montedori 2011 | No separate drug or device data. |
| Montori 2005 | No relevant outcomes. |
| Moteshafi 2012 | No industry versus non-industry comparison. |
| Nkansah 2009 | Calcium supplementation, not a drug. |
| Okike 2007 | Conflicts of interest, not funding. |
| Okike 2008 | No relevant outcomes. |
| Peura 2012 | Includes economic analyses. |


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

(*Continued*)

| | |
|---|---|
| Phillips 2012 | No quantitative data. |
| Polyzos 2011 | Includes economic analyses. |
| Probst 2014 | Study protocol. |
| Procyshyn 2004 | No relevant data for non-industry studies. |
| Purgato 2014 | No relevant outcomes. |
| Radecki 2011 | No relevant outcomes. |
| Ramagopalan 2014 | No relevant outcomes. |
| Rattehalli 2010 | No relevant outcomes. |
| Roach 2008 | No separate drug or device data. |
| Sanossian 2006 | No relevant outcomes. |
| Sawata 2011 | No separate drug or device data. |
| Schott 2010 | No quantitative data. |
| Schott 2010a | No relevant outcomes. |
| Schott 2013 | No relevant outcomes. |
| Shah 2005 | No separate drug or device data. |
| Shamliyan 2012 | No relevant outcomes. |
| Shen 2014 | No relevant outcomes. |
| Stamatakis 2013 | No quantitative data. |
| Strupp 2010 | No quantitative data. |
| Sun 2011 | No relevant outcomes. |
| Sun 2013 | No separate drug or device data. |
| Thirugnanam 2012 | Includes economic analyses. |
| Thomas 2008 | No relevant outcomes (not methodological quality, but reporting quality) |
| Thomson 2010 | No separate drug or device data. |


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

(*Continued*)

| | |
|---|---|
| Valachis 2012 | Includes economic analyses. |
| van Lent 2013 | No quantitative data. |
| Wang 2010 | Conflicts of interest, not funding. |
| Watanabe 2010 | No relevant outcomes. |
| Yao 2007 | No separate drug or device data. |
| Yaphe 2001 | No separate drug or device data. |
| Yuan 2011 | No relevant outcomes. |
| Yue 2013 | No separate drug or device data. |
| Zani 2011 | No relevant outcomes. |
| Zulman 2011 | No relevant outcomes. |


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

## DATA AND ANALYSES

### Comparison 1. Results: Industry sponsored versus non-industry sponsored studies

| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 Number of studies with favorable efficacy results | 25 | 2923 | Risk Ratio (M-H, Random, 95% CI) | 1.27 [1.17, 1.37] |
| 2 Number of studies with favorable harms results | 4 | 826 | Risk Ratio (M-H, Random, 95% CI) | 1.37 [0.64, 2.93] |

### Comparison 2. Results: Industry sponsorship by test treatment company versus sponsorship by comparator treatment company

| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 Number of studies with favorable test treatment efficacy results | 2 | 131 | Risk Ratio (M-H, Random, 95% CI) | 3.88 [1.26, 11.94] |

### Comparison 3. Conclusions: industry sponsored versus non-industry sponsored studies

| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 Number of studies with favorable conclusions | 29 | 4583 | Risk Ratio (M-H, Random, 95% CI) | 1.34 [1.19, 1.51] |

### Comparison 4. Conclusions: Industry sponsorship by test treatment company versus sponsorship by comparator treatment company

| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 Number of studies with favorable test treatment conclusions | 3 | 154 | Risk Ratio (M-H, Random, 95% CI) | 5.92 [2.80, 12.54] |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Comparison 5. Risk of bias: industry sponsored versus non-industry sponsored studies**

| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 Number of studies with low risk of bias from sequence generation | 9 | 913 | Risk Ratio (M-H, Random, 95% CI) | 0.99 [0.78, 1.27] |
| 2 Number of studies with low risk of bias from concealment of allocation | 16 | 1886 | Risk Ratio (M-H, Random, 95% CI) | 1.06 [0.85, 1.31] |
| 3 Number of studies with low risk of bias from blinding-overall | 13 | 1578 | Risk Ratio (M-H, Random, 95% CI) | 1.25 [1.05, 1.50] |
| 4 Number of studies with low risk from blinding-performance bias | 3 | 128 | Risk Ratio (M-H, Random, 95% CI) | 1.26 [0.60, 2.62] |
| 5 Number of studies with low risk from blinding-detection bias | 4 | 307 | Risk Ratio (M-H, Random, 95% CI) | 1.47 [1.02, 2.12] |
| 6 Number of studies with low risk of bias from loss to follow-up | 6 | 416 | Risk Ratio (M-H, Random, 95% CI) | 1.05 [0.92, 1.18] |
| 7 Number of studies with low risk of bias from selective outcome reporting | 2 | 193 | Risk Ratio (M-H, Random, 95% CI) | 1.49 [0.61, 3.60] |

**Comparison 6. Concordance between study results and conclusions: industry sponsored versus non-industry sponsored studies**

| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 Number of studies with concordant study results and conclusions | 6 | 751 | Risk Ratio (M-H, Random, 95% CI) | 0.83 [0.70, 0.98] |

**Comparison 7. Subgroup analysis**

| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 Number of studies with favorable efficacy results, stratified by risk of bias | 25 | 2923 | Risk Ratio (M-H, Random, 95% CI) | 1.27 [1.17, 1.37] |
| 1.1 High risk of bias | 20 | 2107 | Risk Ratio (M-H, Random, 95% CI) | 1.20 [1.11, 1.30] |
| 1.2 Low risk of bias | 5 | 816 | Risk Ratio (M-H, Random, 95% CI) | 1.46 [1.25, 1.71] |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

| | | | | |
|---|---|---|---|---|
| 2 Number of studies with favorable harms results, stratified by risk of bias | 4 | 826 | Risk Ratio (M-H, Random, 95% CI) | 1.37 [0.64, 2.93] |
| 2.1 High risk of bias | 3 | 561 | Risk Ratio (M-H, Random, 95% CI) | 1.87 [1.54, 2.27] |
| 2.2 Low risk of bias | 1 | 265 | Risk Ratio (M-H, Random, 95% CI) | 0.82 [0.72, 0.93] |
| 3 Number of studies with favorable conclusions, stratified by risk of bias | 29 | 4583 | Risk Ratio (M-H, Random, 95% CI) | 1.34 [1.19, 1.51] |
| 3.1 High risk of bias | 23 | 3515 | Risk Ratio (M-H, Random, 95% CI) | 1.32 [1.15, 1.50] |
| 3.2 Low risk of bias | 6 | 1068 | Risk Ratio (M-H, Random, 95% CI) | 1.42 [1.12, 1.79] |
| 4 Number of studies with favorable efficacy results, stratified by type of intervention | 25 | 2923 | Risk Ratio (M-H, Random, 95% CI) | 1.26 [1.15, 1.38] |
| 4.1 Drug studies | 25 | 2904 | Risk Ratio (M-H, Random, 95% CI) | 1.27 [1.17, 1.38] |
| 4.2 Device studies | 1 | 19 | Risk Ratio (M-H, Random, 95% CI) | 0.50 [0.26, 0.97] |
| 5 Number of studies with favorable conclusions, stratified by type of intervention | 29 | 4583 | Risk Ratio (M-H, Random, 95% CI) | 1.33 [1.18, 1.49] |
| 5.1 Drug studies | 27 | 4179 | Risk Ratio (M-H, Random, 95% CI) | 1.33 [1.17, 1.52] |
| 5.2 Device studies | 4 | 404 | Risk Ratio (M-H, Random, 95% CI) | 1.33 [1.13, 1.57] |
| 6 Number of studies with favorable efficacy results, stratified by type of domain | 25 | 2923 | Risk Ratio (M-H, Random, 95% CI) | 1.27 [1.17, 1.37] |
| 6.1 Specific treatments or diseases | 20 | 1845 | Risk Ratio (M-H, Random, 95% CI) | 1.27 [1.13, 1.42] |
| 6.2 Mixed domain | 5 | 1078 | Risk Ratio (M-H, Random, 95% CI) | 1.31 [1.18, 1.46] |
| 7 Number of studies with favorable harms results, stratified by type of domain | 4 | 826 | Risk Ratio (M-H, Random, 95% CI) | 1.37 [0.64, 2.93] |
| 7.1 Specific treatments or diseases | 3 | 561 | Risk Ratio (M-H, Random, 95% CI) | 1.87 [1.54, 2.27] |
| 7.2 Mixed study domain | 1 | 265 | Risk Ratio (M-H, Random, 95% CI) | 0.82 [0.72, 0.93] |
| 8 Number of studies with favorable conclusions, stratified by type of domain | 29 | 4583 | Risk Ratio (M-H, Random, 95% CI) | 1.34 [1.19, 1.51] |
| 8.1 Specific treatments or diseases | 24 | 3416 | Risk Ratio (M-H, Random, 95% CI) | 1.37 [1.17, 1.61] |
| 8.2 Mixed study domain | 5 | 1167 | Risk Ratio (M-H, Random, 95% CI) | 1.26 [1.07, 1.49] |

## Comparison 8. Sensitivity analysis

| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 Number of studies with favorable efficacy results, sponsorship recoded | 8 | 726 | Risk Ratio (M-H, Random, 95% CI) | 1.35 [1.18, 1.55] |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

| | | | | |
|---|---|---|---|---|
| 2 Number of studies with favorable harms results, sponsorship recoded | 3 | 501 | Risk Ratio (M-H, Random, 95% CI) | 1.42 [0.31, 6.50] |
| 3 Number of studies with favorable conclusions, sponsorship recoded | 8 | 1029 | Risk Ratio (M-H, Random, 95% CI) | 1.24 [1.04, 1.47] |
| 4 Number of studies with favorable efficacy results, analysis adjusted for confounders | 3 | | Odds Ratio (Random, 95% CI) | 3.15 [2.07, 4.80] |
| 5 Number of studies with favorable conclusions, analysis adjusted for confounders | 4 | | Odds Ratio (Random, 95% CI) | 3.13 [1.66, 5.93] |
| 6 Number of studies with favorable efficacy results, fixed-effect model | 25 | 2923 | Risk Ratio (M-H, Fixed, 95% CI) | 1.31 [1.23, 1.40] |
| 7 Number of studies with favorable harms results, fixed-effect model | 4 | 826 | Risk Ratio (M-H, Fixed, 95% CI) | 1.29 [1.15, 1.46] |
| 8 Number of studies with favorable test treatment efficacy results, fixed-effect model | 2 | 131 | Risk Ratio (M-H, Fixed, 95% CI) | 4.64 [2.08, 10.32] |
| 9 Number of studies with favorable conclusions, fixed-effect model | 29 | 4583 | Risk Ratio (M-H, Fixed, 95% CI) | 1.29 [1.24, 1.35] |
| 10 Number of studies with favorable test treatment conclusions, fixed-effect model | 3 | 154 | Risk Ratio (M-H, Fixed, 95% CI) | 5.90 [2.79, 12.49] |
| 11 Number of studies with favorable conclusions, papers with unpublished studies excluded | 27 | 4436 | Risk Ratio (M-H, Random, 95% CI) | 1.35 [1.19, 1.54] |
| 12 Number of studies with favorable efficacy results, restricted to specific domains | 13 | 797 | Risk Ratio (M-H, Random, 95% CI) | 1.28 [1.07, 1.51] |
| 13 Number of studies with favorable harms results, restricted to specific domains | 3 | 561 | Risk Ratio (M-H, Random, 95% CI) | 1.87 [1.54, 2.27] |
| 14 Number of studies with favorable test treatment efficacy results, restricted to specific domains | 2 | 131 | Risk Ratio (M-H, Random, 95% CI) | 3.88 [1.26, 11.94] |
| 15 Number of studies with favorable conclusions, restricted to specific domains | 15 | 1803 | Risk Ratio (M-H, Random, 95% CI) | 1.42 [1.25, 1.61] |
| 16 Number of studies with favorable test treatment conclusions, restricted to specific domains | 3 | 154 | Risk Ratio (M-H, Random, 95% CI) | 5.92 [2.80, 12.54] |


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Analysis 1.1. Comparison 1 Results: Industry sponsored versus non-industry sponsored studies, Outcome 1 Number of studies with favorable efficacy results.**

Review: Industry sponsorship and research outcome

Comparison: 1 Results: Industry sponsored versus non-industry sponsored studies

Outcome: 1 Number of studies with favorable efficacy results

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Alasbali 2009 | 7/29 | 2/10 | | 0.3 % | 1.21 [ 0.30, 4.88 ] |
| Bariani 2013 | 32/56 | 25/49 | | 4.0 % | 1.12 [ 0.78, 1.60 ] |
| Bero 2007 | 65/94 | 48/97 | | 6.8 % | 1.40 [ 1.10, 1.78 ] |
| Bond 2012 | 56/67 | 2/4 | | 0.7 % | 1.67 [ 0.62, 4.48 ] |
| Booth 2008 | 49/120 | 50/165 | | 4.8 % | 1.35 [ 0.98, 1.85 ] |
| Bourgeois 2010 | 222/260 | 48/85 | | 8.6 % | 1.51 [ 1.25, 1.83 ] |
| Clark 2002 | 8/16 | 1/3 | | 0.2 % | 1.50 [ 0.28, 8.00 ] |
| Clifford 2002 | 46/66 | 21/34 | | 5.0 % | 1.13 [ 0.83, 1.54 ] |
| Djulbegovic 2013 | 19/33 | 17/52 | | 2.4 % | 1.76 [ 1.08, 2.87 ] |
| Etter 2007 | 25/49 | 9/41 | | 1.5 % | 2.32 [ 1.23, 4.40 ] |
| Flacco 2015 | 152/182 | 86/137 | | 11.0 % | 1.33 [ 1.15, 1.54 ] |
| Gan 2012 | 70/162 | 25/91 | | 3.7 % | 1.57 [ 1.08, 2.29 ] |
| Kelly 2006 | 12/13 | 4/8 | | 1.2 % | 1.85 [ 0.91, 3.76 ] |
| Khan 2012 | 39/54 | 24/32 | | 6.2 % | 0.96 [ 0.74, 1.25 ] |
| Momeni 2009 | 20/24 | 69/85 | | 8.1 % | 1.03 [ 0.84, 1.26 ] |
| Moncrieff 2003 | 2/2 | 2/7 | | 0.5 % | 2.67 [ 0.85, 8.39 ] |
| Perlis 2005b | 93/113 | 37/49 | | 9.2 % | 1.09 [ 0.91, 1.31 ] |
| Rasmussen 2009 | 66/109 | 14/28 | | 3.4 % | 1.21 [ 0.81, 1.81 ] |
| Rattinger 2009 | 26/36 | 18/25 | | 4.8 % | 1.00 [ 0.73, 1.38 ] |
| Roper 2014 | 91/152 | 34/64 | | 6.1 % | 1.13 [ 0.87, 1.47 ] |
| Spanemberg 2012 | 10/14 | 6/16 | | 1.2 % | 1.90 [ 0.93, 3.89 ] |
| Sung 2013 | 22/28 | 13/25 | | 3.1 % | 1.51 [ 0.99, 2.31 ] |
| Tulikangas 2006 | 15/15 | 7/9 | | 3.8 % | 1.29 [ 0.89, 1.87 ] |
| van Lent 2014 | 46/71 | 14/27 | | 3.3 % | 1.25 [ 0.84, 1.87 ] |

(*Continued . . .*)


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

(. . . *Continued*)

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Vlad 2007 | 5/11 | 0/4 | | 0.1 % | 4.58 [ 0.31, 68.24 ] |
| **Total (95% CI)** | **1776** | **1147** | | **100.0 %** | **1.27 [ 1.17, 1.37 ]** |

Total events: 1198 (Industry), 576 (Non-industry)

Heterogeneity: Tau$^2$ = 0.01; Chi$^2$ = 33.55, df = 24 (P = 0.09); I$^2$ =28%

Test for overall effect: Z = 5.63 (P < 0.00001)

Test for subgroup differences: Not applicable

**Analysis 1.2. Comparison 1 Results: Industry sponsored versus non-industry sponsored studies, Outcome 2 Number of studies with favorable harms results.**

Review: Industry sponsorship and research outcome

Comparison: 1 Results: Industry sponsored versus non-industry sponsored studies

Outcome: 2 Number of studies with favorable harms results

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Als-Nielsen 2003 | 117/164 | 88/101 | | 34.6 % | 0.82 [ 0.72, 0.93 ] |
| Halpern 2005 | 1/3 | 10/45 | | 12.8 % | 1.50 [ 0.28, 8.14 ] |
| Nieto 2007 | 180/275 | 80/229 | | 34.1 % | 1.87 [ 1.54, 2.28 ] |
| Kemmeren 2001 | 3/4 | 2/5 | | 18.5 % | 1.88 [ 0.56, 6.31 ] |
| **Total (95% CI)** | **446** | **380** | | **100.0 %** | **1.37 [ 0.64, 2.93 ]** |

Total events: 301 (Industry), 180 (Non-industry)

Heterogeneity: Tau$^2$ = 0.43; Chi$^2$ = 67.64, df = 3 (P<0.00001); I$^2$ =96%

Test for overall effect: Z = 0.81 (P = 0.42)

Test for subgroup differences: Not applicable

**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Analysis 2.1. Comparison 2 Results: Industry sponsorship by test treatment company versus sponsorship by comparator treatment company, Outcome 1 Number of studies with favorable test treatment efficacy results.**

Review: Industry sponsorship and research outcome

Comparison: 2 Results: Industry sponsorship by test treatment company versus sponsorship by comparator treatment company

Outcome: 1 Number of studies with favorable test treatment efficacy results

| Study or subgroup | Test treatment sponsor n/N | Comparator sponsor n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Bero 2007 | 43/65 | 3/30 | | 51.4 % | 6.62 [ 2.23, 19.63 ] |
| Rattinger 2009 | 22/30 | 2/6 | | 48.6 % | 2.20 [ 0.70, 6.96 ] |
| **Total (95% CI)** | **95** | **36** | | **100.0 %** | **3.88 [ 1.26, 11.94 ]** |

Total events: 65 (Test treatment sponsor), 5 (Comparator sponsor)

Heterogeneity: $Tau^2 = 0.33$; $Chi^2 = 2.02$, df = 1 (P = 0.16); $I^2 = 50\%$

Test for overall effect: Z = 2.36 (P = 0.018)

Test for subgroup differences: Not applicable





Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Analysis 3.1. Comparison 3 Conclusions: industry sponsored versus non-industry sponsored studies, Outcome 1 Number of studies with favorable conclusions.**

Review: Industry sponsorship and research outcome

Comparison: 3 Conclusions: industry sponsored versus non-industry sponsored studies

Outcome: 1 Number of studies with favorable conclusions

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Ahmer 2005 | 125/138 | 39/50 | | 4.3 % | 1.16 [ 0.99, 1.36 ] |
| Alasbali 2009 | 26/29 | 2/10 | | 0.8 % | 4.48 [ 1.29, 15.58 ] |
| Als-Nielsen 2003 | 92/197 | 43/173 | | 3.6 % | 1.88 [ 1.39, 2.53 ] |
| Bariani 2013 | 39/56 | 39/49 | | 4.0 % | 0.88 [ 0.70, 1.09 ] |
| Bartels 2012 | 28/31 | 76/129 | | 4.2 % | 1.53 [ 1.27, 1.84 ] |
| Bero 2007 | 66/94 | 39/97 | | 3.7 % | 1.75 [ 1.32, 2.30 ] |
| Booth 2008 | 66/118 | 55/153 | | 3.8 % | 1.56 [ 1.19, 2.03 ] |
| Buchkowsky 2004 | 138/181 | 224/319 | | 4.4 % | 1.09 [ 0.97, 1.21 ] |
| Chard 2000 | 106/108 | 373/383 | | 4.6 % | 1.01 [ 0.98, 1.04 ] |
| Cho 1996 | 39/40 | 89/112 | | 4.4 % | 1.23 [ 1.10, 1.36 ] |
| Clark 2002 | 21/23 | 5/7 | | 2.6 % | 1.28 [ 0.79, 2.08 ] |
| Davidson 1986 | 32/36 | 31/49 | | 3.9 % | 1.41 [ 1.10, 1.79 ] |
| DeGeorge 2015 | 18/18 | 77/106 | | 4.3 % | 1.34 [ 1.17, 1.54 ] |
| Djulbegovic 2000 | 26/35 | 50/95 | | 3.7 % | 1.41 [ 1.07, 1.85 ] |
| Djulbegovic 2013 | 29/32 | 29/52 | | 3.8 % | 1.63 [ 1.24, 2.12 ] |
| Finucane 2004 | 30/30 | 12/18 | | 3.4 % | 1.50 [ 1.08, 2.07 ] |
| Jefferson 2009 | 64/76 | 131/194 | | 4.3 % | 1.25 [ 1.09, 1.43 ] |
| Kjaergard 2002 | 28/38 | 16/22 | | 3.5 % | 1.01 [ 0.74, 1.39 ] |
| Lee 2012 | 15/43 | 4/10 | | 1.4 % | 0.87 [ 0.37, 2.06 ] |
| Liss 2006 | 62/63 | 12/37 | | 2.7 % | 3.03 [ 1.90, 4.84 ] |
| Lynch 2007 | 26/34 | 49/65 | | 3.9 % | 1.01 [ 0.80, 1.28 ] |
| Peppercorn 2007 | 52/67 | 48/73 | | 4.0 % | 1.18 [ 0.96, 1.46 ] |
| Perlis 2005a | 87/102 | 47/77 | | 4.1 % | 1.40 [ 1.15, 1.70 ] |
| Printz 2013 | 12/30 | 1/3 | | 0.5 % | 1.20 [ 0.23, 6.31 ] |
| Rasmussen 2009 | 83/109 | 15/28 | | 3.3 % | 1.42 [ 0.99, 2.04 ] |




(*Continued . . .*)


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

(. . . *Continued*)

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Rattinger 2009 | 31/36 | 21/25 | | 4.0 % | 1.03 [ 0.83, 1.27 ] |
| Ridker 2006 | 121/189 | 21/51 | | 3.3 % | 1.55 [ 1.10, 2.20 ] |
| Sung 2013 | 15/28 | 5/25 | | 1.4 % | 2.68 [ 1.14, 6.31 ] |
| Tungaraza 2007 | 124/146 | 28/44 | | 3.9 % | 1.33 [ 1.06, 1.69 ] |
| **Total (95% CI)** | **2127** | **2456** | | **100.0 %** | **1.34 [ 1.19, 1.51 ]** |

Total events: 1601 (Industry), 1581 (Non-industry)

Heterogeneity: Tau$^2$ = 0.08; Chi$^2$ = 336.13, df = 28 (P<0.00001); I$^2$ =92%

Test for overall effect: Z = 4.77 (P < 0.00001)

Test for subgroup differences: Not applicable

**Analysis 4.1. Comparison 4 Conclusions: Industry sponsorship by test treatment company versus sponsorship by comparator treatment company, Outcome 1 Number of studies with favorable test treatment conclusions.**

Review: Industry sponsorship and research outcome

Comparison: 4 Conclusions: Industry sponsorship by test treatment company versus sponsorship by comparator treatment company

Outcome: 1 Number of studies with favorable test treatment conclusions

| Study or subgroup | Test treatment sponsor n/N | Comparator sponsor n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Bero 2007 | 51/65 | 4/30 | | 66.4 % | 5.88 [ 2.34, 14.78 ] |
| Heres 2006 | 10/12 | 1/9 | | 16.2 % | 7.50 [ 1.16, 48.43 ] |
| Rattinger 2009 | 26/32 | 1/6 | | 17.4 % | 4.88 [ 0.81, 29.40 ] |
| **Total (95% CI)** | **109** | **45** | | **100.0 %** | **5.92 [ 2.80, 12.54 ]** |

Total events: 87 (Test treatment sponsor), 6 (Comparator sponsor)

Heterogeneity: Tau$^2$ = 0.0; Chi$^2$ = 0.11, df = 2 (P = 0.95); I$^2$ =0.0%

Test for overall effect: Z = 4.65 (P < 0.00001)

Test for subgroup differences: Not applicable





**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Analysis 5.1. Comparison 5 Risk of bias: industry sponsored versus non-industry sponsored studies, Outcome 1 Number of studies with low risk of bias from sequence generation.**

Review: Industry sponsorship and research outcome

Comparison: 5 Risk of bias: industry sponsored versus non-industry sponsored studies

Outcome: 1 Number of studies with low risk of bias from sequence generation

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Als-Nielsen 2003 | 62/197 | 43/173 | | 16.6 % | 1.27 [ 0.91, 1.76 ] |
| Avni 2014 | 16/30 | 1/6 | | 1.7 % | 3.20 [ 0.52, 19.75 ] |
| Clark 2002 | 7/16 | 2/3 | | 5.0 % | 0.66 [ 0.25, 1.74 ] |
| Corona 2014 | 37/37 | 38/38 | | 23.5 % | 1.00 [ 0.95, 1.05 ] |
| Crocetti 2010 | 11/32 | 21/25 | | 11.7 % | 0.41 [ 0.25, 0.68 ] |
| Khan 2012 | 22/64 | 14/39 | | 11.0 % | 0.96 [ 0.56, 1.64 ] |
| Killin 2014 | 5/10 | 2/4 | | 3.8 % | 1.00 [ 0.31, 3.19 ] |
| Kjaergard 2002 | 34/38 | 19/22 | | 20.5 % | 1.04 [ 0.85, 1.26 ] |
| Naci 2014 | 49/143 | 5/36 | | 6.2 % | 2.47 [ 1.06, 5.74 ] |
| **Total (95% CI)** | **567** | **346** | | **100.0 %** | **0.99 [ 0.78, 1.27 ]** |

Total events: 243 (Industry), 145 (Non-industry)

Heterogeneity: $Tau^2 = 0.07$; $Chi^2 = 29.21$, df = 8 (P = 0.00029); $I^2 = 73\%$

Test for overall effect: Z = 0.07 (P = 0.94)

Test for subgroup differences: Not applicable

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Analysis 5.2. Comparison 5 Risk of bias: industry sponsored versus non-industry sponsored studies, Outcome 2 Number of studies with low risk of bias from concealment of allocation.**

Review: Industry sponsorship and research outcome

Comparison: 5 Risk of bias: industry sponsored versus non-industry sponsored studies

Outcome: 2 Number of studies with low risk of bias from concealment of allocation

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Als-Nielsen 2003 | 55/197 | 27/173 | | 8.7 % | 1.79 [ 1.18, 2.70 ] |
| Avni 2014 | 12/30 | 1/6 | | 1.3 % | 2.40 [ 0.38, 15.14 ] |
| Bero 2007 | 19/95 | 21/97 | | 7.0 % | 0.92 [ 0.53, 1.60 ] |
| Clifford 2002 | 22/66 | 14/34 | | 7.3 % | 0.81 [ 0.48, 1.37 ] |
| Crocetti 2010 | 14/32 | 16/25 | | 7.7 % | 0.68 [ 0.42, 1.12 ] |
| Jones 2010 | 23/31 | 35/56 | | 10.3 % | 1.19 [ 0.89, 1.59 ] |
| Khan 2012 | 20/64 | 11/39 | | 6.3 % | 1.11 [ 0.60, 2.06 ] |
| Killin 2014 | 2/10 | 2/4 | | 1.7 % | 0.40 [ 0.08, 1.94 ] |
| Kjaergard 2002 | 26/38 | 15/22 | | 9.4 % | 1.00 [ 0.70, 1.44 ] |
| Naci 2014 | 22/143 | 2/36 | | 2.0 % | 2.77 [ 0.68, 11.24 ] |
| Pengel 2009 | 63/154 | 34/126 | | 9.6 % | 1.52 [ 1.07, 2.14 ] |
| Rattinger 2009 | 10/36 | 5/25 | | 3.8 % | 1.39 [ 0.54, 3.57 ] |
| Rios 2008 | 6/42 | 4/47 | | 2.7 % | 1.68 [ 0.51, 5.54 ] |
| Roper 2014 | 141/152 | 62/64 | | 12.5 % | 0.96 [ 0.90, 1.02 ] |
| Vlad 2007 | 2/11 | 3/4 | | 2.1 % | 0.24 [ 0.06, 0.96 ] |
| Xu 2013 | 8/13 | 11/14 | | 7.5 % | 0.78 [ 0.47, 1.30 ] |
| **Total (95% CI)** | **1114** | **772** | | **100.0 %** | **1.06 [ 0.85, 1.31 ]** |

Total events: 445 (Industry), 263 (Non-industry)

Heterogeneity: $Tau^2 = 0.10$; $Chi^2 = 52.52$, df = 15 ($P<0.00001$); $I^2 = 71\%$

Test for overall effect: Z = 0.48 (P = 0.63)

Test for subgroup differences: Not applicable

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Analysis 5.3. Comparison 5 Risk of bias: industry sponsored versus non-industry sponsored studies, Outcome 3 Number of studies with low risk of bias from blinding-overall.**

Review: Industry sponsorship and research outcome

Comparison: 5 Risk of bias: industry sponsored versus non-industry sponsored studies

Outcome: 3 Number of studies with low risk of bias from blinding-overall

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Als-Nielsen 2003 | 150/197 | 84/157 | | 12.4 % | 1.42 [ 1.21, 1.68 ] |
| Avni 2014 | 16/30 | 1/6 | | 0.9 % | 3.20 [ 0.52, 19.75 ] |
| Bero 2007 | 53/95 | 36/97 | | 9.8 % | 1.50 [ 1.10, 2.06 ] |
| Clark 2002 | 6/16 | 1/3 | | 1.0 % | 1.13 [ 0.20, 6.29 ] |
| Corona 2014 | 32/37 | 32/38 | | 12.1 % | 1.03 [ 0.85, 1.24 ] |
| Crocetti 2010 | 28/32 | 23/25 | | 12.3 % | 0.95 [ 0.80, 1.13 ] |
| Khan 2012 | 55/64 | 20/39 | | 9.6 % | 1.68 [ 1.21, 2.31 ] |
| Kjaergard 2002 | 26/38 | 13/22 | | 8.1 % | 1.16 [ 0.77, 1.74 ] |
| Perlis 2005a | 71/102 | 27/77 | | 9.5 % | 1.99 [ 1.43, 2.76 ] |
| Rasmussen 2009 | 33/109 | 3/28 | | 2.2 % | 2.83 [ 0.93, 8.54 ] |
| Rattinger 2009 | 20/36 | 15/25 | | 7.7 % | 0.93 [ 0.60, 1.43 ] |
| Rios 2008 | 7/42 | 13/47 | | 3.6 % | 0.60 [ 0.27, 1.37 ] |
| Roper 2014 | 89/152 | 35/64 | | 10.8 % | 1.07 [ 0.83, 1.39 ] |
| **Total (95% CI)** | **950** | **628** | | **100.0 %** | **1.25 [ 1.05, 1.50 ]** |

Total events: 586 (Industry), 303 (Non-industry)

Heterogeneity: $Tau^2 = 0.06$; $Chi^2 = 43.06$, df = 12 (P = 0.00002); $I^2 = 72\%$

Test for overall effect: Z = 2.44 (P = 0.015)

Test for subgroup differences: Not applicable





Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Analysis 5.4. Comparison 5 Risk of bias: industry sponsored versus non-industry sponsored studies, Outcome 4 Number of studies with low risk from blinding-performance bias.**

Review: Industry sponsorship and research outcome

Comparison: 5 Risk of bias: industry sponsored versus non-industry sponsored studies

Outcome: 4 Number of studies with low risk from blinding-performance bias

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Jones 2010 | 16/31 | 14/56 | | 39.0 % | 2.06 [ 1.17, 3.64 ] |
| Killin 2014 | 4/10 | 3/4 | | 27.5 % | 0.53 [ 0.21, 1.37 ] |
| Xu 2013 | 8/13 | 6/14 | | 33.5 % | 1.44 [ 0.68, 3.02 ] |
| **Total (95% CI)** | **54** | **74** | | **100.0 %** | **1.26 [ 0.60, 2.62 ]** |

Total events: 28 (Industry), 23 (Non-industry)

Heterogeneity: $Tau^2 = 0.28$; $Chi^2 = 5.91$, df = 2 (P = 0.05); $I^2 = 66\%$

Test for overall effect: Z = 0.62 (P = 0.54)

Test for subgroup differences: Not applicable





Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Analysis 5.5. Comparison 5 Risk of bias: industry sponsored versus non-industry sponsored studies, Outcome 5 Number of studies with low risk from blinding-detection bias.**

Review: Industry sponsorship and research outcome

Comparison: 5 Risk of bias: industry sponsored versus non-industry sponsored studies

Outcome: 5 Number of studies with low risk from blinding-detection bias

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Jones 2010 | 15/31 | 15/56 | | 41.8 % | 1.81 [ 1.03, 3.18 ] |
| Killin 2014 | 5/10 | 2/4 | | 9.9 % | 1.00 [ 0.31, 3.19 ] |
| Naci 2014 | 60/143 | 10/36 | | 42.5 % | 1.51 [ 0.86, 2.65 ] |
| Xu 2013 | 2/13 | 4/14 | | 5.8 % | 0.54 [ 0.12, 2.46 ] |
| **Total (95% CI)** | **197** | **110** | | **100.0 %** | **1.47 [ 1.02, 2.12 ]** |

Total events: 82 (Industry), 31 (Non-industry)

Heterogeneity: $Tau^2 = 0.0$; $Chi^2 = 2.63$, df = 3 (P = 0.45); $I^2 = 0.0\%$

Test for overall effect: Z = 2.07 (P = 0.038)

Test for subgroup differences: Not applicable

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Analysis 5.6. Comparison 5 Risk of bias: industry sponsored versus non-industry sponsored studies, Outcome 6 Number of studies with low risk of bias from loss to follow-up.**

Review: Industry sponsorship and research outcome

Comparison: 5 Risk of bias: industry sponsored versus non-industry sponsored studies

Outcome: 6 Number of studies with low risk of bias from loss to follow-up

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Corona 2014 | 32/37 | 27/38 | | 26.0 % | 1.22 [ 0.96, 1.55 ] |
| Crocetti 2010 | 28/32 | 22/25 | | 38.4 % | 0.99 [ 0.82, 1.21 ] |
| Killin 2014 | 3/10 | 0/4 | | 0.2 % | 3.18 [ 0.20, 50.69 ] |
| Naci 2014 | 79/143 | 18/36 | | 11.8 % | 1.10 [ 0.77, 1.58 ] |
| Rattinger 2009 | 28/36 | 20/25 | | 21.8 % | 0.97 [ 0.75, 1.26 ] |
| Spanemberg 2012 | 4/14 | 9/16 | | 1.8 % | 0.51 [ 0.20, 1.29 ] |
| **Total (95% CI)** | **272** | **144** | | **100.0 %** | **1.05 [ 0.92, 1.18 ]** |

Total events: 174 (Industry), 96 (Non-industry)

Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 5.10$, df = 5 (P = 0.40); $I^2 = 2\%$

Test for overall effect: Z = 0.71 (P = 0.48)

Test for subgroup differences: Not applicable





Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Analysis 5.7. Comparison 5 Risk of bias: industry sponsored versus non-industry sponsored studies, Outcome 7 Number of studies with low risk of bias from selective outcome reporting.**

Review: Industry sponsorship and research outcome

Comparison: 5 Risk of bias: industry sponsored versus non-industry sponsored studies

Outcome: 7 Number of studies with low risk of bias from selective outcome reporting

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Killin 2014 | 7/10 | 3/4 | | 45.4 % | 0.93 [ 0.47, 1.87 ] |
| Naci 2014 | 113/143 | 13/36 | | 54.6 % | 2.19 [ 1.41, 3.41 ] |
| **Total (95% CI)** | **153** | **40** | | **100.0 %** | **1.49 [ 0.61, 3.60 ]** |

Total events: 120 (Industry), 16 (Non-industry)

Heterogeneity: $Tau^2 = 0.32$; $Chi^2 = 4.65$, df = 1 (P = 0.03); $I^2 = 79\%$

Test for overall effect: Z = 0.88 (P = 0.38)

Test for subgroup differences: Not applicable





Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Analysis 6.1. Comparison 6 Concordance between study results and conclusions: industry sponsored versus non-industry sponsored studies, Outcome 1 Number of studies with concordant study results and conclusions.**

Review: Industry sponsorship and research outcome

Comparison: 6 Concordance between study results and conclusions: industry sponsored versus non-industry sponsored studies

Outcome: 1 Number of studies with concordant study results and conclusions

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Alasbali 2009 | 11/29 | 10/10 | | 8.5 % | 0.40 [ 0.25, 0.64 ] |
| Bero 2007 | 72/95 | 80/97 | | 23.4 % | 0.92 [ 0.79, 1.06 ] |
| Djulbegovic 2013 | 18/32 | 40/52 | | 12.9 % | 0.73 [ 0.52, 1.03 ] |
| Jefferson 2009 | 39/66 | 120/172 | | 18.8 % | 0.85 [ 0.68, 1.06 ] |
| Rasmussen 2009 | 86/109 | 23/28 | | 20.3 % | 0.96 [ 0.79, 1.17 ] |
| Rattinger 2009 | 27/36 | 20/25 | | 16.1 % | 0.94 [ 0.71, 1.23 ] |
| **Total (95% CI)** | **367** | **384** | | **100.0 %** | **0.83 [ 0.70, 0.98 ]** |

Total events: 253 (Industry), 293 (Non-industry)

Heterogeneity: $Tau^2 = 0.02$; $Chi^2 = 13.42$, df = 5 (P = 0.02); $I^2 = 63\%$

Test for overall effect: Z = 2.24 (P = 0.025)

Test for subgroup differences: Not applicable





Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Analysis 7.1. Comparison 7 Subgroup analysis, Outcome 1 Number of studies with favorable efficacy results, stratified by risk of bias.**

Review: Industry sponsorship and research outcome

Comparison: 7 Subgroup analysis

Outcome: 1 Number of studies with favorable efficacy results, stratified by risk of bias

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| 1 High risk of bias | | | | | |
| Alasbali 2009 | 7/29 | 2/10 | | 0.3 % | 1.21 [ 0.30, 4.88 ] |
| Bond 2012 | 56/67 | 2/4 | | 0.7 % | 1.67 [ 0.62, 4.48 ] |
| Booth 2008 | 49/120 | 50/165 | | 4.8 % | 1.35 [ 0.98, 1.85 ] |
| Clark 2002 | 8/16 | 1/3 | | 0.2 % | 1.50 [ 0.28, 8.00 ] |
| Clifford 2002 | 46/66 | 21/34 | | 5.0 % | 1.13 [ 0.83, 1.54 ] |
| Flacco 2015 | 152/182 | 86/137 | | 11.0 % | 1.33 [ 1.15, 1.54 ] |
| Gan 2012 | 70/162 | 25/91 | | 3.7 % | 1.57 [ 1.08, 2.29 ] |
| Kelly 2006 | 12/13 | 4/8 | | 1.2 % | 1.85 [ 0.91, 3.76 ] |
| Khan 2012 | 39/54 | 24/32 | | 6.2 % | 0.96 [ 0.74, 1.25 ] |
| Momeni 2009 | 20/24 | 69/85 | | 8.1 % | 1.03 [ 0.84, 1.26 ] |
| Moncrieff 2003 | 2/2 | 2/7 | | 0.5 % | 2.67 [ 0.85, 8.39 ] |
| Perlis 2005b | 93/113 | 37/49 | | 9.2 % | 1.09 [ 0.91, 1.31 ] |
| Rasmussen 2009 | 66/109 | 14/28 | | 3.4 % | 1.21 [ 0.81, 1.81 ] |
| Rattinger 2009 | 26/36 | 18/25 | | 4.8 % | 1.00 [ 0.73, 1.38 ] |
| Roper 2014 | 91/152 | 34/64 | | 6.1 % | 1.13 [ 0.87, 1.47 ] |
| Spanemberg 2012 | 10/14 | 6/16 | | 1.2 % | 1.90 [ 0.93, 3.89 ] |
| Sung 2013 | 22/28 | 13/25 | | 3.1 % | 1.51 [ 0.99, 2.31 ] |
| Tulikangas 2006 | 15/15 | 7/9 | | 3.8 % | 1.29 [ 0.89, 1.87 ] |
| van Lent 2014 | 46/71 | 14/27 | | 3.3 % | 1.25 [ 0.84, 1.87 ] |
| Vlad 2007 | 5/11 | 0/4 | | 0.1 % | 4.58 [ 0.31, 68.24 ] |
| **Subtotal (95% CI)** | **1284** | **823** | | **76.6 %** | **1.20 [ 1.11, 1.30 ]** |
| Total events: 835 (Industry), 429 (Non-industry) | | | | | |
| Heterogeneity: Tau$^2$ = 0.00; Chi$^2$ = 21.08, df = 19 (P = 0.33); I$^2$ =10% | | | | | |
| Test for overall effect: Z = 4.55 (P < 0.00001) | | | | | |
| 2 Low risk of bias | | | | | |




(*Continued . . .*)


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

(. . . *Continued*)

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Bariani 2013 | 32/56 | 25/49 | | 4.0 % | 1.12 [ 0.78, 1.60 ] |
| Bero 2007 | 65/94 | 48/97 | | 6.8 % | 1.40 [ 1.10, 1.78 ] |
| Bourgeois 2010 | 222/260 | 48/85 | | 8.6 % | 1.51 [ 1.25, 1.83 ] |
| Djulbegovic 2013 | 19/33 | 17/52 | | 2.4 % | 1.76 [ 1.08, 2.87 ] |
| Etter 2007 | 25/49 | 9/41 | | 1.5 % | 2.32 [ 1.23, 4.40 ] |
| **Subtotal (95% CI)** | **492** | **324** | | **23.4 %** | **1.46 [ 1.25, 1.71 ]** |
| Total events: 363 (Industry), 147 (Non-industry) | | | | | |
| Heterogeneity: Tau$^2$ = 0.01; Chi$^2$ = 5.04, df = 4 (P = 0.28); I$^2$ =21% | | | | | |
| Test for overall effect: Z = 4.72 (P < 0.00001) | | | | | |
| **Total (95% CI)** | **1776** | **1147** | | **100.0 %** | **1.27 [ 1.17, 1.37 ]** |
| Total events: 1198 (Industry), 576 (Non-industry) | | | | | |
| Heterogeneity: Tau$^2$ = 0.01; Chi$^2$ = 33.55, df = 24 (P = 0.09); I$^2$ =28% | | | | | |
| Test for overall effect: Z = 5.63 (P < 0.00001) | | | | | |
| Test for subgroup differences: Chi$^2$ = 4.80, df = 1 (P = 0.03), I$^2$ =79% | | | | | |

**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Analysis 7.2. Comparison 7 Subgroup analysis, Outcome 2 Number of studies with favorable harms results, stratified by risk of bias.**

Review: Industry sponsorship and research outcome

Comparison: 7 Subgroup analysis

Outcome: 2 Number of studies with favorable harms results, stratified by risk of bias

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| 1 High risk of bias | | | | | |
| Halpern 2005 | 180/275 | 80/229 | | 34.1 % | 1.87 [ 1.54, 2.28 ] |
| Kemmeren 2001 | 3/4 | 2/5 | | 18.5 % | 1.88 [ 0.56, 6.31 ] |
| Nieto 2007 | 1/3 | 10/45 | | 12.8 % | 1.50 [ 0.28, 8.14 ] |
| **Subtotal (95% CI)** | **282** | **279** | | **65.4 %** | **1.87 [ 1.54, 2.27 ]** |
| Total events: 184 (Industry), 92 (Non-industry) | | | | | |
| Heterogeneity: Tau$^2$ = 0.0; Chi$^2$ = 0.07, df = 2 (P = 0.97); I$^2$ =0.0% | | | | | |
| Test for overall effect: Z = 6.36 (P < 0.00001) | | | | | |
| 2 Low risk of bias | | | | | |
| Als-Nielsen 2003 | 117/164 | 88/101 | | 34.6 % | 0.82 [ 0.72, 0.93 ] |
| **Subtotal (95% CI)** | **164** | **101** | | **34.6 %** | **0.82 [ 0.72, 0.93 ]** |
| Total events: 117 (Industry), 88 (Non-industry) | | | | | |
| Heterogeneity: not applicable | | | | | |
| Test for overall effect: Z = 3.20 (P = 0.0014) | | | | | |
| **Total (95% CI)** | **446** | **380** | | **100.0 %** | **1.37 [ 0.64, 2.93 ]** |
| Total events: 301 (Industry), 180 (Non-industry) | | | | | |
| Heterogeneity: Tau$^2$ = 0.43; Chi$^2$ = 67.64, df = 3 (P<0.00001); I$^2$ =96% | | | | | |
| Test for overall effect: Z = 0.81 (P = 0.42) | | | | | |
| Test for subgroup differences: Chi$^2$ = 50.11, df = 1 (P = 0.00), I$^2$ =98% | | | | | |

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Analysis 7.3. Comparison 7 Subgroup analysis, Outcome 3 Number of studies with favorable conclusions, stratified by risk of bias.**

Review: Industry sponsorship and research outcome

Comparison: 7 Subgroup analysis

Outcome: 3 Number of studies with favorable conclusions, stratified by risk of bias

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| 1 High risk of bias | | | | | |
| Ahmer 2005 | 125/138 | 39/50 | | 4.3 % | 1.16 [ 0.99, 1.36 ] |
| Alasbali 2009 | 26/29 | 2/10 | | 0.8 % | 4.48 [ 1.29, 15.58 ] |
| Bartels 2012 | 28/31 | 76/129 | | 4.2 % | 1.53 [ 1.27, 1.84 ] |
| Booth 2008 | 66/118 | 55/153 | | 3.8 % | 1.56 [ 1.19, 2.03 ] |
| Buchkowsky 2004 | 138/181 | 224/319 | | 4.4 % | 1.09 [ 0.97, 1.21 ] |
| Chard 2000 | 106/108 | 373/383 | | 4.6 % | 1.01 [ 0.98, 1.04 ] |
| Cho 1996 | 39/40 | 89/112 | | 4.4 % | 1.23 [ 1.10, 1.36 ] |
| Clark 2002 | 21/23 | 5/7 | | 2.6 % | 1.28 [ 0.79, 2.08 ] |
| Davidson 1986 | 32/36 | 31/49 | | 3.9 % | 1.41 [ 1.10, 1.79 ] |
| DeGeorge 2015 | 18/18 | 77/106 | | 4.3 % | 1.34 [ 1.17, 1.54 ] |
| Djulbegovic 2000 | 26/35 | 50/95 | | 3.7 % | 1.41 [ 1.07, 1.85 ] |
| Kjaergard 2002 | 28/38 | 16/22 | | 3.5 % | 1.01 [ 0.74, 1.39 ] |
| Lee 2012 | 15/43 | 4/10 | | 1.4 % | 0.87 [ 0.37, 2.06 ] |
| Liss 2006 | 62/63 | 12/37 | | 2.7 % | 3.03 [ 1.90, 4.84 ] |
| Lynch 2007 | 26/34 | 49/65 | | 3.9 % | 1.01 [ 0.80, 1.28 ] |
| Peppercorn 2007 | 52/67 | 48/73 | | 4.0 % | 1.18 [ 0.96, 1.46 ] |
| Perlis 2005a | 87/102 | 47/77 | | 4.1 % | 1.40 [ 1.15, 1.70 ] |
| Printz 2013 | 12/30 | 1/3 | | 0.5 % | 1.20 [ 0.23, 6.31 ] |
| Rasmussen 2009 | 83/109 | 15/28 | | 3.3 % | 1.42 [ 0.99, 2.04 ] |
| Rattinger 2009 | 31/36 | 21/25 | | 4.0 % | 1.03 [ 0.83, 1.27 ] |
| Ridker 2006 | 121/189 | 21/51 | | 3.3 % | 1.55 [ 1.10, 2.20 ] |
| Sung 2013 | 15/28 | 5/25 | | 1.4 % | 2.68 [ 1.14, 6.31 ] |
| Tungaraza 2007 | 124/146 | 28/44 | | 3.9 % | 1.33 [ 1.06, 1.69 ] |

(*Continued . . .*)


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

(. . . *Continued*)

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| **Subtotal (95% CI)** | **1642** | **1873** | | **77.2 %** | **1.32 [ 1.15, 1.50 ]** |
| Total events: 1281 (Industry), 1288 (Non-industry) | | | | | |
| Heterogeneity: Tau² = 0.07; Chi² = 251.86, df = 22 (P<0.00001); I² =91% | | | | | |
| Test for overall effect: Z = 4.09 (P = 0.000043) | | | | | |
| 2 Low risk of bias | | | | | |
| Als-Nielsen 2003 | 92/197 | 43/173 | | 3.6 % | 1.88 [ 1.39, 2.53 ] |
| Bariani 2013 | 39/56 | 39/49 | | 4.0 % | 0.88 [ 0.70, 1.09 ] |
| Bero 2007 | 66/94 | 39/97 | | 3.7 % | 1.75 [ 1.32, 2.30 ] |
| Djulbegovic 2013 | 29/32 | 29/52 | | 3.8 % | 1.63 [ 1.24, 2.12 ] |
| Finucane 2004 | 30/30 | 12/18 | | 3.4 % | 1.50 [ 1.08, 2.07 ] |
| Jefferson 2009 | 64/76 | 131/194 | | 4.3 % | 1.25 [ 1.09, 1.43 ] |
| **Subtotal (95% CI)** | **485** | **583** | | **22.8 %** | **1.42 [ 1.12, 1.79 ]** |
| Total events: 320 (Industry), 293 (Non-industry) | | | | | |
| Heterogeneity: Tau² = 0.07; Chi² = 28.80, df = 5 (P = 0.00003); I² =83% | | | | | |
| Test for overall effect: Z = 2.89 (P = 0.0038) | | | | | |
| **Total (95% CI)** | **2127** | **2456** | | **100.0 %** | **1.34 [ 1.19, 1.51 ]** |
| Total events: 1601 (Industry), 1581 (Non-industry) | | | | | |
| Heterogeneity: Tau² = 0.08; Chi² = 336.13, df = 28 (P<0.00001); I² =92% | | | | | |
| Test for overall effect: Z = 4.77 (P < 0.00001) | | | | | |
| Test for subgroup differences: Chi² = 0.28, df = 1 (P = 0.60), I² =0.0% | | | | | |

**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Analysis 7.4. Comparison 7 Subgroup analysis, Outcome 4 Number of studies with favorable efficacy results, stratified by type of intervention.**

Review: Industry sponsorship and research outcome

Comparison: 7 Subgroup analysis

Outcome: 4 Number of studies with favorable efficacy results, stratified by type of intervention

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| 1 Drug studies | | | | | |
| Alasbali 2009 | 7/29 | 2/10 | | 0.4 % | 1.21 [ 0.30, 4.88 ] |
| Bariani 2013 | 32/56 | 25/49 | | 4.2 % | 1.12 [ 0.78, 1.60 ] |
| Bero 2007 | 65/94 | 48/97 | | 6.5 % | 1.40 [ 1.10, 1.78 ] |
| Bond 2012 | 56/67 | 2/4 | | 0.8 % | 1.67 [ 0.62, 4.48 ] |
| Booth 2008 | 49/120 | 50/165 | | 4.9 % | 1.35 [ 0.98, 1.85 ] |
| Bourgeois 2010 | 222/260 | 48/85 | | 7.9 % | 1.51 [ 1.25, 1.83 ] |
| Clark 2002 | 8/16 | 1/3 | | 0.3 % | 1.50 [ 0.28, 8.00 ] |
| Clifford 2002 | 46/66 | 21/34 | | 5.1 % | 1.13 [ 0.83, 1.54 ] |
| Djulbegovic 2013 | 19/33 | 17/52 | | 2.7 % | 1.76 [ 1.08, 2.87 ] |
| Etter 2007 | 25/49 | 9/41 | | 1.7 % | 2.32 [ 1.23, 4.40 ] |
| Flacco 2015 | 152/182 | 86/137 | | 9.4 % | 1.33 [ 1.15, 1.54 ] |
| Gan 2012 | 70/162 | 25/91 | | 3.9 % | 1.57 [ 1.08, 2.29 ] |
| Kelly 2006 | 12/13 | 4/8 | | 1.4 % | 1.85 [ 0.91, 3.76 ] |
| Khan 2012 | 39/54 | 24/32 | | 6.1 % | 0.96 [ 0.74, 1.25 ] |
| Momeni 2009 | 20/24 | 69/85 | | 7.5 % | 1.03 [ 0.84, 1.26 ] |
| Moncrieff 2003 | 2/2 | 2/7 | | 0.6 % | 2.67 [ 0.85, 8.39 ] |
| Perlis 2005b | 93/113 | 37/49 | | 8.2 % | 1.09 [ 0.91, 1.31 ] |
| Rasmussen 2009 | 66/109 | 14/28 | | 3.6 % | 1.21 [ 0.81, 1.81 ] |
| Rattinger 2009 | 26/36 | 18/25 | | 4.9 % | 1.00 [ 0.73, 1.38 ] |
| Roper 2014 | 84/136 | 31/61 | | 5.6 % | 1.22 [ 0.92, 1.61 ] |
| Spanemberg 2012 | 10/14 | 6/16 | | 1.4 % | 1.90 [ 0.93, 3.89 ] |
| Sung 2013 | 22/28 | 13/25 | | 3.3 % | 1.51 [ 0.99, 2.31 ] |
| Tulikangas 2006 | 15/15 | 7/9 | | 4.0 % | 1.29 [ 0.89, 1.87 ] |

(*Continued . . .*)


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

(. . . *Continued*)

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| van Lent 2014 | 46/71 | 14/27 | | 3.6 % | 1.25 [ 0.84, 1.87 ] |
| Vlad 2007 | 5/11 | 0/4 | | 0.1 % | 4.58 [ 0.31, 68.24 ] |
| **Subtotal (95% CI)** | **1760** | **1144** | | **98.3 %** | **1.27 [ 1.17, 1.38 ]** |
| Total events: 1191 (Industry), 573 (Non-industry) | | | | | |
| Heterogeneity: Tau$^2$ = 0.01; Chi$^2$ = 33.06, df = 24 (P = 0.10); I$^2$ =27% | | | | | |
| Test for overall effect: Z = 5.77 (P < 0.00001) | | | | | |
| 2 Device studies | | | | | |
| Roper 2014 | 7/16 | 3/3 | | 1.7 % | 0.50 [ 0.26, 0.97 ] |
| **Subtotal (95% CI)** | **16** | **3** | | **1.7 %** | **0.50 [ 0.26, 0.97 ]** |
| Total events: 7 (Industry), 3 (Non-industry) | | | | | |
| Heterogeneity: not applicable | | | | | |
| Test for overall effect: Z = 2.06 (P = 0.039) | | | | | |
| **Total (95% CI)** | **1776** | **1147** | | **100.0 %** | **1.26 [ 1.15, 1.38 ]** |
| Total events: 1198 (Industry), 576 (Non-industry) | | | | | |
| Heterogeneity: Tau$^2$ = 0.02; Chi$^2$ = 40.88, df = 25 (P = 0.02); I$^2$ =39% | | | | | |
| Test for overall effect: Z = 5.00 (P < 0.00001) | | | | | |
| Test for subgroup differences: Chi$^2$ = 7.64, df = 1 (P = 0.01), I$^2$ =87% | | | | | |

**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Analysis 7.5. Comparison 7 Subgroup analysis, Outcome 5 Number of studies with favorable conclusions, stratified by type of intervention.**

Review: Industry sponsorship and research outcome

Comparison: 7 Subgroup analysis

Outcome: 5 Number of studies with favorable conclusions, stratified by type of intervention

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| 1 Drug studies | | | | | |
| Ahmer 2005 | 125/138 | 39/50 | | 4.1 % | 1.16 [ 0.99, 1.36 ] |
| Alasbali 2009 | 26/29 | 2/10 | | 0.7 % | 4.48 [ 1.29, 15.58 ] |
| Als-Nielsen 2003 | 92/197 | 43/173 | | 3.4 % | 1.88 [ 1.39, 2.53 ] |
| Bariani 2013 | 39/56 | 39/49 | | 3.8 % | 0.88 [ 0.70, 1.09 ] |
| Bero 2007 | 66/94 | 39/97 | | 3.5 % | 1.75 [ 1.32, 2.30 ] |
| Booth 2008 | 66/118 | 55/153 | | 3.6 % | 1.56 [ 1.19, 2.03 ] |
| Buchkowsky 2004 | 138/181 | 224/319 | | 4.2 % | 1.09 [ 0.97, 1.21 ] |
| Chard 2000 | 106/108 | 373/383 | | 4.4 % | 1.01 [ 0.98, 1.04 ] |
| Cho 1996 | 39/40 | 89/112 | | 4.3 % | 1.23 [ 1.10, 1.36 ] |
| Clark 2002 | 21/23 | 5/7 | | 2.5 % | 1.28 [ 0.79, 2.08 ] |
| Davidson 1986 | 32/36 | 31/49 | | 3.7 % | 1.41 [ 1.10, 1.79 ] |
| Djulbegovic 2000 | 26/35 | 50/95 | | 3.6 % | 1.41 [ 1.07, 1.85 ] |
| Djulbegovic 2013 | 29/32 | 29/52 | | 3.6 % | 1.63 [ 1.24, 2.12 ] |
| Finucane 2004 | 30/30 | 12/18 | | 3.3 % | 1.50 [ 1.08, 2.07 ] |
| Jefferson 2009 | 64/76 | 131/194 | | 4.2 % | 1.25 [ 1.09, 1.43 ] |
| Kjaergard 2002 | 28/38 | 16/22 | | 3.3 % | 1.01 [ 0.74, 1.39 ] |
| Lee 2012 | 15/43 | 4/10 | | 1.3 % | 0.87 [ 0.37, 2.06 ] |
| Liss 2006 | 62/63 | 12/37 | | 2.6 % | 3.03 [ 1.90, 4.84 ] |
| Lynch 2007 | 7/8 | 9/9 | | 3.3 % | 0.88 [ 0.63, 1.21 ] |
| Peppercorn 2007 | 52/67 | 48/73 | | 3.9 % | 1.18 [ 0.96, 1.46 ] |
| Perlis 2005a | 87/102 | 47/77 | | 3.9 % | 1.40 [ 1.15, 1.70 ] |
| Printz 2013 | 12/30 | 1/3 | | 0.5 % | 1.20 [ 0.23, 6.31 ] |
| Rasmussen 2009 | 83/109 | 15/28 | | 3.1 % | 1.42 [ 0.99, 2.04 ] |

(*Continued . . .*)


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

(. . . *Continued*)

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Rattinger 2009 | 31/36 | 21/25 | | 3.8 % | 1.03 [ 0.83, 1.27 ] |
| Ridker 2006 | 98/159 | 17/43 | | 3.0 % | 1.56 [ 1.06, 2.30 ] |
| Sung 2013 | 15/28 | 5/25 | | 1.3 % | 2.68 [ 1.14, 6.31 ] |
| Tungaraza 2007 | 124/146 | 28/44 | | 3.8 % | 1.33 [ 1.06, 1.69 ] |
| **Subtotal (95% CI)** | **2022** | **2157** | | **86.7 %** | **1.33 [ 1.17, 1.52 ]** |
| Total events: 1513 (Industry), 1384 (Non-industry) | | | | | |
| Heterogeneity: Tau$^2$ = 0.09; Chi$^2$ = 327.29, df = 26 (P<0.00001); I$^2$ =92% | | | | | |
| Test for overall effect: Z = 4.21 (P = 0.000025) | | | | | |
| 2 Device studies | | | | | |
| Bartels 2012 | 28/31 | 76/129 | | 4.0 % | 1.53 [ 1.27, 1.84 ] |
| DeGeorge 2015 | 18/18 | 77/106 | | 4.2 % | 1.34 [ 1.17, 1.54 ] |
| Lynch 2007 | 19/26 | 40/56 | | 3.5 % | 1.02 [ 0.77, 1.36 ] |
| Ridker 2006 | 23/30 | 4/8 | | 1.7 % | 1.53 [ 0.75, 3.15 ] |
| **Subtotal (95% CI)** | **105** | **299** | | **13.3 %** | **1.33 [ 1.13, 1.57 ]** |
| Total events: 88 (Industry), 197 (Non-industry) | | | | | |
| Heterogeneity: Tau$^2$ = 0.01; Chi$^2$ = 5.71, df = 3 (P = 0.13); I$^2$ =47% | | | | | |
| Test for overall effect: Z = 3.42 (P = 0.00062) | | | | | |
| **Total (95% CI)** | **2127** | **2456** | | **100.0 %** | **1.33 [ 1.18, 1.49 ]** |
| Total events: 1601 (Industry), 1581 (Non-industry) | | | | | |
| Heterogeneity: Tau$^2$ = 0.08; Chi$^2$ = 338.21, df = 30 (P<0.00001); I$^2$ =91% | | | | | |
| Test for overall effect: Z = 4.71 (P < 0.00001) | | | | | |
| Test for subgroup differences: Chi$^2$ = 0.00, df = 1 (P = 0.98), I$^2$ =0.0% | | | | | |

**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Analysis 7.6. Comparison 7 Subgroup analysis, Outcome 6 Number of studies with favorable efficacy results, stratified by type of domain.**

Review: Industry sponsorship and research outcome

Comparison: 7 Subgroup analysis

Outcome: 6 Number of studies with favorable efficacy results, stratified by type of domain

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| 1 Specific treatments or diseases | | | | | |
| Alasbali 2009 | 7/29 | 2/10 | | 0.3 % | 1.21 [ 0.30, 4.88 ] |
| Bariani 2013 | 32/56 | 25/49 | | 4.0 % | 1.12 [ 0.78, 1.60 ] |
| Bero 2007 | 65/94 | 48/97 | | 6.8 % | 1.40 [ 1.10, 1.78 ] |
| Bond 2012 | 56/67 | 2/4 | | 0.7 % | 1.67 [ 0.62, 4.48 ] |
| Booth 2008 | 49/120 | 50/165 | | 4.8 % | 1.35 [ 0.98, 1.85 ] |
| Clark 2002 | 8/16 | 1/3 | | 0.2 % | 1.50 [ 0.28, 8.00 ] |
| Djulbegovic 2013 | 19/33 | 17/52 | | 2.4 % | 1.76 [ 1.08, 2.87 ] |
| Etter 2007 | 25/49 | 9/41 | | 1.5 % | 2.32 [ 1.23, 4.40 ] |
| Gan 2012 | 70/162 | 25/91 | | 3.7 % | 1.57 [ 1.08, 2.29 ] |
| Kelly 2006 | 12/13 | 4/8 | | 1.2 % | 1.85 [ 0.91, 3.76 ] |
| Khan 2012 | 39/54 | 24/32 | | 6.2 % | 0.96 [ 0.74, 1.25 ] |
| Momeni 2009 | 20/24 | 69/85 | | 8.1 % | 1.03 [ 0.84, 1.26 ] |
| Moncrieff 2003 | 2/2 | 2/7 | | 0.5 % | 2.67 [ 0.85, 8.39 ] |
| Perlis 2005b | 93/113 | 37/49 | | 9.2 % | 1.09 [ 0.91, 1.31 ] |
| Rasmussen 2009 | 66/109 | 14/28 | | 3.4 % | 1.21 [ 0.81, 1.81 ] |
| Rattinger 2009 | 26/36 | 18/25 | | 4.8 % | 1.00 [ 0.73, 1.38 ] |
| Spanemberg 2012 | 10/14 | 6/16 | | 1.2 % | 1.90 [ 0.93, 3.89 ] |
| Sung 2013 | 22/28 | 13/25 | | 3.1 % | 1.51 [ 0.99, 2.31 ] |
| Tulikangas 2006 | 15/15 | 7/9 | | 3.8 % | 1.29 [ 0.89, 1.87 ] |
| Vlad 2007 | 5/11 | 0/4 | | 0.1 % | 4.58 [ 0.31, 68.24 ] |
| **Subtotal (95% CI)** | **1045** | **800** | | **66.0 %** | **1.27 [ 1.13, 1.42 ]** |
| Total events: 641 (Industry), 373 (Non-industry) | | | | | |
| Heterogeneity: Tau$^2$ = 0.02; Chi$^2$ = 29.02, df = 19 (P = 0.07); I$^2$ =35% | | | | | |
| Test for overall effect: Z = 4.16 (P = 0.000032) | | | | | |
| 2 Mixed domain | | | | | |




(*Continued . . .*)


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

(. . . *Continued*)

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Bourgeois 2010 | 222/260 | 48/85 | | 8.6 % | 1.51 [ 1.25, 1.83 ] |
| Clifford 2002 | 46/66 | 21/34 | | 5.0 % | 1.13 [ 0.83, 1.54 ] |
| Flacco 2015 | 152/182 | 86/137 | | 11.0 % | 1.33 [ 1.15, 1.54 ] |
| Roper 2014 | 91/152 | 34/64 | | 6.1 % | 1.13 [ 0.87, 1.47 ] |
| van Lent 2014 | 46/71 | 14/27 | | 3.3 % | 1.25 [ 0.84, 1.87 ] |
| **Subtotal (95% CI)** | **731** | **347** | | **34.0 %** | **1.31 [ 1.18, 1.46 ]** |
| Total events: 557 (Industry), 203 (Non-industry) | | | | | |
| Heterogeneity: Tau$^2$ = 0.00; Chi$^2$ = 4.34, df = 4 (P = 0.36); I$^2$ =8% | | | | | |
| Test for overall effect: Z = 5.14 (P < 0.00001) | | | | | |
| **Total (95% CI)** | **1776** | **1147** | | **100.0 %** | **1.27 [ 1.17, 1.37 ]** |
| Total events: 1198 (Industry), 576 (Non-industry) | | | | | |
| Heterogeneity: Tau$^2$ = 0.01; Chi$^2$ = 33.55, df = 24 (P = 0.09); I$^2$ =28% | | | | | |
| Test for overall effect: Z = 5.63 (P < 0.00001) | | | | | |
| Test for subgroup differences: Chi$^2$ = 0.18, df = 1 (P = 0.67), I$^2$ =0.0% | | | | | |

**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Analysis 7.7. Comparison 7 Subgroup analysis, Outcome 7 Number of studies with favorable harms results, stratified by type of domain.**

Review: Industry sponsorship and research outcome

Comparison: 7 Subgroup analysis

Outcome: 7 Number of studies with favorable harms results, stratified by type of domain

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| 1 Specific treatments or diseases | | | | | |
| Kemmeren 2001 | 180/275 | 80/229 | | 34.1 % | 1.87 [ 1.54, 2.28 ] |
| Naci 2014 | 3/4 | 2/5 | | 18.5 % | 1.88 [ 0.56, 6.31 ] |
| Nieto 2007 | 1/3 | 10/45 | | 12.8 % | 1.50 [ 0.28, 8.14 ] |
| **Subtotal (95% CI)** | **282** | **279** | | **65.4 %** | **1.87 [ 1.54, 2.27 ]** |
| Total events: 184 (Industry), 92 (Non-industry) | | | | | |
| Heterogeneity: Tau$^2$ = 0.0; Chi$^2$ = 0.07, df = 2 (P = 0.97); I$^2$ =0.0% | | | | | |
| Test for overall effect: Z = 6.36 (P < 0.00001) | | | | | |
| 2 Mixed study domain | | | | | |
| Als-Nielsen 2003 | 117/164 | 88/101 | | 34.6 % | 0.82 [ 0.72, 0.93 ] |
| **Subtotal (95% CI)** | **164** | **101** | | **34.6 %** | **0.82 [ 0.72, 0.93 ]** |
| Total events: 117 (Industry), 88 (Non-industry) | | | | | |
| Heterogeneity: not applicable | | | | | |
| Test for overall effect: Z = 3.20 (P = 0.0014) | | | | | |
| **Total (95% CI)** | **446** | **380** | | **100.0 %** | **1.37 [ 0.64, 2.93 ]** |
| Total events: 301 (Industry), 180 (Non-industry) | | | | | |
| Heterogeneity: Tau$^2$ = 0.43; Chi$^2$ = 67.64, df = 3 (P<0.00001); I$^2$ =96% | | | | | |
| Test for overall effect: Z = 0.81 (P = 0.42) | | | | | |
| Test for subgroup differences: Chi$^2$ = 50.11, df = 1 (P = 0.00), I$^2$ =98% | | | | | |

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Analysis 7.8. Comparison 7 Subgroup analysis, Outcome 8 Number of studies with favorable conclusions, stratified by type of domain.**

Review: Industry sponsorship and research outcome

Comparison: 7 Subgroup analysis

Outcome: 8 Number of studies with favorable conclusions, stratified by type of domain

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| 1 Specific treatments or diseases | | | | | |
| Ahmer 2005 | 125/138 | 39/50 | | 4.3 % | 1.16 [ 0.99, 1.36 ] |
| Alasbali 2009 | 26/29 | 2/10 | | 0.8 % | 4.48 [ 1.29, 15.58 ] |
| Bariani 2013 | 39/56 | 39/49 | | 4.0 % | 0.88 [ 0.70, 1.09 ] |
| Bartels 2012 | 28/31 | 76/129 | | 4.2 % | 1.53 [ 1.27, 1.84 ] |
| Bero 2007 | 66/94 | 39/97 | | 3.7 % | 1.75 [ 1.32, 2.30 ] |
| Booth 2008 | 66/118 | 55/153 | | 3.8 % | 1.56 [ 1.19, 2.03 ] |
| Chard 2000 | 106/108 | 373/383 | | 4.6 % | 1.01 [ 0.98, 1.04 ] |
| Clark 2002 | 21/23 | 5/7 | | 2.6 % | 1.28 [ 0.79, 2.08 ] |
| DeGeorge 2015 | 18/18 | 77/106 | | 4.3 % | 1.34 [ 1.17, 1.54 ] |
| Djulbegovic 2000 | 26/35 | 50/95 | | 3.7 % | 1.41 [ 1.07, 1.85 ] |
| Djulbegovic 2013 | 29/32 | 29/52 | | 3.8 % | 1.63 [ 1.24, 2.12 ] |
| Finucane 2004 | 30/30 | 12/18 | | 3.4 % | 1.50 [ 1.08, 2.07 ] |
| Jefferson 2009 | 64/76 | 131/194 | | 4.3 % | 1.25 [ 1.09, 1.43 ] |
| Lee 2012 | 15/43 | 4/10 | | 1.4 % | 0.87 [ 0.37, 2.06 ] |
| Liss 2006 | 62/63 | 12/37 | | 2.7 % | 3.03 [ 1.90, 4.84 ] |
| Lynch 2007 | 26/34 | 49/65 | | 3.9 % | 1.01 [ 0.80, 1.28 ] |
| Peppercorn 2007 | 52/67 | 48/73 | | 4.0 % | 1.18 [ 0.96, 1.46 ] |
| Perlis 2005a | 87/102 | 47/77 | | 4.1 % | 1.40 [ 1.15, 1.70 ] |
| Printz 2013 | 12/30 | 1/3 | | 0.5 % | 1.20 [ 0.23, 6.31 ] |
| Rasmussen 2009 | 83/109 | 15/28 | | 3.3 % | 1.42 [ 0.99, 2.04 ] |
| Rattinger 2009 | 31/36 | 21/25 | | 4.0 % | 1.03 [ 0.83, 1.27 ] |
| Ridker 2006 | 121/189 | 21/51 | | 3.3 % | 1.55 [ 1.10, 2.20 ] |
| Sung 2013 | 15/28 | 5/25 | | 1.4 % | 2.68 [ 1.14, 6.31 ] |

(*Continued . . .*)


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

(. . . *Continued*)

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Tungaraza 2007 | 124/146 | 28/44 | | 3.9 % | 1.33 [ 1.06, 1.69 ] |
| **Subtotal (95% CI)** | **1635** | **1781** | | **80.1 %** | **1.37 [ 1.17, 1.61 ]** |
| Total events: 1272 (Industry), 1178 (Non-industry) | | | | | |
| Heterogeneity: Tau² = 0.12; Chi² = 341.62, df = 23 (P<0.00001); I² =93% | | | | | |
| Test for overall effect: Z = 3.87 (P = 0.00011) | | | | | |
| 2 Mixed study domain | | | | | |
| Als-Nielsen 2003 | 92/197 | 43/173 | | 3.6 % | 1.88 [ 1.39, 2.53 ] |
| Buchkowsky 2004 | 138/181 | 224/319 | | 4.4 % | 1.09 [ 0.97, 1.21 ] |
| Cho 1996 | 39/40 | 89/112 | | 4.4 % | 1.23 [ 1.10, 1.36 ] |
| Davidson 1986 | 32/36 | 31/49 | | 3.9 % | 1.41 [ 1.10, 1.79 ] |
| Kjaergard 2002 | 28/38 | 16/22 | | 3.5 % | 1.01 [ 0.74, 1.39 ] |
| **Subtotal (95% CI)** | **492** | **675** | | **19.9 %** | **1.26 [ 1.07, 1.49 ]** |
| Total events: 329 (Industry), 403 (Non-industry) | | | | | |
| Heterogeneity: Tau² = 0.02; Chi² = 16.38, df = 4 (P = 0.003); I² =76% | | | | | |
| Test for overall effect: Z = 2.80 (P = 0.0052) | | | | | |
| **Total (95% CI)** | **2127** | **2456** | | **100.0 %** | **1.34 [ 1.19, 1.51 ]** |
| Total events: 1601 (Industry), 1581 (Non-industry) | | | | | |
| Heterogeneity: Tau² = 0.08; Chi² = 336.13, df = 28 (P<0.00001); I² =92% | | | | | |
| Test for overall effect: Z = 4.77 (P < 0.00001) | | | | | |
| Test for subgroup differences: Chi² = 0.48, df = 1 (P = 0.49), I² =0.0% | | | | | |

**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Analysis 8.1. Comparison 8 Sensitivity analysis, Outcome 1 Number of studies with favorable efficacy results, sponsorship recoded.**

Review: Industry sponsorship and research outcome

Comparison: 8 Sensitivity analysis

Outcome: 1 Number of studies with favorable efficacy results, sponsorship recoded

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Bariani 2013 | 24/35 | 23/43 | | 14.0 % | 1.28 [ 0.90, 1.83 ] |
| Bero 2007 | 54/76 | 10/23 | | 7.7 % | 1.63 [ 1.00, 2.66 ] |
| Bond 2012 | 53/64 | 2/2 | | 6.8 % | 0.99 [ 0.59, 1.66 ] |
| Bourgeois 2010 | 188/220 | 48/85 | | 43.2 % | 1.51 [ 1.25, 1.84 ] |
| Clifford 2002 | 30/44 | 15/28 | | 11.3 % | 1.27 [ 0.85, 1.90 ] |
| Khan 2012 | 37/49 | 11/16 | | 13.4 % | 1.10 [ 0.76, 1.59 ] |
| Moncrieff 2003 | 2/2 | 1/6 | | 0.8 % | 3.89 [ 0.86, 17.54 ] |
| Rattinger 2009 | 25/32 | 1/1 | | 2.8 % | 1.03 [ 0.45, 2.34 ] |
| **Total (95% CI)** | **522** | **204** | | **100.0 %** | **1.35 [ 1.18, 1.55 ]** |

Total events: 413 (Industry), 111 (Non-industry)

Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 7.24$, df = 7 (P = 0.40); $I^2 = 3\%$

Test for overall effect: Z = 4.33 (P = 0.000015)

Test for subgroup differences: Not applicable





Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Analysis 8.2. Comparison 8 Sensitivity analysis, Outcome 2 Number of studies with favorable harms results, sponsorship recoded.**

Review: Industry sponsorship and research outcome

Comparison: 8 Sensitivity analysis

Outcome: 2 Number of studies with favorable harms results, sponsorship recoded

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Als-Nielsen 2003 | 95/128 | 29/32 | | 37.5 % | 0.82 [ 0.70, 0.95 ] |
| Halpern 2005 | 1/3 | 10/38 | | 25.7 % | 1.27 [ 0.23, 6.84 ] |
| Nieto 2007 | 166/226 | 20/74 | | 36.8 % | 2.72 [ 1.85, 3.98 ] |
| **Total (95% CI)** | **357** | **144** | | **100.0 %** | **1.42 [ 0.31, 6.50 ]** |

Total events: 262 (Industry), 59 (Non-industry)

Heterogeneity: $Tau^2 = 1.59$; $Chi^2 = 78.09$, df = 2 ($P<0.00001$); $I^2 = 97\%$

Test for overall effect: Z = 0.46 (P = 0.65)

Test for subgroup differences: Not applicable

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Analysis 8.3. Comparison 8 Sensitivity analysis, Outcome 3 Number of studies with favorable conclusions, sponsorship recoded.**

Review: Industry sponsorship and research outcome

Comparison: 8 Sensitivity analysis

Outcome: 3 Number of studies with favorable conclusions, sponsorship recoded

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Ahmer 2005 | 75/84 | 34/43 | | 18.5 % | 1.13 [ 0.95, 1.34 ] |
| Als-Nielsen 2003 | 74/146 | 11/67 | | 6.5 % | 3.09 [ 1.76, 5.42 ] |
| Bariani 2013 | 27/35 | 32/43 | | 15.2 % | 1.04 [ 0.81, 1.33 ] |
| Bero 2007 | 57/76 | 10/23 | | 8.0 % | 1.73 [ 1.06, 2.80 ] |
| Buchkowsky 2004 | 76/104 | 121/180 | | 19.1 % | 1.09 [ 0.93, 1.27 ] |
| Jefferson 2009 | 23/29 | 89/130 | | 16.5 % | 1.16 [ 0.93, 1.44 ] |
| Kjaergard 2002 | 21/23 | 10/13 | | 12.5 % | 1.19 [ 0.86, 1.64 ] |
| Rattinger 2009 | 28/32 | 1/1 | | 3.7 % | 1.15 [ 0.51, 2.59 ] |
| **Total (95% CI)** | **529** | **500** | | **100.0 %** | **1.24 [ 1.04, 1.47 ]** |

Total events: 381 (Industry), 308 (Non-industry)

Heterogeneity: $Tau^2 = 0.03$; $Chi^2 = 20.22$, df = 7 (P = 0.01); $I^2 = 65\%$

Test for overall effect: Z = 2.44 (P = 0.015)

Test for subgroup differences: Not applicable





Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Analysis 8.4. Comparison 8 Sensitivity analysis, Outcome 4 Number of studies with favorable efficacy results, analysis adjusted for confounders.**

Review: Industry sponsorship and research outcome

Comparison: 8 Sensitivity analysis

Outcome: 4 Number of studies with favorable efficacy results, analysis adjusted for confounders

| Study or subgroup | log [Odds Ratio] (SE) | Odds Ratio IV,Random,95% CI | Weight | Odds Ratio IV,Random,95% CI |
|---|---|---|---|---|
| Bourgeois 2010 | 1.5686 (0.5142) | | 17.4 % | 4.80 [ 1.75, 13.15 ] |
| Etter 2007 | 1.1569 (0.4846) | | 19.6 % | 3.18 [ 1.23, 8.22 ] |
| Flacco 2015 | 1.0296 (0.2698) | | 63.1 % | 2.80 [ 1.65, 4.75 ] |
| **Total (95% CI)** | | | **100.0 %** | **3.15 [ 2.07, 4.80 ]** |

Heterogeneity: $Tau^2 = 0.0$; $Chi^2 = 0.86$, df = 2 (P = 0.65); $I^2 = 0.0\%$

Test for overall effect: Z = 5.36 (P < 0.00001)

Test for subgroup differences: Not applicable

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Analysis 8.5. Comparison 8 Sensitivity analysis, Outcome 5 Number of studies with favorable conclusions, analysis adjusted for confounders.**

Review: Industry sponsorship and research outcome

Comparison: 8 Sensitivity analysis

Outcome: 5 Number of studies with favorable conclusions, analysis adjusted for confounders

| Study or subgroup | log [Odds Ratio] (SE) | Odds Ratio IV,Random,95% CI | Weight | Odds Ratio IV,Random,95% CI |
|---|---|---|---|---|
| Als-Nielsen 2003 | 1.6677 (0.5082) | | 25.3 % | 5.30 [ 1.96, 14.35 ] |
| Bariani 2013 | 0.1508 (0.5373) | | 23.6 % | 1.16 [ 0.41, 3.33 ] |
| Booth 2008 | 1.2528 (0.3868) | | 34.1 % | 3.50 [ 1.64, 7.47 ] |
| Perlis 2005a | 1.5129 (0.6776) | | 17.1 % | 4.54 [ 1.20, 17.13 ] |
| **Total (95% CI)** | | | **100.0 %** | **3.13 [ 1.66, 5.93 ]** |

Heterogeneity: $Tau^2 = 0.16$; $Chi^2 = 4.85$, df = 3 (P = 0.18); $I^2 = 38\%$

Test for overall effect: Z = 3.51 (P = 0.00045)

Test for subgroup differences: Not applicable





Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## Analysis 8.6. Comparison 8 Sensitivity analysis, Outcome 6 Number of studies with favorable efficacy results, fixed-effect model.

Review: Industry sponsorship and research outcome

Comparison: 8 Sensitivity analysis

Outcome: 6 Number of studies with favorable efficacy results, fixed-effect model

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Fixed,95% CI | Weight | Risk Ratio M-H,Fixed,95% CI |
|---|---|---|---|---|---|
| Alasbali 2009 | 7/29 | 2/10 | | 0.5 % | 1.21 [ 0.30, 4.88 ] |
| Bariani 2013 | 32/56 | 25/49 | | 4.2 % | 1.12 [ 0.78, 1.60 ] |
| Bero 2007 | 65/94 | 48/97 | | 7.4 % | 1.40 [ 1.10, 1.78 ] |
| Bond 2012 | 56/67 | 2/4 | | 0.6 % | 1.67 [ 0.62, 4.48 ] |
| Booth 2008 | 49/120 | 50/165 | | 6.6 % | 1.35 [ 0.98, 1.85 ] |
| Bourgeois 2010 | 222/260 | 48/85 | | 11.4 % | 1.51 [ 1.25, 1.83 ] |
| Clark 2002 | 8/16 | 1/3 | | 0.3 % | 1.50 [ 0.28, 8.00 ] |
| Clifford 2002 | 46/66 | 21/34 | | 4.4 % | 1.13 [ 0.83, 1.54 ] |
| Djulbegovic 2013 | 19/33 | 17/52 | | 2.1 % | 1.76 [ 1.08, 2.87 ] |
| Etter 2007 | 25/49 | 9/41 | | 1.5 % | 2.32 [ 1.23, 4.40 ] |
| Flacco 2015 | 152/182 | 86/137 | | 15.4 % | 1.33 [ 1.15, 1.54 ] |
| Gan 2012 | 70/162 | 25/91 | | 5.0 % | 1.57 [ 1.08, 2.29 ] |
| Kelly 2006 | 12/13 | 4/8 | | 0.8 % | 1.85 [ 0.91, 3.76 ] |
| Khan 2012 | 39/54 | 24/32 | | 4.7 % | 0.96 [ 0.74, 1.25 ] |
| Momeni 2009 | 20/24 | 69/85 | | 4.8 % | 1.03 [ 0.84, 1.26 ] |
| Moncrieff 2003 | 2/2 | 2/7 | | 0.2 % | 2.67 [ 0.85, 8.39 ] |
| Perlis 2005b | 93/113 | 37/49 | | 8.1 % | 1.09 [ 0.91, 1.31 ] |
| Rasmussen 2009 | 66/109 | 14/28 | | 3.5 % | 1.21 [ 0.81, 1.81 ] |
| Rattinger 2009 | 26/36 | 18/25 | | 3.3 % | 1.00 [ 0.73, 1.38 ] |
| Roper 2014 | 91/152 | 34/64 | | 7.5 % | 1.13 [ 0.87, 1.47 ] |
| Spanemberg 2012 | 10/14 | 6/16 | | 0.9 % | 1.90 [ 0.93, 3.89 ] |
| Sung 2013 | 22/28 | 13/25 | | 2.2 % | 1.51 [ 0.99, 2.31 ] |
| Tulikangas 2006 | 15/15 | 7/9 | | 1.4 % | 1.29 [ 0.89, 1.87 ] |
| van Lent 2014 | 46/71 | 14/27 | | 3.2 % | 1.25 [ 0.84, 1.87 ] |
| Vlad 2007 | 5/11 | 0/4 | | 0.1 % | 4.58 [ 0.31, 68.24 ] |

(*Continued . . .*)


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

(. . . *Continued*)

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Fixed,95% CI | Weight | Risk Ratio M-H,Fixed,95% CI |
|---|---|---|---|---|---|
| **Total (95% CI)** | **1776** | **1147** | ♦ | **100.0 %** | **1.31 [ 1.23, 1.40 ]** |

Total events: 1198 (Industry), 576 (Non-industry)

Heterogeneity: $Chi^2$ = 33.55, df = 24 (P = 0.09); $I^2$ =28%

Test for overall effect: Z = 8.00 (P < 0.00001)

Test for subgroup differences: Not applicable

**Analysis 8.7. Comparison 8 Sensitivity analysis, Outcome 7 Number of studies with favorable harms results, fixed-effect model.**

Review: Industry sponsorship and research outcome

Comparison: 8 Sensitivity analysis

Outcome: 7 Number of studies with favorable harms results, fixed-effect model

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Fixed,95% CI | Weight | Risk Ratio M-H,Fixed,95% CI |
|---|---|---|---|---|---|
| Als-Nielsen 2003 | 117/164 | 88/101 | ■ | 54.7 % | 0.82 [ 0.72, 0.93 ] |
| Halpern 2005 | 1/3 | 10/45 | ─ | 0.6 % | 1.50 [ 0.28, 8.14 ] |
| Kemmeren 2001 | 3/4 | 2/5 | ─ | 0.9 % | 1.88 [ 0.56, 6.31 ] |
| Nieto 2007 | 180/275 | 80/229 | ■ | 43.8 % | 1.87 [ 1.54, 2.28 ] |
| **Total (95% CI)** | **446** | **380** | ◆ | **100.0 %** | **1.29 [ 1.15, 1.46 ]** |

Total events: 301 (Industry), 180 (Non-industry)

Heterogeneity: $Chi^2$ = 67.64, df = 3 (P<0.00001); $I^2$ =96%

Test for overall effect: Z = 4.30 (P = 0.000017)

Test for subgroup differences: Not applicable

**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Analysis 8.8. Comparison 8 Sensitivity analysis, Outcome 8 Number of studies with favorable test treatment efficacy results, fixed-effect model.**

Review: Industry sponsorship and research outcome

Comparison: 8 Sensitivity analysis

Outcome: 8 Number of studies with favorable test treatment efficacy results, fixed-effect model

| Study or subgroup | Test treatment sponsor n/N | Comparator treatm sponsor n/N | Risk Ratio M-H,Fixed,95% CI | Weight | Risk Ratio M-H,Fixed,95% CI |
|---|---|---|---|---|---|
| Bero 2007 | 43/65 | 3/30 | | 55.2 % | 6.62 [ 2.23, 19.63 ] |
| Rattinger 2009 | 22/30 | 2/6 | | 44.8 % | 2.20 [ 0.70, 6.96 ] |
| **Total (95% CI)** | **95** | **36** | | **100.0 %** | **4.64 [ 2.08, 10.32 ]** |

Total events: 65 (Test treatment sponsor), 5 (Comparator treatm sponsor)

Heterogeneity: $Chi^2 = 2.02$, df = 1 (P = 0.16); $I^2 = 50\%$

Test for overall effect: Z = 3.76 (P = 0.00017)

Test for subgroup differences: Not applicable

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Analysis 8.9. Comparison 8 Sensitivity analysis, Outcome 9 Number of studies with favorable conclusions, fixed-effect model.**

Review: Industry sponsorship and research outcome

Comparison: 8 Sensitivity analysis

Outcome: 9 Number of studies with favorable conclusions, fixed-effect model

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Fixed,95% CI | Weight | Risk Ratio M-H,Fixed,95% CI |
|---|---|---|---|---|---|
| Ahmer 2005 | 125/138 | 39/50 | | 5.0 % | 1.16 [ 0.99, 1.36 ] |
| Alasbali 2009 | 26/29 | 2/10 | | 0.3 % | 4.48 [ 1.29, 15.58 ] |
| Als-Nielsen 2003 | 92/197 | 43/173 | | 4.0 % | 1.88 [ 1.39, 2.53 ] |
| Bariani 2013 | 39/56 | 39/49 | | 3.7 % | 0.88 [ 0.70, 1.09 ] |
| Bartels 2012 | 28/31 | 76/129 | | 2.6 % | 1.53 [ 1.27, 1.84 ] |
| Bero 2007 | 66/94 | 39/97 | | 3.4 % | 1.75 [ 1.32, 2.30 ] |
| Booth 2008 | 66/118 | 55/153 | | 4.2 % | 1.56 [ 1.19, 2.03 ] |
| Buchkowsky 2004 | 138/181 | 224/319 | | 14.2 % | 1.09 [ 0.97, 1.21 ] |
| Chard 2000 | 106/108 | 373/383 | | 14.4 % | 1.01 [ 0.98, 1.04 ] |
| Cho 1996 | 39/40 | 89/112 | | 4.1 % | 1.23 [ 1.10, 1.36 ] |
| Clark 2002 | 21/23 | 5/7 | | 0.7 % | 1.28 [ 0.79, 2.08 ] |
| Davidson 1986 | 32/36 | 31/49 | | 2.3 % | 1.41 [ 1.10, 1.79 ] |
| DeGeorge 2015 | 18/18 | 77/106 | | 2.1 % | 1.34 [ 1.17, 1.54 ] |
| Djulbegovic 2000 | 26/35 | 50/95 | | 2.4 % | 1.41 [ 1.07, 1.85 ] |
| Djulbegovic 2013 | 29/32 | 29/52 | | 1.9 % | 1.63 [ 1.24, 2.12 ] |
| Finucane 2004 | 30/30 | 12/18 | | 1.4 % | 1.50 [ 1.08, 2.07 ] |
| Jefferson 2009 | 64/76 | 131/194 | | 6.5 % | 1.25 [ 1.09, 1.43 ] |
| Kjaergard 2002 | 28/38 | 16/22 | | 1.8 % | 1.01 [ 0.74, 1.39 ] |
| Lee 2012 | 15/43 | 4/10 | | 0.6 % | 0.87 [ 0.37, 2.06 ] |
| Liss 2006 | 62/63 | 12/37 | | 1.3 % | 3.03 [ 1.90, 4.84 ] |
| Lynch 2007 | 26/34 | 49/65 | | 3.0 % | 1.01 [ 0.80, 1.28 ] |
| Peppercorn 2007 | 52/67 | 48/73 | | 4.0 % | 1.18 [ 0.96, 1.46 ] |
| Perlis 2005a | 87/102 | 47/77 | | 4.7 % | 1.40 [ 1.15, 1.70 ] |
| Printz 2013 | 12/30 | 1/3 | | 0.2 % | 1.20 [ 0.23, 6.31 ] |
| Rasmussen 2009 | 83/109 | 15/28 | | 2.1 % | 1.42 [ 0.99, 2.04 ] |

(*Continued . . .*)


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

(. . . *Continued*)

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Fixed,95% CI | Weight | Risk Ratio M-H,Fixed,95% CI |
|---|---|---|---|---|---|
| Rattinger 2009 | 31/36 | 21/25 | | 2.2 % | 1.03 [ 0.83, 1.27 ] |
| Ridker 2006 | 121/189 | 21/51 | | 2.9 % | 1.55 [ 1.10, 2.20 ] |
| Sung 2013 | 15/28 | 5/25 | | 0.5 % | 2.68 [ 1.14, 6.31 ] |
| Tungaraza 2007 | 124/146 | 28/44 | | 3.8 % | 1.33 [ 1.06, 1.69 ] |
| **Total (95% CI)** | **2127** | **2456** | | **100.0 %** | **1.29 [ 1.24, 1.35 ]** |

Total events: 1601 (Industry), 1581 (Non-industry)

Heterogeneity: $Chi^2$ = 336.13, df = 28 (P<0.00001); $I^2$ =92%

Test for overall effect: Z = 12.11 (P < 0.00001)

Test for subgroup differences: Not applicable

**Analysis 8.10. Comparison 8 Sensitivity analysis, Outcome 10 Number of studies with favorable test treatment conclusions, fixed-effect model.**

Review: Industry sponsorship and research outcome

Comparison: 8 Sensitivity analysis

Outcome: 10 Number of studies with favorable test treatment conclusions, fixed-effect model

| Study or subgroup | Test treatment sponsor n/N | Comparator treatm sponsor n/N | Risk Ratio M-H,Fixed,95% CI | Weight | Risk Ratio M-H,Fixed,95% CI |
|---|---|---|---|---|---|
| Bero 2007 | 51/65 | 4/30 | | 65.9 % | 5.88 [ 2.34, 14.78 ] |
| Heres 2006 | 10/12 | 1/9 | | 13.8 % | 7.50 [ 1.16, 48.43 ] |
| Rattinger 2009 | 26/32 | 1/6 | | 20.3 % | 4.88 [ 0.81, 29.40 ] |
| **Total (95% CI)** | **109** | **45** | | **100.0 %** | **5.90 [ 2.79, 12.49 ]** |

Total events: 87 (Test treatment sponsor), 6 (Comparator treatm sponsor)

Heterogeneity: $Chi^2$ = 0.11, df = 2 (P = 0.95); $I^2$ =0.0%

Test for overall effect: Z = 4.64 (P < 0.00001)

Test for subgroup differences: Not applicable

**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

## Analysis 8.11. Comparison 8 Sensitivity analysis, Outcome 11 Number of studies with favorable conclusions, papers with unpublished studies excluded.

Review: Industry sponsorship and research outcome

Comparison: 8 Sensitivity analysis

Outcome: 11 Number of studies with favorable conclusions, papers with unpublished studies excluded

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Ahmer 2005 | 125/138 | 39/50 | | 4.6 % | 1.16 [ 0.99, 1.36 ] |
| Alasbali 2009 | 26/29 | 2/10 | | 0.9 % | 4.48 [ 1.29, 15.58 ] |
| Als-Nielsen 2003 | 92/197 | 43/173 | | 3.9 % | 1.88 [ 1.39, 2.53 ] |
| Bariani 2013 | 39/56 | 39/49 | | 4.3 % | 0.88 [ 0.70, 1.09 ] |
| Bartels 2012 | 28/31 | 76/129 | | 4.5 % | 1.53 [ 1.27, 1.84 ] |
| Bero 2007 | 66/94 | 39/97 | | 4.0 % | 1.75 [ 1.32, 2.30 ] |
| Booth 2008 | 66/118 | 55/153 | | 4.1 % | 1.56 [ 1.19, 2.03 ] |
| Buchkowsky 2004 | 138/181 | 224/319 | | 4.8 % | 1.09 [ 0.97, 1.21 ] |
| Chard 2000 | 106/108 | 373/383 | | 4.9 % | 1.01 [ 0.98, 1.04 ] |
| Cho 1996 | 39/40 | 89/112 | | 4.8 % | 1.23 [ 1.10, 1.36 ] |
| Clark 2002 | 21/23 | 5/7 | | 2.9 % | 1.28 [ 0.79, 2.08 ] |
| Davidson 1986 | 32/36 | 31/49 | | 4.2 % | 1.41 [ 1.10, 1.79 ] |
| DeGeorge 2015 | 18/18 | 77/106 | | 4.7 % | 1.34 [ 1.17, 1.54 ] |
| Djulbegovic 2000 | 26/35 | 50/95 | | 4.0 % | 1.41 [ 1.07, 1.85 ] |
| Djulbegovic 2013 | 29/32 | 29/52 | | 4.1 % | 1.63 [ 1.24, 2.12 ] |
| Jefferson 2009 | 64/76 | 131/194 | | 4.7 % | 1.25 [ 1.09, 1.43 ] |
| Kjaergard 2002 | 28/38 | 16/22 | | 3.8 % | 1.01 [ 0.74, 1.39 ] |
| Lee 2012 | 15/43 | 4/10 | | 1.5 % | 0.87 [ 0.37, 2.06 ] |
| Liss 2006 | 62/63 | 12/37 | | 3.0 % | 3.03 [ 1.90, 4.84 ] |
| Peppercorn 2007 | 52/67 | 48/73 | | 4.4 % | 1.18 [ 0.96, 1.46 ] |
| Perlis 2005a | 87/102 | 47/77 | | 4.4 % | 1.40 [ 1.15, 1.70 ] |

(*Continued . . .*)


**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

(. . . *Continued*)

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Printz 2013 | 12/30 | 1/3 | | 0.5 % | 1.20 [ 0.23, 6.31 ] |
| Rasmussen 2009 | 83/109 | 15/28 | | 3.5 % | 1.42 [ 0.99, 2.04 ] |
| Rattinger 2009 | 31/36 | 21/25 | | 4.3 % | 1.03 [ 0.83, 1.27 ] |
| Ridker 2006 | 121/189 | 21/51 | | 3.6 % | 1.55 [ 1.10, 2.20 ] |
| Sung 2013 | 15/28 | 5/25 | | 1.5 % | 2.68 [ 1.14, 6.31 ] |
| Tungaraza 2007 | 124/146 | 28/44 | | 4.2 % | 1.33 [ 1.06, 1.69 ] |
| **Total (95% CI)** | **2063** | **2373** | | **100.0 %** | **1.35 [ 1.19, 1.54 ]** |

Total events: 1545 (Industry), 1520 (Non-industry)

Heterogeneity: $Tau^2 = 0.09$; $Chi^2 = 340.82$, df = 26 (P<0.00001); $I^2 = 92\%$

Test for overall effect: Z = 4.62 (P < 0.00001)

Test for subgroup differences: Not applicable

**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Analysis 8.12. Comparison 8 Sensitivity analysis, Outcome 12 Number of studies with favorable efficacy results, restricted to specific domains.**

Review: Industry sponsorship and research outcome

Comparison: 8 Sensitivity analysis

Outcome: 12 Number of studies with favorable efficacy results, restricted to specific domains

| Study or subgroup | Industry n/N | Non industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Alasbali 2009 | 7/29 | 2/10 | | 1.4 % | 1.21 [ 0.30, 4.88 ] |
| Bero 2007 | 65/94 | 48/97 | | 15.9 % | 1.40 [ 1.10, 1.78 ] |
| Bond 2012 | 56/67 | 2/4 | | 2.7 % | 1.67 [ 0.62, 4.48 ] |
| Clark 2002 | 8/16 | 1/3 | | 1.0 % | 1.50 [ 0.28, 8.00 ] |
| Etter 2007 | 25/49 | 9/41 | | 5.5 % | 2.32 [ 1.23, 4.40 ] |
| Khan 2012 | 39/54 | 24/32 | | 15.2 % | 0.96 [ 0.74, 1.25 ] |
| Momeni 2009 | 20/24 | 69/85 | | 17.4 % | 1.03 [ 0.84, 1.26 ] |
| Moncrieff 2003 | 2/2 | 2/7 | | 2.0 % | 2.67 [ 0.85, 8.39 ] |
| Rattinger 2009 | 26/36 | 18/25 | | 13.0 % | 1.00 [ 0.73, 1.38 ] |
| Spanemberg 2012 | 10/14 | 6/16 | | 4.6 % | 1.90 [ 0.93, 3.89 ] |
| Sung 2013 | 22/28 | 13/25 | | 9.6 % | 1.51 [ 0.99, 2.31 ] |
| Tulikangas 2006 | 15/15 | 7/9 | | 11.2 % | 1.29 [ 0.89, 1.87 ] |
| Vlad 2007 | 5/11 | 0/4 | | 0.4 % | 4.58 [ 0.31, 68.24 ] |
| **Total (95% CI)** | **439** | **358** | | **100.0 %** | **1.28 [ 1.07, 1.51 ]** |

Total events: 300 (Industry), 201 (Non industry)

Heterogeneity: $Tau^2 = 0.03$; $Chi^2 = 20.91$, df = 12 (P = 0.05); $I^2 = 43\%$

Test for overall effect: Z = 2.79 (P = 0.0053)

Test for subgroup differences: Not applicable

**Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

**Analysis 8.13. Comparison 8 Sensitivity analysis, Outcome 13 Number of studies with favorable harms results, restricted to specific domains.**

Review: Industry sponsorship and research outcome

Comparison: 8 Sensitivity analysis

Outcome: 13 Number of studies with favorable harms results, restricted to specific domains

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Halpern 2005 | 1/3 | 10/45 | | 1.3 % | 1.50 [ 0.28, 8.14 ] |
| Kemmeren 2001 | 3/4 | 2/5 | | 2.5 % | 1.88 [ 0.56, 6.31 ] |
| Nieto 2007 | 180/275 | 80/229 | | 96.2 % | 1.87 [ 1.54, 2.28 ] |
| **Total (95% CI)** | **282** | **279** | | **100.0 %** | **1.87 [ 1.54, 2.27 ]** |

Total events: 184 (Industry), 92 (Non-industry)

Heterogeneity: $Tau^2 = 0.0$; $Chi^2 = 0.07$, df = 2 (P = 0.97); $I^2 = 0.0\%$

Test for overall effect: Z = 6.36 (P < 0.00001)

Test for subgroup differences: Not applicable

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Analysis 8.14. Comparison 8 Sensitivity analysis, Outcome 14 Number of studies with favorable test treatment efficacy results, restricted to specific domains.**

Review: Industry sponsorship and research outcome

Comparison: 8 Sensitivity analysis

Outcome: 14 Number of studies with favorable test treatment efficacy results, restricted to specific domains

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Bero 2007 | 43/65 | 3/30 | | 51.4 % | 6.62 [ 2.23, 19.63 ] |
| Rattinger 2009 | 22/30 | 2/6 | | 48.6 % | 2.20 [ 0.70, 6.96 ] |
| **Total (95% CI)** | **95** | **36** | | **100.0 %** | **3.88 [ 1.26, 11.94 ]** |

Total events: 65 (Industry), 5 (Non-industry)

Heterogeneity: $Tau^2 = 0.33$; $Chi^2 = 2.02$, df = 1 (P = 0.16); $I^2 = 50\%$

Test for overall effect: Z = 2.36 (P = 0.018)

Test for subgroup differences: Not applicable

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## Analysis 8.15. Comparison 8 Sensitivity analysis, Outcome 15 Number of studies with favorable conclusions, restricted to specific domains.

Review: Industry sponsorship and research outcome

Comparison: 8 Sensitivity analysis

Outcome: 15 Number of studies with favorable conclusions, restricted to specific domains

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Alasbali 2009 | 26/29 | 2/10 | | 0.9 % | 4.48 [ 1.29, 15.58 ] |
| Bartels 2012 | 28/31 | 76/129 | | 10.4 % | 1.53 [ 1.27, 1.84 ] |
| Bero 2007 | 66/94 | 39/97 | | 8.1 % | 1.75 [ 1.32, 2.30 ] |
| Clark 2002 | 21/23 | 5/7 | | 4.5 % | 1.28 [ 0.79, 2.08 ] |
| DeGeorge 2015 | 18/18 | 77/106 | | 11.5 % | 1.34 [ 1.17, 1.54 ] |
| Djulbegovic 2000 | 26/35 | 50/95 | | 8.2 % | 1.41 [ 1.07, 1.85 ] |
| Jefferson 2009 | 64/76 | 131/194 | | 11.5 % | 1.25 [ 1.09, 1.43 ] |
| Lee 2012 | 15/43 | 4/10 | | 1.8 % | 0.87 [ 0.37, 2.06 ] |
| Liss 2006 | 62/63 | 12/37 | | 4.7 % | 3.03 [ 1.90, 4.84 ] |
| Peppercorn 2007 | 52/67 | 48/73 | | 9.7 % | 1.18 [ 0.96, 1.46 ] |
| Perlis 2005a | 87/102 | 47/77 | | 10.1 % | 1.40 [ 1.15, 1.70 ] |
| Printz 2013 | 12/30 | 1/3 | | 0.6 % | 1.20 [ 0.23, 6.31 ] |
| Rattinger 2009 | 31/36 | 21/25 | | 9.6 % | 1.03 [ 0.83, 1.27 ] |
| Ridker 2006 | 121/189 | 21/51 | | 6.7 % | 1.55 [ 1.10, 2.20 ] |
| Sung 2013 | 15/28 | 5/25 | | 1.9 % | 2.68 [ 1.14, 6.31 ] |
| **Total (95% CI)** | **864** | **939** | | **100.0 %** | **1.42 [ 1.25, 1.61 ]** |

Total events: 644 (Industry), 539 (Non-industry)

Heterogeneity: $Tau^2 = 0.03$; $Chi^2 = 39.99$, df = 14 (P = 0.00026); $I^2 = 65\%$

Test for overall effect: Z = 5.49 (P < 0.00001)

Test for subgroup differences: Not applicable

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Analysis 8.16. Comparison 8 Sensitivity analysis, Outcome 16 Number of studies with favorable test treatment conclusions, restricted to specific domains.**

Review: Industry sponsorship and research outcome

Comparison: 8 Sensitivity analysis

Outcome: 16 Number of studies with favorable test treatment conclusions, restricted to specific domains

| Study or subgroup | Industry n/N | Non-industry n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|---|---|---|---|---|---|
| Bero 2007 | 51/65 | 4/30 | | 66.4 % | 5.88 [ 2.34, 14.78 ] |
| Heres 2006 | 10/12 | 1/9 | | 16.2 % | 7.50 [ 1.16, 48.43 ] |
| Rattinger 2009 | 26/32 | 1/6 | | 17.4 % | 4.88 [ 0.81, 29.40 ] |
| **Total (95% CI)** | **109** | **45** | | **100.0 %** | **5.92 [ 2.80, 12.54 ]** |

Total events: 87 (Industry), 6 (Non-industry)

Heterogeneity: $Tau^2 = 0.0$; $Chi^2 = 0.11$, df = 2 (P = 0.95); $I^2 = 0.0\%$

Test for overall effect: Z = 4.65 (P < 0.00001)

Test for subgroup differences: Not applicable




# APPENDICES

## Appendix 1. Search strategy

**MEDLINE via OvidSP (2010 - February 2015)**

1. Drug Industry/
2. ((drug$ or pharmaceutical or device$ or for-profit or commercial$) adj2 (industr$ or company or companies or manufacturer$ or organi#ation$ or agency or agencies or source$ or party or parties)).ti,ab.
3. private industr$.ti,ab.
4. (industr$ or nonindustr$ or non-industr$).ti,ab.
5. or/1-4
6. "Conflict of Interest"/
7. Financial Support/
8. Research Support as Topic/
9. (influenc$ or funded or funding or sponsor$ or support$ or financ$ or involvement).ti,ab.
10. competing interest$.ti,ab.
11. or/6-10
12. and/5,11
13. Publication Bias/
14. "bias (epidemiology)"/
15. bias$.ti,ab.


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

16. or/13-15
17. and/12,16
18. Treatment Outcome/
19. "Outcome Assessment (Health Care)"/
20. (outcome$ or finding$).ti,ab.
21. or/18-20
22. (favo?r$ or positive or significan$ or beneficial or benefit$ or effective or effectual or efficacious).ti,ab.
23. (insignificant$ or nonsignificant$ or negative or adverse or ineffectiv$ or ineffectual or unfavo?rabl$ or detrimental).ti,ab.
24. or/22-23
25. and/21,24
26. and/12,25
27. ((favo?r$ or positive or significan$ or insignificant$ or nonsignificant$ or negative or unfavo?rabl$ or detrimental) adj2 (event$ or result$ or outcome$ or conclusion$)).ti,ab.
28. and/12,27
29. or/17,26,28

## WHAT'S NEW

Last assessed as up-to-date: 23 June 2015.

| Date | Event | Description |
|---|---|---|
| 7 February 2017 | New search has been performed | Updated version of review from Issue 12 in 2012. Including updated search (February 2015) and inclusion of 27 new papers (now total of 75 papers) |
| 7 February 2017 | New citation required but conclusions have not changed | Addition of new papers did not change conclusions. |

## CONTRIBUTIONS OF AUTHORS

Development of protocol (AL, BM, JL, JS and LB); study inclusion (BM, JL, JS and LB); data extraction (AL, BM, JL and JS); data analysis and interpretation of results (all authors); writing of manuscript (all authors).

## DECLARATIONS OF INTEREST

Andreas Lundh, Joel Lexchin and Lisa Bero are authors of the some of the previous reviews and included studies.

In 2015 to 2016, Joel Lexchin received payment from non-profit entities for being a consultant on two projects, one looking at indications-based prescribing and a second looking at which drugs should be provided free of charge by general practitioners. He received payment from a for-profit company for being on a panel that discussed expanding drug coverage in Canada. He is on the Foundation Board of Health Action International.

In 2014, Barbara Mintzes was retained as an expert witness by the law firm representing the plaintiffs in a Canadian class action on hormone replacement therapy and breast cancer, and in 2015 to 2016 in an application for a Canadian class action on cardiovascular risks of testosterone supplements. She was a member of the Health Action International - Europe Association Board from 2012 to 2015.

The review authors have no other relevant interests.


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## SOURCES OF SUPPORT

### Internal sources

- Center for Evidence-Based Medicine, Odense, Denmark.

The author was personally salaried by his institution during some period of the review.

- The Nordic Cochrane Centre, Copenhagen, Denmark.

The author was externally affiliated with The Nordic Cochrane Centre for this work and received no financial support during the period of the review.

- University of Sydney, Sydney, Australia.

The authors were personally salaried by their institution during the period of the review.

- York University, Toronto, Canada.

The author was personally salaried by his institutions during the period of the review.

### External sources

- No sources of support supplied


## DIFFERENCES BETWEEN PROTOCOL AND REVIEW

In this update, we decided to analyze data with the random-effects model due to heterogeneity of data encountered in our previous review. In addition, we included four new sensitivity analysis in this update: 1) fixed-effect model; 2) excluding papers including unpublished studies: 3) restricting analyses restricted to papers on specific treatments or diseases: and 4) including unstructured letters and conference abstracts. All decisions were made prior to data analysis.

## INDEX TERMS

### Medical Subject Headings (MeSH)

*Conflict of Interest; *Equipment and Supplies; *Industry; Data Interpretation, Statistical; Drug Industry; Publication Bias; Research Report [*standards]; Research Support as Topic [*standards]; Treatment Outcome


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.